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Summary 
Epidemiological studies indicate a reduced risk and a lower incidence of hormone-dependent cancer 
types in populations following a traditional Asian diet rich in phytoestrogens such as isoflavones (IF). 
Lifestyle and timing of exposure to IF seems to be a critical factor. In rodent models, especially multi-
generational or prepubertal exposure was shown to modulate mammary gland (MG) morphology, 
resulting in anti-tumorigenic activity. Many processes during early development are regulated by 
epigenetic mechanisms, therefore IF might alter the epigenetic reprogramming of the MG affecting 
normal cell growth and susceptibility to breast cancer. Several investigations provide evidence for 
the impact of IF on DNA methylation but most of the work focused on selected candidate genes. 
Investigations of genome-wide changes of DNA methylation in the MG upon IF treatment are scarce.  
The present thesis was aimed to analyzed DNA methylation profiles in MGs of healthy rats and during 
estrogen-induced mammary carcinogenesis on a genome-wide scale. Our focus was to clarify the 
impact of different IF doses and identify critical developmental windows of exposure in Wistar rats, 
and to investigate the chemopreventive efficacy of IF during estrogen-induced MG tumor 
development in ACI rats.  
Genome-wide methylation analyses were initially performed with Wistar rats bred on a diet with 
medium IF levels that were switched to either IF-free or high dose IF diet for two weeks after 
ovariectomy (OVX). We observed only few IF-related DNA methylation changes (measured by MCIp-
Seq technology). This weak epigenetic effect was attributed to the fact that all rats had been exposed 
to the phytoestrogens during all critical developmental phases until adult life. Most methylation 
changes were observed outside of classical regulatory regions (promoters, CpG islands or 5’ UTRs) 
but interestingly were enriched for binding sites for ETS-domain and basic leucine zipper-domain 
containing transcription factors. For validation of the genome-wide results, selected candidate genes 
were analyzed quantitatively by EpiTYPER MassARRAY technology. Two groups of rats with lifelong 
exposure (from conception to post OVX) to low and high IF doses were included to consider dose 
effects. We observed a U-shaped dose-response pattern, with the low IF concentration reducing 
methylation levels, whereas medium and high doses increased methylation compared to an IF-
unexposed control group. The relevance of these changes needs to be further investigated. However, 
lifelong exposure to high IF levels significantly reduced estrogenic and proliferative response of the 
MG, whereas lower IF concentrations were not sufficient to induce the beneficial health effects and 
even provoked opposing effects, i.e., significantly induced PCNA and PR protein expression. 
Different from the lifelong exposure to high IF levels, IF intervention exclusively during puberty 
exhibited only minor effects on DNA methylation and mRNA expression levels of candidate genes. 
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Also, expression of proliferation markers were not affected. An exception was an increase in Vdr and 
Gata3 mRNA expression which might sensitize the MG towards enhanced differentiation. 
In contrast, short term IF exposure only after OVX affected DNA methylation patterns of candidate 
regions mostly in an opposed direction when compared to the lifelong IF exposure. Post OVX 
exposure to IF also induced pro-proliferative as well as pro-estrogenic properties and sensitized the 
animals towards the estrogen treatment. These results contradict the use of high IF concentrations, 
e.g., for hormone replacement therapy after menopause. 
In order to investigate lifelong IF-mediated effects on estrogen-induced rat mammary carcinogenesis, 
ACI were exposed lifelong to the highest IF dose. IF intervention reduced incidence and multiplicity 
(56 %, p=0.018) of MG tumors but shortened tumor latency by 5 weeks (p<0.0001) and enhanced 
tumor growth (>2 fold), if tumors escaped the preventive effect. IF intake increased the estrogenic 
and proliferative response of the MG during puberty when carcinogenesis was induced by exogenous 
estrogen exposure, and epigenetic modifying enzymes such as DNMT3a and 3b were significantly 
downregulated. Genome-wide methylation profiling analyzed by quantitative reduced 
representation bisulfite sequencing (RRBS) again indicated hypo- and hypermethylation mainly 
outside of classical regulatory regions. Genes with differential promoter methylation induced during 
carcinogenesis which could be modulated by IF exposure were enriched for biological processes and 
signaling pathways involved in reproductive tissue homeostasis and endocrine system. After applying 
stringent selection criteria, we were able to validate selected methylation changes from the RRBS 
analysis by MassARRAY. In all regions investigated, the carcinogenic process significantly modified 
methylation levels up to 30 %, inducing both, hypo- and hypermethylation. Interestingly, lifelong 
intervention with the highest IF dose prevented this carcinogenesis-mediated loss and/or gain in 
methylation. For half of the selected candidate genes methylation changes significantly correlated 
with mRNA expression. Interestingly, lifelong high dose IF exposure significantly reduced mRNA 
levels of DNMT1 in healthy MGs and prevented the estrogen-induced upregulation of DNMT1 during 
tumor formation. 
In conclusion, we identified genome wide DNA methylation changes induced by dietary IF. The 
impact of IF on DNA methylation is highly dependent on exposure time and IF dose. Lifelong 
exposure to IF reduced estrogen-induced MG tumor incidence but shorted tumor latency. This 
phenomenon might be partly explained by the downregulation of epigenetic modifiers such as 
DNMTs during early MG development as well as during breast carcinogenesis. Additional 
investigations are required to gain a comprehensive insight on IF-induced epigenetic regulation 
unraveling the functional mechanisms of biological effects exerted by phytoestrogenic soy IF. 
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Zusammenfassung 
Epidemiologische Studien zeigen, dass das Risiko für hormonabhängige Krebsarten sowie deren 
Inzidenz in asiatischen Regionen vermindert ist, in denen traditionell Lebensmittel mit einem hohen 
Gehalt an phytoöstrogenen Isoflavonen (IF) verzehrt werden. Die Lebensweise sowie der Zeitpunkt 
der Exposition stellen dabei vermutlich besonders kritische Faktoren dar. In Tiermodellen konnte 
gezeigt werden, dass vor allem eine generationsübergreifende und präpubertäre IF Exposition über 
Veränderungen in der Morphologie der Brustdrüse zu einer verminderten Tumorentstehung beiträgt. 
Da die frühe Brustentwicklung durch eine Vielzahl von epigenetischen Prozessen reguliert wird, 
könnte es sein, dass IF die epigenetische Reprogrammierung der Brust modulieren und so nicht nur 
das normale Zellwachstum beeinflussen, sondern auch die Empfindlichkeit der Brust gegenüber der 
Mammakarzinogenese verändern. Verschiedene Untersuchungen konnten bereits zeigen, dass IF 
Einfluss auf die DNA Methylierung nehmen können. Da in den meisten Studien nur ausgewählte 
Kandidatengene untersucht wurden, gibt es kaum Erhebungen, die IF-induzierte Veränderungen 
bezogen auf das gesamte Genom zeigen. 
Das Ziel der vorliegenden Arbeit bestand darin, Veränderungen im DNA Methylierungsmuster im 
gesunden Brustgewebe weiblicher Wistar Ratten sowie während der Östrogen-induzierten 
Mammakarzinogenese genomweit zu erfassen. Besonderes Augenmerk wurde dabei auf den Einfluss 
der applizierten Dosis und des Zeitpunktes der Exposition gelegt sowie auf das chemopräventive 
Potential der IF während der Östrogen-induzierten Karzinogenese in ACI Ratten. 
Genomweite Analysen mittels MCIp-Seq Technologie wurden zunächst mit Wistar Ratten 
durchgeführt, die unter Verwendung von IF-haltigem Futter (mittlere Dosis) gezüchtet worden 
waren. Nach Ovarektomie (OVX, vergleichbar mit der Menopause) bekamen die Tiere entweder IF-
freies Futter oder eine Diät mit hoher IF Konzentration. Wir konnten nur geringe Unterschiede im 
DNA Methylierungsprofil zwischen beiden Gruppen detektieren. Dies lässt sich vermutlich dadurch 
erklären, dass die Ratten während aller kritischen Entwicklungsphasen bis zum Erwachsenenalter den 
Phytoöstrogenen ausgesetzt waren. Differentiell methylierte Regionen wurden vornehmlich 
außerhalb von klassischen Expressions-regulierenden Bereichen (Promoter, CpG Inseln oder 5' UTR) 
gefunden, aber waren interessanterweise in Bindestellen für Transkriptionsfaktoren mit Leucin-
Zipper (bZIP)- und ETS-Domäne angereichert. Für die Validierung der genomweiten Ergebnisse 
wurden interessante Kandidatengene quantitativ mittels EpiTYPER MassARRAY analysiert. Um eine 
Dosisabhängigkeit der Methylierungsveränderungen zu beurteilen, wurden zusätzlich zwei Gruppen 
von Ratten untersucht, die lebenslang (von der Zeugung bis post OVX) niedrigen oder hohen IF 
Konzentrationen ausgesetzt waren. Wir konnten zeigen, dass im Vergleich zu einer Kontrollgruppe 
mit IF-freiem Futter die niedrige IF Dosis die DNA Methylierung überwiegend reduzierte, während die 
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mittlere und hohe IF Konzentration zu erhöhten Methylierungswerten und somit zu einem 
U-förmigen Dosis-Wirkungsprofil führen. Die Relevanz dieser Ergebnisse muss in weiterführenden 
Studien untersucht werden. Allerdings zeigte sich, dass bei lebenslanger Exposition mit hoher IF 
Konzentration die östrogene sowie proliferative Antwort der Brustdrüse signifikant vermindert 
wurde. Im Gegensatz dazu konnte eine niedrige IF Dosis diese gesundheitlich positiven Effekte nicht 
induzieren und hatte einen eher negativen Einfluss, der z.B. zu einer signifikant erhöhten PCNA und 
PR Proteinexpression führte.  
Im Unterschied zur lebenslangen Exposition zeigten sich nur geringe Effekte auf die DNA 
Methylierung und mRNA Expression von Kandidatengenen, wenn die Intervention mit hohen IF-
Konzentrationen kurzzeitig und ausschließlich während der Pubertät durchgeführt wurde. Auch das 
Expressionsmuster der Proliferationsmarker war unverändert. Eine Ausnahme bildet dabei eine 
erhöhte Genexpression von Vdr und Gata3, welche die Brustdrüse möglicherweise für eine verstärkte 
Differenzierung sensibilisieren kann. 
Interessanterweise führte eine Exposition mit hoher IF Konzentration ausschließlich nach der OVX zu 
Veränderungen in der DNA Methylierung, die denen der lebenslangen Exposition häufig 
entgegengesetzt waren. Die post OVX IF Intervention entfaltete außerdem pro-proliferative und pro-
östrogene Eigenschaften und verstärkte die Sensibilität der Tiere gegenüber der exogenen Östrogen 
Gabe. Diese Ergebnisse sprechen gegen die Einnahme von IF Supplementen in hohen 
Konzentrationen als Hormonersatztherapie nach der Menopause. 
Der Einfluss einer lebenslangen Exposition mit hoher IF Konzentration auf die Östrogen-induzierte 
Brustkarzinogenese wurden in ACI Ratten untersucht. Die Intervention resultierte in einer 
verminderten Tumor-Inzidenz sowie Multiplizität (56 %, p=0.018). Wenn aber Tumoren den 
präventiven Effekten der IF entgingen, führte die Intervention zu einer signifikant verkürzten Tumor-
Latenz (um 5 Wochen) sowie zu einem verstärkten Tumorwachstum (>2 fach). Detaillierte Unter-
suchungen während des Pubertätszeitraumes zeigten, dass die östrogene und proliferative Antwort 
der Brustdrüse durch die hohe IF Dosis erhöht wurde, während die Expression der epigenetisch 
aktiven Enzyme DNMT3a und 3b signifikant durch die lebenslange IF-reiche Diät vermindert wurde. 
Genomweite Methylierungsanalysen mittels RRBS deuten erneut darauf hin, dass differentiell 
methylierte Regionen weitestgehend außerhalb der klassischen Expressions-regulierenden Bereiche 
nachweisbar sind. Allerdings konnten wir zeigen, dass Gene, bei denen Krebs-induzierte 
Methylierungsveränderungen in der Promoter Region durch die IF Intervention beeinflusst werden 
konnten, sich auf eine Vielzahl von Funktionen und Signalwegen in Reproduktionsgewebe sowie im 
endokrinen System auswirken. Nach Anwendung stringenter Auswahlkriterien konnten wir 
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Methylierungsveränderungen aus der RRBS Analyse mittels MassARRAY Technologie validieren. Die 
Östrogen-induzierte Mammakarzinogenese führte zu Hyper- als auch Hypomethylierung bis zu 30 %. 
Interessanterweise verminderte die lebenslange IF-Hochdosis diese Karzinogenese-vermittelte Zu- 
und Abnahme der DNA Methylierung in den meisten Fällen. Für die Hälfte der ausgewählten Gene 
korrelierte die Methylierungsveränderung signifikant mit Expressionsunterschieden, womit der 
Einfluss der IF auf epigenetische Regulationsmechanismen unterstrichen wird. In Übereinstimmung 
damit reduzierte die lebenslange IF-Hochdosis die DNMT1 Genexpression in gesunden Brustdrüsen 
und verhinderte ebenfalls die Östrogen-induzierte Expression während der Tumorentwicklung. Somit 
konnte abermals gezeigt werden, dass eine lebenslange Intervention mit hohen IF Konzentrationen 
die Expression epigenetisch aktiver Enzyme und dadurch das DNA Methylierungsmuster beeinflussen 
kann.  
Schlussfolgernd lässt sich feststellen, dass in den Rattenmodellen eine IF Exposition über das Futter 
zu genomweiten Veränderungen in der DNA Methylierung führte. Wir konnten zeigen, dass die 
Auswirkungen der IF Intervention stark von der applizierten Dosis sowie vom Expositionszeitraum 
abhängen. Desweiteren verminderte eine lebenslang IF Hochdosis die Östrogen-induzierte Inzidenz 
von Brusttumoren, verkürzte allerdings die Tumor-Latenz. Dieses Phänomen könnte dadurch erklärt 
werden, dass die IF Intervention bereits in der frühen Brustentwicklung sowie während der 
Mammakarzinogenese Einfluss auf die Expression epigenetisch aktiver Enzyme, wie den DNA 
Methyltransferasen nimmt. Weiterführende Untersuchungen sind notwendig, um einen 
umfassenden Einblick in die IF-induzierte epigenetische Regulation zu erhalten. Diese Erkenntnisse 
können maßgeblich zur Klärung der funktionellen Mechanismen beitragen, die den biologischen 
Effekten der phytoöstrogen Soja-IF zugrunde liegen. 
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5caC 5-carboxylcytosine 
5fC 5-formylcytosine 
5hmC 5-hydroxymethylcytosine 
5mC 5-methylcytosine 
ACI August Copenhagen Irish rat 
β-ME β-mercapto-ethanol 
BMD Bone mineral density 
cDNA Complementary DNA 
CGIs CpG islands 
CoA Coenzyme A 
Ct Cycle threshold 
DAI Daidzein 
DCIS Ductal carcinoma in situ 
DNA Desoxyribonucleic acid 
DMR Differentially methylated region 
DMS Differentially methylated site 
DNMT  DNA methyltransferase 
E2  17β-estradiol 
EB Elution buffer 
ECM Extracellular matrix 
EDTA Ethylendiaminetetraacetic acid 
EMCA Estrogen-induced mammary cancer 
ER, Esr Estrogen receptor (ER refers to protein, Esr refers to gene) 
GEN Genistein 
GLY Glycitein 
HAT  Histone acetyltransferase 
HDAC  Histone deacetylase 
HDL High-density lipoprotein 
HMT Histone methyltransferase 
HRT Hormone replacement therapy 
HS High salt elution 
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IF Isoflavones 
LCM Laser capture microdissection 
LDL Low-density lipoprotein 
lncRNA Long non-coding RNA 
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MBD-Fc Methyl-CpG-binding domain-Fc 
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NGS, Seq Next Generation Sequencing 
OR Odds ratio 
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PND  Post natal day 
PPC PCR primer cocktail 
PR, Pgr Progestrone receptor (PR refers to protein, Pgr refers to gene) 
PRC2 Polycomb repressive complex 2 
RNA Ribonucleic acid 
RRBS Reduced representation bisulfite sequencing 
RT-qPCR Real time quantitative PCR 
SAP Shrimp alkaline phosphatase 
SF Single fraction elution 
SNP Single nucleotide polymorphism 
T Tumor 
TDLU Terminal ductal lobular unit 
TEB Terminal end buds 
TET Ten-eleven translocation, methylcytosine dioxygenase 
TF Transcription factor 
tRNA transfer RNA 
TSS Transcription start site 
TBE  TRIS/Borate/EDTA buffer 
UTR Untranslated regions 
WHI Women Health Initiative 
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1. Introduction 
1.1 Isoflavones 
1.1.1 Sources, chemistry and dietary intake 
Isoflavones (IF) are a class of plant estrogens (phytoestrogens) mainly present as glycoside 
conjugates in the Leguminosae plant family. The most prevalent dietary IF including genistein (GEN), 
daidzein (DAI), and glycitein (GLY) occur in nutritionally relevant amounts in soybeans and soy-based 
foodstuffs (Figure 1). Concentrations of total IF (sum of all aglycone equivalents) differ in soy flour 
(150-210 mg/100 g), Tofu (9-50 mg/100 g), and soy milk (1-10 mg/100 g); IF amounts in soy sauce are 
generally low (<1 mg/100 g). Nowadays, more processed foodstuffs such as soy cheese 
(6-25 mg/100 g), soy burgers (6-30 mg/100 g), and meatless soy sausages (3-15 mg/100 g) gain 
increasing interest and substantially contribute to the daily dietary IF intake [1].  
 
 
Figure 1: Chemical structures of soy isoflavones. 
Chemical structures are depicted as aglycones for predominant isoflavones from soy: Genistein, Daidzein, and Glycitein, as 
well as the microbial Daidzein metabolite Equol (modified from [2]). 
 
IF levels in soy products vary depending on the soybean cultivar, crop year and weather conditions at 
time of cultivation. Additionally, processing and storage conditions affect the total IF quantity as well 
as the IF pattern. Daily dietary intake of IF varies drastically between Western and Asian Countries. 
Since fermented soy products like Tofu, Tempeh and Miso are part of the regular diet in many Asian 
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countries, dietary intake of IF has been estimated from 25 mg/day in China [3] and 60 mg/day in 
Singapore [4] up to 200 mg/day in Japan. 
Intakes in the Western society are much lower and do not exceed one to several mg/day [5] with 
individuals following a vegetarian- (12 mg/day) or vegan-based nutrition (70 mg/day) showing a 
higher IF intake than the general population. Subgroups with highest IF ingestions are infants fed a 
soy-based formula (6-47 mg/day), and consumers of soy supplements (50-200 mg/tablet) [6, 7].  
1.1.2 Bioavailability of IF 
The main requirement for IF to exert biological effects in humans is an effective bioavailability which 
is determined by their absorption, metabolism, distribution, and excretion. 
1.1.2.1 Absorption and excretion 
IF are mainly ingested as glycosides which can be hydrolyzed by bacterial or membrane-bound 
β-glucosidases or β-glucuronidases releasing IF as aglycones that can be either transported across the 
intestinal wall or get further metabolized by the gut microbiota in the colon. IF show a biphasic 
pattern of absorption, reflecting constant uptake from the gastrointestinal tract (1-2 h) as well as 
enterohepatic recirculation (4-6 h) yielding to plasma concentrations of several µmol/L (e.g., after 
intake of 50 mg IF) [8]. IF metabolites are mainly excreted via the urine; half-life values for 
elimination of IF are >6 h (reviewed in: [9]). 
1.1.2.2 Metabolism and distribution 
IF undergo considerable biotransformation by the intestinal bacteria. DAI, GEN, and GLY are 
converted to many specific products via demethylation, dehydroxylation, reduction, and ring 
cleavage. There is extensive interindividual diversity in bacterial metabolism, i.e., 30 % of the adult 
Western vs. 60 % of the vegetarians and Asian population are able to produce Equol, a DAI meta-
bolite with high binding capacities to the estrogen receptor (ER) (reviewed in: [10]).  
Absorbed aglycones are extensively modified by xenobiotic-metabolizing enzymes during Phase I and 
Phase II metabolism: reduction via cytochrome P450 enzymes as well as conjugation with glucuronic 
acid and sulfate. Hence, IF mainly exist as mono- and di-glucuronides, mono- and di-sulfates, and 
sulfoglucuronides in human plasma which are not able to pass the cell membrane via passive 
diffusion. Specific carriers have been identified that actively transport DAI metabolites (i.e., organic 
anion transporter (OAT4), organic anion transporting polypeptide (OATP2B), sodium-dependent 
organic anion transporter (SOAT), Na+-taurocholate co-transporting polypeptide (NTCP)) which may 
also play a role in the cellular uptake of other IF conjugates [11].  
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It is not well known whether IF metabolites are distributed equally in the human body, and whether 
IF concentrations in human plasma are a representative marker for concentrations in specific target 
organs, for example, in breast or adipose tissue. However, it has been reported that consumption of 
soy products lead to clinically relevant IF levels in mammary glands [8]. 
1.1.3 Biological effects 
In this section, the main observations regarding the impact of IF on physiological and pathological 
processes will be briefly recapitulated. There is a variety of preclinical in vitro and in vivo studies 
investigating the biological effects of IF [12-14]). Numerous reports about transcriptomic, proteomic 
and metabolomic findings have contributed to describe the complex nature of IF activities (reviewed 
in: [10, 15-19]). 
1.1.3.1 ER-mediated dualistic mode of action 
Due to the structural similarity to endogenous 17β-estradiol (E2), the polyphenolic IF are able to 
selectively bind to ER, modulating the recruitment of co-repressors and co-activators thus affecting 
ER-signaling [20].  
There are two types of ER: ERα and ERβ encoded by Esr1 and Esr2, located on different 
chromosomes with numerous mRNA splice variants. Upon ligand binding, cytosolic ERs homo and/or 
heterodimerize and subsequently translocate into the nucleus. Binding to the DNA via ER-responsive 
elements (ERE) recruits co-activators and co-repressors which enables regulation of gene expression 
of downstream targets. Although ERs share >50 % homology at the ligand binding domain the affinity 
and response, also to the same ligand, differs and elicits divergent signaling cascades. In addition, the 
activating function domain (AF1), responsible for recruitment of co-activators and co-repressors, is 
only conserved by about 20 % between ERα and ERβ. Therefore, binding of the same ligand induces 
different conformational changes. Binding of E2 to ERα favors agonistic effects via recruitment of co-
activators and favorable antagonistic effects via recruitment of co-repressors to ERβ. ERα and ERβ 
have opposing effects regarding proliferation, differentiation, and apoptosis and have been shown to 
regulate one another by forming heterodimers. This interaction influences DNA binding and 
availability of the respective receptor and results in repressed transcriptional activity [21]. 
Estrogen-responsive genes are involved in sexual reproduction including development of the 
mammary gland, reduced cholesterol levels, and plaque production in coronary arteries, as well as 
increased bone health by balancing bone resorption and bone formation [22]. ERs are expressed in 
various E2-sensitive tissues, i.e., ERα in endometrium, breast, ovary, and hypothalamic tissue and 
ERβ in kidney, brain, bone, heart, lungs, intestine, prostate, and epithelial cells [23].  
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GEN shows affinity to both ERα and ERβ as the opposing hydroxyl groups at 4′- and 7-position are 
appropriately positioned to interact with the amino acids in the ER binding pockets in a similar 
fashion as E2. For a structural comparison of GEN and E2 see Figure 2. However, binding capacity is 
15-fold higher for ERβ than for ERα as amino acid residues vary between the ER subtypes [24, 25].  
 
 
Figure 2: Chemical structures of Genistein in comparison with 17β-estradiol. 
Modified from [2]) 
 
In principal, IF affinity is approximately 1/1000 of the affinity of E2 to the ER, but their biological 
effects cannot be ignored since their plasma levels typically exceed circulating endogenous E2 levels 
by 20-40-fold after consumption of soy-based foodstuffs [8].  
IF-binding occurs with distinct affinities in a cell- and tissue-specific manner. Depending on the 
conformational change of the ER and expression of associated co-regulator proteins IF exert 
estrogenic effects or anti-estrogenic actions [26]. Since ER are not distributed equally among tissues, 
IF have been categorized as natural selective estrogen receptor modulators (SERM) [27, 28]. 
1.1.3.2 E2-independant mechanisms of action  
In addition to phytoestrogenic activity, IF display a broad spectrum of mechanisms of actions 
contributing to cancer preventive potential (reviewed in: [2, 19]). They exhibit antioxidant activity in 
vitro by scavenging free radicals and regulation of enzymes involved in anti-oxidative defense such as 
catalase and superoxide dismutase thus preventing cells from oxidative stress. 
IF also affect synthesis and metabolism of endogenous steroids, e.g., by inhibiting aromatase 
(CYP19A1), a key enzyme involved in the conversion of testosterone to estrogens. Modulation of 
xenobiotic metabolism by inhibition of certain Phase I enzymes (e.g., CYP1A1, 1A2, 1B1) and 
concomitant induction of Phase II enzymes (e.g., GSTs, NQO1, UDPGTs) by IF results in enhanced 
carcinogen inactivation and detoxification in both in vitro and in vivo studies.  
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Cell proliferation is inhibited by IF by regulating cyclin-dependent kinases (CDKs) or their inhibitors 
(e.g., p21, p16) and promote cell cycle arrest in G2/M. By inducing pro-apoptotic proteins from the 
BCL2 family, IF treatment was shown to induce apoptosis in numerous studies in cell culture, but also 
in vivo. 
IF further inhibit angiogenesis by down-regulating vascular endothelial growth factor (VEGF). 
Reduced expression of matrix metalloproteinases (MMPs) by IF blocks cell invasiveness and 
metastasis in vitro and in vivo.  
A number of studies highlight that IF are involved in the modulation of signaling pathways such as 
epidermal growth factor (EGF) and insulin-like growth factor (IGF-1) signaling, promoting cell 
differentiation over growth factor-stimulated proliferation and progression.  
Further, upregulation of PTEN and inhibition of phosphorylation of IκB and ERK1/2 abrogated Akt and 
NF-κB signaling in vitro and in vivo. These pathways are known to be involved in sustained cell 
proliferation and cell survival. 
Interestingly, recent evidence, mainly derived from in vitro studies, also suggest that IF-mediated 
impact on epigenetic mechanisms might contribute to their cancer preventive potential (see section 
1.3.2.5) (reviewed in [2]). 
1.1.3.3 Specific disease endpoints 
As described above IF are able to exert complex biological effects through various mechanisms. 
Perceiving potential beneficial health effects, they are advertised intensively to prevent symptoms 
associated with the decline of endogenous estrogens (reviewed in [10, 29]).  
Menopausal symptoms 
With increasing life span, women spend one-third of their lifetime after menopause. Vasomotor 
symptoms, i.e., hot flushes and night sweats, sleep disturbances, and urogenital atrophy resulting in 
vaginal discomfort and sexual dysfunction, affect peri- and postmenopausal women and result in 
reduced quality of life.  
For several decades, relief of these symptoms was achieved by prolonged use of hormone 
replacement therapy (HRT), with concomitant prevention of osteoporosis and occurrence of 
fractures, without any alarming data published before 2002. With the Women Health Initiative (WHI) 
trial in 2002, the acceptance of the common HRT treatment regime changed and lead to a fast 
decline in usage. The WHI investigated 16,608 postmenopausal women aged 50-79 years for 8.5 
years on HRT using the most commonly used combined hormone preparation in the US. After 5.2 
years of follow-up the WHI trial was stopped due to adverse effects with statistically significant 
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increased risk for cardiovascular events as well for invasive breast cancer. Since these statistically 
calculated risks exceeded the benefits observed for prevention of endometrial cancer and 
osteoporotic fractures, acceptance of HRT was reduced and the application of HRT was stopped [30, 
31]. 
Observation of lower incidence of hot flushes in perimenopausal women in Asian countries (Japan 
and China) suggested a potential role of IF in reducing menopausal symptoms and shed light on 
phytoestrogens being an alternative for HRT. Recent systematic reviews propose a slight to modest 
but significant reduction of the number of daily flushes in menopausal women with a greater benefit 
for women experiencing a high number of flushes per day [32, 33]. 
Bone health 
So far, epidemiological studies on the impact of IF on bone turnover and mineral density are not fully 
conclusive. Studies with cultured bone cells and rodent models of postmenopausal osteoporosis 
clearly support a significant effect of IF and soy protein on bone formation and prevention of bone 
loss [34, 35]. Kenny et al. did not detect effects on bone mineral density (BMD) after interventions of 
postmenopausal women with soy protein powder (18 g/d), IF-containing capsules (105 mg/d), or a 
combination of both for a period of one year [36]. Results were independent of whether individuals 
were Equol producers or not. In addition, evaluating BMD in women participating in the Shanghai 
Breast Cancer Survival Study, Baglia et al. illustrated an inverse association of soy intake (mean 
48 mg/d) with BMD and an increased odds ratio for osteoporosis in women surviving breast cancer 
when comparing lowest vs. highest quartiles of IF intake [37]. 
In contrast, previous reviews clearly stated positive correlations between IF intake and bone health 
[6, 38]. Ma et al. published a meta-analysis considering all studies available assessing markers for 
bone resorption (Deoxypyridinoline, Dpyr) in urine and bone formation (Bone-specific alkaline 
phosphatase, BAP) in serum of pre- and postmenopausal women that ingested soy products or IF for 
at least 4 weeks. The study discovered that IF intake even below 90 mg/d significantly decreased 
urinary Dpyr and increased BAP levels, illustrating a positive effect on bone health [39]. 
Most clinical studies deduced bone turnover from measurement of surrogate markers of osteoblast 
and osteoclast activity or examined changes in BMD. In order to examine the effects on fracture 
rates, more long-term studies are needed to provide clear evidence on whether IF affect 
osteoporosis positively. 
Cardiovascular effects 
There are numerous epidemiological investigations pointing out the hypocholesterolemic effects of 
IF leading to reduced low-density lipoprotein (LDL)- and increased high-density lipoprotein (HDL)-
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cholesterol levels in human plasma. In a meta-analysis Jenkins et al. assessed 53 studies investigating 
the potential of soy to reduce LDL-cholesterol in participants independent of gender or menopausal 
status. Addition of soy protein (50-100 g/d) to the daily diet significantly reduced serum cholesterol 
by roughly 4 % [40]. Hooper et al. systematically reviewed the effects of different flavonoid products 
and identified reduced diastolic blood pressure and LDL-cholesterol as significantly affected 
endpoints after soy protein ingestion, using estimated intakes of 2 mg IF and 25–50 g/d soy protein 
for studies referring to US and Asian population, respectively [41]. 
In a recent study by Meléndez et al., cynomolgus monkeys (crab-eating macaque) were exposed to 
an IF-enriched diet (30 mg/d approximating a human intake of 140 mg /d) or control diet during pre- 
and postmenopause, or diets were swapped after menopause. Total plasma cholesterol and LDL 
levels were significantly reduced and HDL concentrations were increased in groups receiving IF diet 
lifelong as well as after menopause. Interestingly, plaque size in coronary arteries was significantly 
reduced by lifelong IF exposure, although severity of plaques (AHA grade >III) was also reduced when 
IF intake was stopped at menopause [42]. In addition, the anti-oxidative potential of IF resulting in 
reduced LDL oxidation and lipid peroxidation further positively influenced cardiovascular health [43, 
44].  
Endothelial function (EF) is an independent marker for coronary heart disease and predicts 
cardiovascular morbidity. In a meta-analysis published by Beavers et al., 17 studies were summarized 
that determine EF by flow mediated vasodilation (FMD) in postmenopausal women and men after IF 
supplementation. Seven studies reported a significant increase in FMD, indicating an improved EF 
beneficially influencing vascular health after >4 weeks of IF exposure (average intake 33-120 mg/d) 
[45]. These vasodilatory effects might be due to an IF-mediated activation of endothelial nitric 
oxidation synthase (eNOS) reported by others [46]. 
 
In summary, the current literature supports the protective association between IF intake and 
beneficial health effects regarding cardio vascular disease and reduced menopausal symptoms 
particularly when women suffer from severely high numbers of hot flushes. Regarding bone 
maintenance, more research is needed to gain clear evidence for the beneficial influence of IF on 
bone health and the prevention of osteoporosis, as available data are partly inconsistent. Differences 
in IF uptake and variability in the gut microbiota composition may influence IF bioavailability as well 
as gene polymorphisms, e.g., in Esr1 and Esr2 may explain discrepancies and individual variability 
observed in clinical studies investigating biological response to IF.  
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1.2 Epigenetic regulation of gene expression 
The term "epigenetics" was firstly stated in early 1942 by Conrad Hal Waddington and was mostly 
used to refer to developmental mechanisms in general to describe processes that could not be 
explained by simply using the terms genotype or phenotype (milestones in epigenetic research 
reviewed in: [47]). 
Nowadays, epigenetics refer to heritable but potentially reversible alterations in gene expression 
that arise from other than DNA sequence changes. In detail, DNA methylation, histone tail 
modifications, and non-coding RNAs, as well as nucleosome positioning act coordinately and affect 
cellular gene expression upon endocrine signals and environmental stimuli such as diet or exposure 
to xenobiotics [48]. These mechanisms form an epigenetic landscape regulated by numerous 
enzymes establishing (writers), interpreting (readers), modifying (editors), or removing (erasers) 
epigenetic marks (reviewed in [49]). 
1.2.1 DNA methylation 
Holliday was the first to hypothesize that DNA methylation is an epigenetic control mechanism that 
when lost could lead to changes in genes expression and might be associated with carcinogenesis 
[50]. This assumption was experimently confirmed by Feinberg and Vogelstein in 1983 who 
demonstrated that certain oncogenes were significantly hypomethylated in primary human 
carcinomas when compared to adjacent normal tissue ([51, 52] reviewed in: [47]). 
Almost exclusively, DNA methylation is characterized as covalent but reversible addition of a methyl-
group to a cytosine base at the carbon-5 position (5-methylcytosine, 5mC). As a consequence of the 
frequent spontaneous or enzymatic deamination of 5mC to thymine, CG dinucleotides are generally 
underrepresented in the genome (non-uniform distribution) and are concentrated at distinct 
genomic regions, so called CpG-island (CGIs). These CGIs often overlap with transcriptional start sites 
(TSS) and per definition have a minumim length of 200 or 500 bp and show a GC content of 50-55 % 
[53].  
1.2.1.1 Plasticity of DNA methylation 
In healthy tissue, promoter CGIs are generally unmethylated and allow for active transcription. About 
6-8 % of all promoters are methylated and associated with gene repression maintaining cell-type 
specific gene transcription. In contrast to methylated CpG-dense regions involved in cellular state 
and memory preservation, methylation in CpG poor regions, i.e., intragenic and exonic regions is 
typically connected to active gene expression as well as to alternative splicing. CGI-shores and distal 
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enhancers are tissue-specificly methylated, whereas intergenic regions, i.e., repetitive sequences and 
transposable elements are mostly methylated, preserving chromosomal stability. Methylation can 
modulate gene transcription by blocking transcription factor (TF, e.g., c-Myc) or insulator binding 
(e.g., CTCF) and, as a consequence, inhibiting transcriptional activation or enabling interaction 
between distal enhancers and promoters [54, 55]. 
It is well known that epigenetic patterns undergo intensive alterations, best exemplified by global 
demethylation in early preimplantation, genome-wide de novo methylation after early 
embryogenesis, and longterm silencing as, for example, with X-chromosome inactivation and 
imprinting. During aging specific epigenetic pattern are altered by sporadic methylation in CGIs and a 
global loss of methylation contributing to aberrant gene expression profiles. During carcinogenesis, 
these alterations are even more pronounced. Global dysregulation of DNA methylation resulting in 
genome-wide DNA hypomethylation at repetitive sequences and retrotransposons as well as in 
introns and gene deserts, facilitate genomic instability and promote chromosomal rearrangements. 
In addition, a decrease in DNA methylation at promoters of proto-oncogenes has been reported as a 
mechanism of their activation. Conversely, region specific hypermethylation of promoter CGIs of 
tumor suppressor genes (TSGs) lead to their transcriptional repression equivalent to an inactivating 
genetic mutation and thus might serve as a second hit according to Alfred Knudson´s "two hit" model 
required for tumor initiation (reviewed in: [56-58]). 
1.2.1.2 Enzymes catalyzing DNA methylation and demethylation 
Writers and erasers 
DNA methyltransferases (DNMTs) are the key enzymes involved in establishing the methylation mark 
either during early development, replication or differentiation. Three families of DNA (5-cytosine) 
methyltransferases have been identified. DNMT1 is involved in maintaining methylation patterns 
with preferences for hemimethylated DNA. Located at the replication fork in a complex together with 
PCNA, DNMT1 methylates newly biosynthesized DNA. DNMT3a and 3b as de novo methyl-
transferases set up new DNA methylation marks. DNMT3-like (DNMT3L), a catalytically inactive 
homologue of DNMT3a and 3b does not possess methyltransferase activity, but interacts with 
DNMT3a and regulates maternal imprinting. DNMT2 rather shows tRNA methyltransferase specificity 
and is not required for DNA methylation [59]. DNMT3a andDNMT3b are highly expressed in early 
embryonic cells where most programmed de novo methylation occurs and are down regulated in 
differentiated somatic tissues. All three DNMTs have been reported to be overexpressed in several 
tumor types such as leukemia and colon, liver, breast and prostate cancer [60]. This upregulation 
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might serve as an underlying mechanism of the regional hypermethylation of promoter CGIs 
observed during tumorigenesis, resulting in subsequent silencing of TSGs [61]. 
The DNA methylation mark can be erased by active and passive processes that work nonexclusively 
to shape the methylation profiles of a cell. Inhibiting or down-regulating DNMT1 can lead to a passive 
loss of DNA methylation through DNA replication and to a subsequent reactivation of previously 
silenced genes. Additionally, re-expression can be achieved by the presence of ten-eleven 
translocation (TET) methylcytosine dioxygenases 1-3 which lead to active demethylation by an iron- 
and α-ketoglutarate-dependent sequential oxidation of 5mC to 5-hydroxymethylcytosine (5hmC) and 
5-formylcytosine (5fC) to 5-carboxylcytosine (5caC) and subsequent thymine DNA glycosylase (TDG)-
mediated base excision repair [62, 63].  
Active demethylation predominantly occurs at the paternal genome when transmitted to the zygote 
leading to rapid loss of paternal epigenomic information. The maternal chromosomes are 
demethylated during later stages of embryonic development after several rounds of cell divisions in a 
passive fashion [64]. TET proteins are also involved in maintenance of pluripotency of embryonic 
stem cells as well as in post-mitotic somatic cells. Particularly, the dynamic response to 
environmental stimuli is suggesting a role of TET protein in demethylation of individual promoters 
[65]. 
Downregulation of TET expression has been observed for various tumor types including breast 
cancer. Interestingly, leukemia patients with inactivating mutations of TET2 are susceptible to 
therapies inhibiting the DNMTs [66, 67]. Furthermore, the oncometabolite α-hydroxyglutarate 
produced by mutant IDH1 and IDH2 inactivates TET enzymatic activity and leads concomitantly to 
aberrant DNA methylation [68]. 
Readers 
DNA methylation readers, i.e., Methyl-CpG-binding domain (MBD) containing proteins, recognize, 
interpret, and bind to methylated CpGs. There are four different MBD proteins that bind to 
methylated DNA and facilitate the binding of the MBD-multiprotein complex 1 (MeCP1). MBD and 
MeCP1 recruit and interact with co-repressor complexes associated with histone tail-modifying 
proteins such as histone deacetylases (HDACs) which remove histone acetyl groups by catalyzing the 
transfer to coenzyme A (CoA). Other co-repressors are histone lysine methyltransferases (HMT) 
which transfer methyl groups from S-adenosyl-L-methionine (SAM) to lysine residues and induce 
chromatin condensation and transcriptional repression. In addition, other chromatin remodelers that 
further promote gene silencing might be recruited [69, 70]. 
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Binding of MBDs to methylated CpGs is favored in highly methylated CpG-dense regions. This 
characteristic can be used to capture DNA fragments according to their degree of methylation by 
gradually impede this ionic strength using sodium chloride (see 3.2.6). 
1.2.2 Methods to detect DNA methylation 
For many years, DNA methylation analysis was restricted to relatively localized regions of the 
genome or even to single CpG sites [71]. With the development of human microarrays and next 
generation sequencing (NGS, Seq) now available at affordable costs, several methods are accessible 
to map DNA methylation on a genome-wide scale. Methods highly vary in the resolution, coverage, 
and input material that is needed for a reliable and reproducible readout as well as in bioinformatics 
effort for analysis of the data. Several recent review articles have compared the advantages and 
limitations of the available methods and summarize considerations for choosing one or the other 
methodology to answer a certain question of interest or hypothesis [53, 72-75]. 
1.2.2.1  Genome-wide methylation profiling 
Since DNMTs are not present during PCR or in biological cloning systems, DNA methylation 
information is erased during DNA amplification. Therefore, almost all sequence-specific DNA 
methylation analysis techniques rely on a methylation-dependent treatment of the DNA before 
amplification or hybridization [53]. In principal, existing technologies rely on three basic approaches:  
i: Digestion with methylation-sensitive restriction endonucleases to fractionate according to the 
methylation status in methylated and unmethylated DNA fragments. Methyl-sensitive Restriction 
Enzyme Sequencing (MRE-Seq/Methyl-Seq) identifies differential methylation by comparing 
sequenced fragments from, e.g., MspI and HpaII (the methyl-sensitive isoschizomer of MspI) digests 
between samples. Information is limited to the recognized cytosine residues, and incomplete 
digestion might be a source of false results obtained with this approach. 
ii: Affinity enrichment of methylated DNA fragments by immunoprecipitation either uses an 
antibody against 5mC (methylated DNA Immunoprecipitation (MeDIP)) or applies the methyl-CpG-
binding domain of the human MBD2 protein (Methyl-CpG Immunoprecipitation (MCIp/MBD 
capture)) to reduce the complexity of the whole genome and to enrich for medium and high 
methylated DNA fragments. MeDIP targets single stranded DNA with regions of lower CpG density. 
By contrast, MCIp enriches preferentially CpG-dense regions originated from double-stranded DNA. 
Both enrichment-based technologies do not offer precise quantification of methylation levels as they 
account for differences in enrichment only. In general, a high nominal coverage of the genome can 
be achieved but not at single CpG site resolution (resolution >100bp). 
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iii: Bisulfite treatment uses the advantage of a chemical reaction with sodium bisulfite that 
deaminates unmethylated cytosine residues to uracil much more rapidly than methylated cytosines 
and converts the epigenetic methylation mark into a genetic mark [76]. The introduction of a DNA 
sequence change enables methylation fingerprinting at a single CpG site resolution. However, using 
bisulfite conversion 5hmC cannot be discriminated from 5mC since 5hmC is not chemically 
deaminated. Therefore, further manipulation such as oxidation of 5hmC to 5fC which then reacts 
with sodium bisulfite and is identified as unmethylated C are necessary to achieve a precise readout 
of 5mC, only [77]. 
Whole Genome Bisulfite Sequencing (WGBS) is the current gold standard for samples for which a 
reference genome is available. This technique provides comprehensive genomic coverage as billions 
of reads per samples are provided at single CpG resolution. WGBS typically requires large amounts of 
input DNA which might be reduced by the use of a tagmentation-based WGBS (TWGBS) protocol. In 
this case, genomic DNA is fragmented and tagged with adapters by the enzyme transposase. 
Intermediate clean-up steps during library preparation are nonessential und input DNA can be 
reduced to <30 ng [78]. However, WGBS is still extreme costly, sequencing depth is rather low (<20x) 
and data analysis requires intense downstream computational support.  
In order to minimize the fraction of the genome to be sequenced reduced representation bisulfite 
sequencing (RRBS) uses restriction endonucleases that digest the genomic DNA at specific 
recognition sites. By reducing the complexity to approximately 1 % of genome but still covering 10 % 
of all available CpGs this technique represents a cost efficient alternative to WGBS and still retains 
single CpG site resolution. 
Illumina arrays are an option apart from sequencing-based methods to profile the human 
methylome at a number of preselected genomic regions. Two platforms are available, Infinium 
HumanMethylation27k and 450k BeadChip arrays, which allow the analysis of 27,578 and 482,422 
DNA methylation sites, respectively, with up to 12 samples at a time. Bisulfite-treated DNA is 
hybridized to bead-bound probes representing the methylated or unmethylated condition of a 
particular locus, and methylation information is detected by fluorescent labels.  
iv: Methods without modification of the DNA are available using Single-Molecule sequencing in Real 
Time (SMRT) instruments and nanopore-based platforms. SMRT sequences single DNA molecules by 
observing a single strand of DNA being replicated in real time. These third generation technologies 
are based on nucleotide incorporation times and the different kinetic signals of 5mC, 5hmC, 5fC and 
5caC [79]. However, error rates in base identification are still high and feasibility to analyze 
mammalian size genomes has to be improved for routine analysis. 
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1.2.2.2 Methyl-CpG immunoprecipitation-sequencing (MCIp-Seq) 
MCIp is one of the affinity enrichment-based methods for genome-wide methylation profiling. The 
MCIp assay enables sensitive detection of CGI-specific methylation using a recombinant bivalent 
methyl-CpG-binding polypeptide that binds methylated DNA fragments and allows fractionated 
binding and subsequent detection of hypermethylation on a genome-wide scale [80, 81]. 
The antibody-like fusion protein MBD-Fc: methyl-CpG-binding domain of the human MBD2 protein 
and the Fc portion of the human IgG1 show very high affinity to double-stranded methylated DNA. 
Affinity is dependent on (i) the amount of salt in washing buffer where higher salt concentrations 
require more 5mC for binding, (ii) number and degree of 5mC in a fragment and (iii) MBD-Fc protein 
density (Figure 3) [81]). MBD2 shows the highest affinity to methylated DNA when compared to 
other MBD proteins, e.g., MeCP2, allowing a smaller scale DNA input with less bias towards certain 
CpG motifs [82]. 
Adjusting the amount of salt in the washing buffer enables the enrichment of DNA fragments 
according to their degree of methylation since affinity to the MDB protein is dependent on ionic 
strength (Figure 3).  
 
 
 
Figure 3: Enrichment of an in vitro partially methylated gene locus after MCIp. 
A: Clonal bisulfite sequencing of DNA fragments fractionated according to increasing NaCl-concentrations in the buffer. The 
CGI depicted on top of the figure was bisulfite treated, amplified, cloned, and sequenced. Squares represent individual 
CpGs (empty: unmethylated; filled methylated). B: Scatter dot plot showing the numbers of methylated CpGs in a 
sequenced fragment according to the enrichment fraction. Horizontal bars represent median number of methylated CpG. 
Modified from [81]. 
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Stepwise elution of the sequences from the MBD protein with increasing amounts of salt (300-
1000 mM) results in enrichment fractions with increasing DNA methylation levels. By using the 
highest salt containing fraction (1000 mM) only or together with the lower salt-containing fractions 
(400-1000 mM), capture of high and medium-to-high methylated DNA fragments, respectively can be 
achieved [73]. For genome-wide analysis, microarray hybridization or NGS technology is used [83, 
84]. MCIp-Seq does not provide precise quantification of methylation levels since differences 
between samples are measured as enrichment scores of fragments and the overall resolution is 
rather low (>100 bp). However, MCIp offers a way to reduce the complexity of the whole genome at 
moderate costs [85]. 
1.2.2.3 Reduced representation bisulfite sequencing (RRBS) 
RRBS represents a quantitative bisulfite treatment-based method. It is a high-throughput technique 
to analyze methylation profiles using restriction endonucleases and bisulfite treatment [86]. With 
this technique single nucleotide resolution of quantitative methylation data is available on a genome-
wide scale by requiring modest amounts of sequencing only [87]. 
The restriction endonuclease MspI is methylation independent and generates a number of DNA 
fragments including highly redundant fragments from microsatellite DNA. Fragments are predictable 
and constant, increasing the utility for comparative DNA methylation analysis in a given specimen. 
Digestion with MspI generates fragments with two terminal CpGs. Thus, each fragment provides at 
least one analyzable CpG measurement per end-sequencing read. Therefore, the number of reads 
required for high coverage and reproducibility of a certain CpG methylation value is reduced.  
Small fragments sequenced by RRBS cover approximately 1 % of the total genome and 10 % of all 
available CpGs. Due to the MspI recognition site, genomic regions with a high CpG density are 
preferentially subjected to library preparation, resulting in a coverage of 75-90 % of all promoters 
and CGIs [74]. Restriction enzyme combinations can further increase the coverage for regions with 
lower CpG density such as CGI shores, intronic, and enhancer regions [88] 
Several modifications have been reported to refine or adapt the RRBS procedure for multiplexing 
[89], for the use of FFPE material [90], for laser capture microdissected specimen [91], or for single-
cell analysis [92]. 
1.2.2.4 EpiTYPER MassARRAY  
Quantification of DNA methylation by Matrix-Assisted Laser Desorption Ionization Time-Of-Flight 
(MALDI-TOF) Mass spectrometry is an alternative approach to sequencing- and hybridization-based 
methods (Figure 4).  
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Figure 4: Schematic overview of the quantitative EpiTYPER technology. 
During bisulfite conversion unmethylated cytosines (C) are chemically deamined to uracils (U), while methylated cytosines 
are protected. In the subsequent PCR amplification thymine is incorporated instead of uracil translating the methylation 
mark into a genetic mark. The reverse strand is in vitro transcribed by T7 R&DNA polymerase and enzymatic restriction 
yields to short fragments that are analyzed using MALDI-TOF Mass spectrometry. Fragments are resolved by mass and 
charge as there is 16 Da mass shift between previous unmethylated (UM) and methylated (M) CpGs due to the change in 
genetic sequence. Three different methylation values (0 %, 30 % and 100 %) are depicted in the spectra, exemplarily 
(modified from [93]). 
 
This technique is not genome-wide but is able to provide accurate quantitative methylation data 
after region-specific amplification. Since this method is implemented in the EpiTYPER platform from 
Sequenom, it is suitable for high throughput and sample automation [93, 94]. Primers are designed 
using the EpiDesigner software, optimal amplicon length vary between 150-500 bp depending on the 
quality of DNA available, e.g., using FFPE material shorter amplicons are recommended. 
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Using bisulfite conversion the methylation information is translated into a genetic mark and stably 
transmitted through PCR amplification. The reverse strand is in vitro transcribed by T7 R&DNA 
polymerase. Subsequent base-specific cleavage yields to short fragments that are quantitatively 
analyzed using MALDI-TOF. Due to the shift in genetic sequence a 16 Da mass difference is 
introduced between unmethylated and methylated CpGs. Fragments are resolved according to their 
mass-to-charge ratio and are quantitatively analyzed by fragment peak calling. 
This method is of particular value for technical validation/confirmation of genome-wide data and 
subsequent high throughput screenings in additional cohorts.  
1.2.3 Histone tail modifications 
The DNA in the nucleus is organized as chromatin, a DNA histone complex with repeating units of 
nucleosomes. 146 base pairs of DNA are wrapped around a histone octamer composed of two 
molecules H2A,H2B, H3 and H4 with H1 serving as linker. Histones are globular basic proteins with a 
flexible N-terminus ("tail") that can be subjected to a number of covalent but reversible post-
translational modifications including acetylation, methylation, phosphorylation, ADP-ribosylation, 
ubiquitination and SUMOylation. Depending on the modified amino acid residue, histone tail 
modifications relax or compact chromatin structure and thereby, facilitate or suppress transcription 
of the downstream genes [95]. 
Histone acetylation is established by the action of histone acetyltransferases (HATs) and represents 
an activating mark opening up the chromatin structure. Thus, proteins with HAT catalytic activity 
such as p300/CBP (CREB-binding protein) or PCAF (p300/CBP-associated factor) are often 
transcriptional co-activators. Removal of histone acetyl groups by catalyzing the transfer to CoA is 
realized by Histone deacetylases (HDACs 1–11) which results in chromatin condensation and 
transcriptional repression. 
Histone methylation is catalyzed by HMTs and takes place at lysine residues. So far, more than 50 
HMTs have been identified in humans that transfer a methyl group from SAM to lysine residues [96]. 
Depending on the methylation status (mono-, di-, or trimethylation) and the lysine residue that is 
methylated, the histone mark possess activating (e.g., K4, K36, K79 in H3) or repressive effects (e.g., 
K9, K27 in H3) on gene expression. Trimethylation at H3K4 (H3K4me3) is mainly associated with 
active TSS, whereas H3K27me3 is a transcription repressing modification introduced by the 
multiprotein repressive complex PRC2 (polycomb repressive complex 2). Also H3K9me2/me3 exhibit 
suppressive effects on active gene transcription and is predominantly found in heterochromatin. 
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Histone lysine demethylases (HDMs) remove histone methylation marks, i.e., by lysine specific 
demethylase 1 (LSD1) or the family of about 20 Jumonji domain-containing (JmjC) HDMs [95, 97]. 
 
During tumorigenesis HDACs and HMTs are often increasingly expressed leading to a dysregulation of 
repressive histone marks. Particularly EZH2 (enhancer of zeste 2), a member of the PRC2, has been 
found to be overexpressed in breast and prostate cancer [98]. HDMs are able to erase methylation 
residues from activating (H3K4me3) as well as from repressive marks (K3K9me3, H3K27me3) and 
have been reported to be upregulated in prostate cancer, although their context specific action has 
not yet been fully understood [99, 100]. 
1.2.4 Non coding RNA (ncRNA) 
The area of epigenetic regulation by long non-coding RNAs (lncRNAs) is an emerging field in current 
cancer research. Some lncRNAs are long known, such as Xist for X-chromosome inactivation in 
mammals or H19 for genomic imprinting. Others have been identified recently such as HOTAIR with 
increased expression in primary breast tumors and metastases, SChLAP1 as a marker and regulator in 
prostate cancer [101, 102], or overexpression of MALAT1 in non-small cell lung cancer [103]. 
The most well studied small ncRNAs are micro RNAs (miRNA or miRs); 18–25 nucleotide long single 
stranded ncRNAs which regulate gene expression at the post-transcriptional levels by silencing their 
target genes. As part of the “RNA-induced silencing-complex” (RISC), miRNAs sequence-specifically 
bind to the 3' untranslated region (3' UTR) of mRNAs and induce target degradation, or block 
translation in the case of perfect or partial base-pairing with the 3' UTR sequence, respectively [104]. 
Since 2002, when Calin et al. provided the first evidence that down-regulation or deletion of miRNAs 
plays a role in leukemogenesis a multitude of miRNAs have been identified as important regulators in 
carcinogenesis and development of other diseases [105]. About 2600 human, 2000 mouse, and 800 
rat miRNAs have been identified, functioning as oncogenes (onco-miRs) or tumor suppressor miRs 
[106]. A number of miRNAs serve as diagnostic and prognostic tools since their expression profiles 
vary in tumor compared to normal tissue. Additionally, they have been suggested to classify tumors 
more efficiently than mRNA-based methods [107]. 
MiRNAs themselves can be affected by the regulation of epigenetic mechanisms, and, on the other 
hand, are able to target the 3' UTRs of writers, readers, editors and erasers of epigenetic marks thus 
modulating epigenetic regulation. The complex interactions of the epigenetic machinery, emphasizes 
their comprehensive probabilities that are available to maintain gene expression and cell identity. 
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Since alterations in gene expression via epigenetic mechanisms are reversible, the epigenome has 
been identified as an attractive target for chemoprevention with dietary factors. The impact of IF on 
DNA methylation of the breast will be introduced in detail in section 1.3.2.5. 
1.3 Mammary glands, breast cancer and preventive impact of IF 
1.3.1 Normal mammary gland development 
The mammary gland (MG) is one of the few organs in mammals that develop after birth. Genetic and 
epigenetic mechanisms control mammogenesis characterized by dramatic changes in size, shape and 
function from lobule formation during puberty, development and differentiation during pregnancy 
and lactation, to regression after menopause [108]. 
Histologically, lobules and ducts are composed of a single layer of luminal epithelial and contractile 
myoepithelial cells originating from the same progenitor stem cells. They are oriented in a transverse 
fashion and surrounded by a basement membrane which separates them from the stroma. The 
surrounding tissue is composed of extra cellular matrix (ECM), fibroblasts, immune cells and 
adipocytes as well as blood vessels and comprise the local microenvironment (Figure 7A). 
1.3.1.1 Childhood, puberty and adolescence 
In newborns, there are primitive structures of ducts which just keep pace with the general growth 
during childhood. Main changes of the MG are initiated at puberty and can be defined from external 
appearance or by determination of the MG area, volume, and degree of branching, as well as the 
level of differentiation by characterizing the lobule type [108]. 
Ducts grow, divide and form terminal end buds (TEB, or terminal ductal lobular unit (TDLU)), highly 
proliferative structures which give rise to branches, ductules, and alveolar buds (AB), morphologically 
more differentiated structures. AB cluster around terminal ducts and form three different lobule 
types composed of increasing numbers of ductules with enhanced degree of differentiation and 
decreasing degree of proliferation (lobule type 1-3) (Figure 5). 
Normal MG epithelium undergoes oscillating phases of cell proliferation and cell death during the 
menstrual cycle leading to phases of normal hyperplasia. Although this seems to be a balanced 
process mammary development never returns to the starting point of the previous cycle resulting in 
increased bud formation with every ovulatory cycle until age 35 [108]. 
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1.3.1.2 Pregnancy, lactation and menopause 
Maximum MG development is achieved during pregnancy by the control of prolactin and placental 
lactogenic hormones. The early stage pregnancy is characterized by proliferation of distal ducts, as 
they increase in size and number, resulting in acini formation and development of lobule type 4. In 
the later stage pregnancy, the secretory activity of the epithelium increases and marks the full term 
glandular differentiation. The proliferation of new acini is reduced and lipids get accumulated in 
epithelial vacuoles. Postpartum, prolactin induces lactation with colostrum being secreted during the 
first week, followed by secretion of transitional milk for 2-3 weeks and finally mature milk. 
No major developmental changes are observed during the lactation period. The accumulation of milk 
in the acini after weaning has an inhibitory effect on milk production and lead to postlactational 
regression due to cell autolysis, collapse of acinar structures, phagocyte infiltration, and regeneration 
of the connective tissue. New proliferation and budding of the terminal ductules lead to more 
glandular tissue in the parous gland compared to the virgin gland until menopausal involution occurs. 
 
 
Figure 5: Developmental phases of the human MG. 
TEB: terminal end bud, AB: alveolar bud, LOB1-3: lobule type 1-3 (from [109]). 
 
During menopause, ovarian hormone production comes to an end leading to amenorrhea and 
regression of the MG to lobule type 1 of both, parous and nulliparous women. Although MGs might 
be composed of identical lobule types, the personal reproductive history might have introduced 
permanent changes in MG, potentially by epigenetic changes, and affect susceptibility of the breast 
to cancer development. 
1.3.2 Breast cancer development 
With an incidence of 1.67 M newly diagnosed women and 521,000 cancer death in 2012, breast 
cancer is the most common form of cancer affecting women worldwide [110-112]. In the US, it is 
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estimated that there will be 231,840 new breast cancer cases in 2015, and 40,290 women will die of 
the disease [113]. The development of breast cancer is highly dependent on endocrinological events 
and reproductive history. Hormone-related risk factors such as early onset of menarche (first 
menstrual cycle), late menopause and advanced age at first pregnancy lead to prolonged exposure to 
elevated serum levels of ovarian-associated hormones and thus increase the risk of developing 
breast cancer [114].  
Whereas most breast cancers arise spontaneously, about 5-10 % might be inheritable, with roughly 
30 % due to germline mutations in the susceptibility genes Breast cancer 1/2, early onset (BRCA1/2). 
Due to rapid expansion of massive parallel sequencing, additional genes that are involved in familial 
breast cancer risk have been identified, i.e., TP53, PTEN, and ATM. Yet, it has not been clarified 
whether mutations in these genes are disease drivers or passenger effects [115]. 
1.3.2.1 Breast cancer progression 
Human breast cancer development is a continuous but non-obligatory linear multistep process 
(Figure 6). There are several stages that defined breast cancer development from TDLU to invasive 
breast cancer (IBC). The shift from TDLU to premalignant hyperplastic breast lesions (hyperplastic 
enlarged lobular units (HELU)) is characterized by increased proliferation of the MG epithelium. 
Atypia (atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH)) differs from HELU by 
alterations in adhesion and cell polarity, since cells pile up and acini enlarge in size. By further 
expansion of the cell volume carcinoma in situ arise (ductal carcinoma in situ (DCIS) and lobular 
carcinoma in situ (LCIS)). Appearance of biological and histological diversity distinguishes well- from 
poor-differentiated DCIS displaying slow and fast proliferative characteristics (low and high grade). 
Further accumulation of epigenetic and genetic alterations lead to breakdown of the basement 
membrane and spreading into the local microenvironment, ultimately called invasive breast 
carcinoma (IBC) [116, 117].  
 
Figure 6: Model of human breast cancer progression focused on the evolution of ductal carcinomas.  
TDLU: terminal ductal lobule unit, HELU: hyperplastic enlarged lobule unit, ADH: atypical ductal hyperplasia, DCIS: ductal 
carcinoma in situ, IDC: invasive ductal carcinoma (modified from [117]). 
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During this process, alterations in the ECM and neo-angiogenesis facilitate the migration of tumor-
associated macrophages (TAM). Growth factor production by TAM and CAF (cancer-associated 
fibroblasts) influence tumor cell migration into the bloodstream. Circulating tumor cells (CTC) that 
escaped the primary tumor eventually form metastasis at distant sites (Figure 7B). 
 
 
Figure 7: Schematic representation of the normal MG and invasive breast carcinoma.  
A: Normal breast architecture and B: microenvironmental alterations in invasive breast carcinoma. ECM: extra cellular 
matrix, rbc: red blood cell, TAM: tumor-associated macrophage, CTC: circulating tumor cell, CAF: cancer associated 
fibroblast (modified from [118]). 
 
1.3.2.2 Breast cancer classification 
The term breast cancer includes a number of heterogeneous tumor entities with different clinico-
pathological characteristics. Multiple subgroups of breast tumors can be classified based on classical 
histological and immunopathological evaluation, hormone receptor status, grading, and molecular 
signature [118]. Invasive ductal carcinoma (IDC, 75 % of cases) and invasive lobular carcinoma (ILC, 
10 % of all cases) are the most frequent histological subtypes of breast cancer, accounting for roughly 
90 % of all cases. The remainder adenocarcinomas are histologically special types, subcategorized as, 
e.g., apocrine, comedo, medullary, mucinous, neuroendocrine, and many more [119, 120].  
The presence of specific histological and immunopathological markers have been used to define 
tumors and to identify adequate treatment therapies. Clinically interesting markers such as ER and 
progesterone receptor (PR, encoded by Pgr) as well as the oncogene human epidermal receptor 2 
(Her2, erb-b2 receptor tyrosine kinase 2 (ERBB2)) are used to assign specific categories, i.e., ER 
positive, HER2 positive, triple negative (ER-, PR-, HER-), and triple positive tumors to predict the 
benefits of endocrine therapy using ER-antagonists and aromatase inhibitors, or monoclonal 
antibodies against HER2, respectively. Molecular subtypes add another layer of detail to the highly 
diverse ductal and lobular tumors by looking at distinct gene expression patterns. Five main subtypes 
A B 
22  1. Introduction 
have been classified to predict patient relapse, overall survival, and response to treatment. Luminal A 
and B subtypes are both ER positive and display the best prognosis for patient survival. Normal 
breast-like cancers are associated with gene expression profiles similar to adipose tissue, and basal-
like and ERBB2 positive (HER2 overexpressing) tumor subtypes have the least favorable outcome 
overall [120-122].  
1.3.2.3 Epidemiology of breast cancer and the impact of IF 
The incidence of certain hormone-dependent cancer types such as breast and prostate cancer has 
been found to be lower in Asian countries than in Western populations (age-standardized number of 
new cases per 100,000 inhabitants in 2012: breast cancer 29.1 vs. 96, prostate cancer 9.4 vs. 95) 
[111]. Furthermore, migration studies showed that Japanese and Chinese American women had a 
60 % higher risk to develop breast cancer if they were born in Western countries compared to those 
born in the East. If their grandparents were also born in the West women possessed an additional 
50 % higher breast cancer risk [123]. 
These studies indicate that lifestyle and environmental factors such as dietary habits, essentially 
affect international incidences of certain cancer types [124, 125]. Since hormone-dependent cancers 
rates are particularly low in populations following a traditional Asian diet rich in soy and soy 
products, IF have attracted much attention regarding their chemopreventive potential. 
Results from epidemiological investigations about beneficial health effects of IF are actively discussed 
[126, 127]. The majority of the case-control studies have shown an inverse association for soy food 
intake, serum GEN levels and breast cancer risk, particularly in Asian women [128-131]. In addition, 
experimental investigations in rodents highlight the protective effects of GEN, especially for 
chemically induced cancer. In contrast, rodent data investigating the impact of GEN on the growth of 
already existing tumors and in xenograft models in immunodeficient mice, revealed stimulatory and 
growth promoting effects on human breast cancer cells [132]. In a further study of the same authors, 
differently processed soy products were investigated to affect growth of MCF-7 breast cancer cells 
transplanted into ovariectomized athymic mice, all providing the same amount of GEN equivalents in 
the diet (750 ppm) [133]. Interestingly, soy extracts (NovaSoy650®), mixed IF or GEN alone, but not 
soy flour increased tumor growth and mRNA expression of estrogen-responsive genes (e.g., pS2, 
cyclinD1). These result demonstrate that IF administered within a complex food matrix show 
drastically different effects on cancer progression compared to isolated IF [134]. The reason for this 
might be the presence of other bioactive compounds like peptides, protease inhibitors, phytic acid 
and saponins and probably other phytoestrogens which differently affect gene expression [135-138]. 
However, a recent meta-analysis investigating 84,450 women in a multiethnic cohort did not find a 
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statistically significant association between IF intake (0-180 mg/d) and breast cancer risk. The authors 
suggested possible ethnic/racial differences in risk estimates and an inverse association in 
populations consuming high amounts of soy products [139]. 
The timing of exposure seems to be the most critical factor [140]. It has been shown that especially a 
multigenerational and prepubertal exposure to IF modulate MG morphology and provide anti-
tumorigenic effects [141]. In a study of Lamartiniere et al., prepubertal IF exposure accelerated 
differentiation of the epithelial cells by transient upregulation of EGF-signaling and protected against 
chemically induced cancer in rats. Following this, EGF-receptor (EGFR) expression was persistently 
reduced in TEBs leading to an increased number of more differentiated alveolar buds [142]. In 
contrast, a short term high dose IF supplementation in pre- and postmenopausal women stimulated 
epithelial cell proliferation and resulted in increased mammographic density (representing a risk 
factor for developing breast cancer [143]). 
Since many processes during early development are regulated by epigenetic mechanisms, it is 
tempting to speculate that early epigenetic reprogramming of the MG is targeted by IF, affecting 
normal cell growth and susceptibility to breast cancer [144].  
1.3.2.4 DNA methylation changes associated with breast cancer 
Several studies investigating tumor-associated candidate genes involved in DNA repair, apoptosis, or 
cell cycle control have shown breast cancer specific aberrant DNA methylation which arises early 
during disease progression, i.e., of APC, RARβ, RASSF1A, HIN-1 and SFRP1 [145, 146]. With the 
availability of genome-wide methylation data of breast tissue, distinct patterns have been associated 
with luminal and myoepithelial differentiation [118]. Luminal genomes harbor twice as many 
hypomethylated enhancer elements and four times the transcriptional output (RNA yield/cell) when 
compared to myoepithelial cells [147]. This transcriptional amplification in luminal cells might be of 
advantage in disease initiation and progression since this phenomenon has been described for c-Myc 
driven tumor types. Less transcriptionally active myoepithelial cells are commonly absent in breast 
tumors [148].  
Moreover, distinct DNA methylation patterns have been associated with molecular subtypes [149]. 
Particularly, luminal breast cancers are characterized by a higher frequency of DNA methylation gain 
compared to basal-like tumors. Further studies reported associations with hormone receptor and 
mutational status as well as disease progression and prognosis [150]. For a comprehensive review 
see [151]. 
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1.3.2.5 Impact of IF on DNA methylation in breast cancer 
Early studies on DNA methylation were mainly interested whether soy IF are capable in reactivating 
TSGs silenced by DNA hypermethylation and were mostly performed in cultured breast and prostate 
cancer cells. Particularly, genes were investigated that were involved in sustained proliferation and 
resisting cell death, i.e., RARβ2, RASSF1, PTEN, cyclinD2 and in DNA repair, i.e., BRCA1, BRCA2 as well 
as detoxification, i.e., GSTP1 and revealed IF-induced demethylation of the promoter region [152-
155]. As an underlying demethylating mechanism IF have been shown to inhibit DNMTs and MeCP 
activity in vitro which might result from enzyme inhibitory effects or down regulation of gene and 
protein expression [156].  
Treatment of breast cancer cell for 1-2 weeks with low GEN concentrations (3.125 µM) slightly 
reduced methylation as measured by methylation-specific PCR of the promoter region of GSTP1, a 
Phase II metabolizing enzyme commonly silenced in breast and prostate cancer, with subsequent but 
weak mRNA re-expression in ERα-negative MDA-MB-468 but not in ERα-positive MCF-7 cells [152]. 
The promoters of two TSGs RARβ2 (Retinoid acid receptor β2, a nuclear transcriptional regulator 
involved in cell growth and differentiation) and HIN1 (high in normal-1, aberrant methylation serves 
as biomarker for prognosis in breast cancer) could be demethylated using the same dose of GEN in 
another ERα-positive cell line MCF-10a.  
In T24 Ha-ras transformed MCF-10aT and MCF-7 cells Li et al. investigated the effects of higher GEN 
doses on expression of the catalytic subunit of human telomerase (hTert, human telomerase reverse 
transcriptase) [157]. HTert is involved in telomeric stabilization and is normally repressed in postnatal 
somatic cells resulting in progressive shortening of telomeres as an important component of cellular 
aging. Reactivation of hTert is a crucial event during cell transformation and promotes proliferation 
and survival potential. Treatment with high doses of GEN (50-100 µM) increased expression of E2F1, 
a repressor of hTert transcription, resulting in enhanced binding to the hTert core promoter and 
reduced levels of hTert mRNA expression. GEN also reduced protein expression of DNMT 1, 3a, and 
3b, and bisulfite sequencing data indicated a shift from methylated to unmethylated CpGs in the E2F-
1 binding site. Although the impact of GEN on methylation was rather weak, the results suggest that 
GEN is working as an epigenetic modulator and might facilitate preventive approaches in breast 
cancer.  
Bosviel et al. showed the impact of moderate doses of GEN (18.5 µM), DAI 78.5 µM) and Equol 
(2 µM) on BRCA1 and BRCA2 involved in DNA repair mechanisms and often mutated in breast cancer. 
Changes in methylation levels were generally low but IF treatments further demethylated CpG sites 
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in the promoter and/or exon region, resulting in a weak increase of gene expression in three breast 
cancer cell lines [153]. 
High concentrations of GEN (60, 100 μM) dose- and time-dependently reduced DNMT1 mRNA and 
protein expression as well as DNMT activity in MCF-7 and MDA-MB-231 breast cancer cells [156]. 
These observations were accompanied by a decrease in cell viability and a global loss of DNA 
methylation. Specifically, promoters of four TSGs that are often deregulated in familial breast cancer 
including ATM (ataxia telangiectasia mutated, an important cell cycle checkpoint kinase), APC 
(adenomatous polyposis coli, an antagonist of the Wnt-signaling pathway), PTEN (phosphatase and 
tensin homolog, a negative regulator of AKT/PKB signaling), and SERPINB5 (mammary serine 
protease inhibitor encoding the anti-proliferative Maspin protein) were hypomethylated due to the 
GEN treatment, resulting in increased gene expression levels. 
So far, there is only limited information on the impact of soy IF on DNA methylation in breast tissue 
in vivo. Li et al. investigated the effects of IF on ER-negative breast cancers. Treatment of ERα-
negative MDA-MB-231 cells with GEN induced re-expression of ERα and ERβ through increased 
histone acetylation at the ERα promoter. Additionally, a re-sensitizing for E2 and tamoxifen 
treatment was demonstrated, especially in combination with Trichostatin A, a HDAC inhibitor, 
demonstrating an interesting strategy for clinical implications. Accordingly, dietary GEN (250 mg/kg 
diet) inhibited growth of breast cancer in a MDA-MB-231 xenograft model and increased therapeutic 
sensitivity of tamoxifen [158]. 
In a prospective, randomized, double-blind intervention trial, 34 healthy premenopausal American 
women received capsules with soy IF representing a typical Asian diet through one menstrual cycle 
(low dose: 37 mg/d; high dose: 128 mg/d, 70 % GEN, 27 %DAI and 1.3 % GLY) [159]. Serum GEN levels 
dose-dependently increased after the intervention leading to lower complement C3 levels as a 
measure of anti-estrogenic activity of the IF intervention (nonsignificant trend). DNA methylation 
was analyzed in breast tissue obtained by mammary ductoscopy. Five candidate genes were 
investigated including p16, RASSF1, RARβ2, cyclinD2, and ER all frequently silenced by methylation in 
breast and prostate cancer and counteracting sustained proliferation potential as well as resisting 
cell death. No significant change in DNA methylation could be detected. However, cyclinD2 and 
RARβ2 promoter methylation increased with high and decreased with low GEN serum levels, 
respectively, suggesting a different mechanism of action for high vs. low GEN levels in healthy 
premenopausal women.  
Of note, methodologies used in these studies often did not provide quantitative methylation 
information (e.g., methylation specific PCR) and mainly focused on selected candidate genes. 
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Genome-wide studies investigating the impact of IF on the methylome would permit a more 
comprehensive evaluation of the IF-induced effects on the reprogramming of the MG and 
consequently on cancer prevention. 
1.4 IsoCross project 
The collaborative research project IsoCross: Isoflavones: Cross-species’ comparison on metabolism, 
estrogen sensitivity, epigenetics and carcinogenesis is a DFG-funded research initiative. It aims to 
identify molecular mechanisms which determine whether the exposure towards IF may be adverse 
or protective regarding the risk to develop E2-induced breast cancer, taking into account the 
influence of dietary fat consumption and obesity. The main research concept is centered on IF 
metabolism and bioavailability, E2 levels and metabolism, modulation of tissue selective E2 
sensitivity, and carcinogenesis of the breast. The strength of the IsoCross project is the integrative 
analysis of metabolite levels and molecular mechanisms including epigenetic modifications as well as 
the cross-species´ comparative interpretation of the results of animal experiments and human 
intervention studies. 
The research project was a collaborative effort of an interdisciplinary team originating from five 
scientific institutions in Germany. Our collaboration partners Prof. Diel from the German Sports 
University Cologne (DSHS) and Prof. Vollmer from Technical University Dresden (TU) performed 
animal experiments in rats, addressing specific research questions on dose and timing of soy 
exposure, influence of dietary and body fat, and influence of soy on E2-induced carcinogenesis, 
providing us with MG tissue for epigenetic analyses. Profs. Kulling and Bub from the Max Rubner 
Institute Karlsruhe (MRI) and Prof. Lehmann from the University Würzburg focused on the human 
aspect of the cross-species´ comparison. Both groups performed human intervention studies with 
soy extracts. Their main interest was on IF and E2 metabolism and levels of IF and E2 metabolites in 
plasma, but also in target tissue such as MGs. Human tissue material including PBMCs, fat biopsies 
and breast tissue are currently investigated in bachelor and master thesis projects.  
The initial focus of the present Ph.D. project was on the impact of IF on DNA methylation during E2-
induced breast carcinogenesis in ACI rats. Since the establishment of the model took more time than 
initially anticipated due to problems with E2-releasing pellets, we took the opportunity to address 
additional aspects of potential IF impact on epigenetic mechanism during MG development, making 
use of tissue material from the other sub-projects in the IsoCross project. The aims of the thesis 
reflect the multitude of addressed research questions. 
 27 
2. Aims 
There are several investigations that provide evidence for the impact of IF on the epigenome in 
cancer prevention. Particularly, research has been done with cancer cell lines and focused on 
selected candidate genes. So far, studies investigating genome-wide changes on DNA methylation 
upon IF treatment are scarce. Also, previous work was mainly carried out in cancer cell lines which 
might have acquired additional methylation changes during in vitro culture that might not be 
susceptible to alterations by intervention with dietary factors. In addition, the activity of IF to 
sustainably affect DNA methylation patterns might be more pronounced when analyzing effects at 
specific time windows of susceptibility and active reprogramming during development. 
In order to address some of the limitations of the existing studies with IF on DNA methylation, the 
aim of this thesis was to analyze DNA methylation profiles in MGs of healthy rats and during E2-
induced mammary carcinogenesis in rats on a genome-wide scale. 
1. In the first part, the goal was to clarify the impact of soy IF at different doses and critical time 
windows on DNA methylation in MGs in healthy Wistar rats. In particular, it was of interest: 
 whether a short term high dose IF exposure after menopause (ovariectomy) as in Western 
countries induces a contraindicative pro-proliferative effect on the MG epithelium? 
 whether dietary IF exposure during puberty, representing the major postnatal phase of MG 
development besides pregnancy, modulates the MG methylome sufficiently as seen for 
lifelong IF exposure? 
 whether low dietary IF doses are sufficient to induce potential beneficial health effects? 
2. In the second part, ACI rats were lifelong exposed to high doses IF to assess the influence on DNA 
methylation during E2-driven carcinogenesis of the MG. The following questions were addressed: 
 does dietary IF exposure during developmentally critical time windows, e.g., embryonic/fetal, 
early postnatal and pubertal periods as in Asian countries, modulate the epigenetic 
programming of the MG? 
 consequently, does this potential impact on DNA methylation lower the susceptibility to breast 
cancer and reveal cancer preventive effects? 
Reports on genome-wide methylation profiles of rat tissues are very limited and reference 
methylomes are not available. Therefore, the project included the establishment of two sequencing-
based methodologies for methylation profiling, i.e., MCIp-Seq and RRBS as well as bioinformatics 
evaluation of results.  
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3. Material and Methods 
3.1 Material 
3.1.1 Instrumentation 
Equipment which is not standard lab equipment is listed here or mentioned in the methods section. 
Name Manufacturer 
MassARRAY Compact System  Sequenom, Hamburg, Germany 
MassARRAY Nanodispenser Sequenom, Hamburg, Germany 
Mastercycler epgradient384 Eppendorf AG, Hamburg, Germany 
Mastercycler epgradient Eppendorf AG, Hamburg, Germany 
 
3.1.2 Software and databases 
Name  URL 
Gene Set Enrichment Analysis http://www.broadinstitute.org/gsea/index.jsp 
Adobe Illustrator https://www.adobe.com/ 
EpiDesigner http://epidesigner.com/ 
EpiTYPER http://www.massarray-
epityper.software.informer.com/ 
EulerAPE http://www.eulerdiagrams.org/eulerAPE/ 
Gene Expression Omnibus https://www.ncbi.nlm.nih.gov/geo/ 
GraphPad Prism® http://www.graphpad.com/ 
Ingenuity Pathway analysis http://www.ingenuity.com/products/ipa 
IGV 2.1 http://www.broadinstitute.org/igv/home 
Homer Suite of tools http://homer.salk.edu/homer/ 
Multi Experiment Viewer http://www.tm4.org/mev.html 
Primer3Plus http://www.primer3plus.com/ 
Qlucore http://www.qlucore.com/ 
R http://www.r-project.org/ 
RnBeads  http://rnbeads.mpi-inf.mpg.de/ 
SNPs info rat ftp://ftp.ncbi.nih.gov/snp/organisms/rat_10116/ 
UCSC Genome Browser  http://genome.ucsc.edu/ 
3. Material and Methods    30 
3.1.3 Primers 
3.1.3.1 MassARRAY primers 
Gene  
Name 
Left Right 
Next 
TSS 
[bp] 
Genomic  
Anno- 
tation 
Length CpGs 
TM 
[°C] 
Aldh1L1 TTGGTTATATTTTGATGTGATGGAG AAACCATTAAAATAAAACAACAATC -664 promoter-TSS 423 18 58 
Arpp21 TTTGGGAAAAAGAAATTGGTATAAA AAAAACACATTAAATTACAAAACCA -1247 promoter-TSS 392 8 60 
Bpgm GGGATTTGGTATTAGAGTTGGAAGT TCTTCCTAAATATATAAAAAACTAAACCCA 822 promoter-TSS 265 5 60 
Cdh13 ATAGTAAGAATTTTGGTTGGTTGGA AACTCTAAATACCACACCCATTCAC 304332 intron (2 of 13) 336 6 58 
Cldn4 TTTGGAGAATGTGAGGGGTTATAG CAAAACCAAAATCATAATCACAACC 716 promoter-TSS 376 20 58 
Cyp2C6v1 TTGATTTTTTGTATTTTAATAGGATGG AAACAACAAAAACCAAACTTAATCC 9598 exon (3 of 9) 324 5 58 
Esr1 TTTTTAGAAATGTTTTATGGGTTTG TATCCCTCTCTTTAACAAAAAACAC -72 promoter-TSS 379 14 60 
Extl1 GTTTTTAGTATGTTTTGGATATGGT AAAACAAAACACAACCATATACCC -1851 promoter-TSS 394 12 60 
Fxyd2 GGATTTATAAGTTAGGTTTTTAGTATTTA AACAAATATTCAACCTTAATTCCTTCA -957 promoter-TSS 94 4 60 
Gadd45b GGAAGATTTTTGTGTGTTTTTATGG AAACCCTTACACTTTCCCTTTCATA 6141 intergenic 328 19 58 
Gbp2 GGGGGTAAGTTTTTTAGTTGTTTTT CATACCAAAAATATCTCCCCACTAA -2504 5' UTR 276 7 60 
Gsn GTTAGTGGGAAGGGAATTTAGATGT ACAACAAAACATACTTACAAAACAAC 59 promoter-TSS 452 32 60 
Lect2 TTTAGTTAGTAGTTGTAGGAAATTTGTGGT TCCTAAAACAACCTATCAACCTAACAC 983 promoter-TSS 224 4 60 
miR-10a GAGAAGGGTAAGTTGAATTAAATTTTTG AAAAAACCACAAACCCCCTC -2532 intergenic 324 16 60 
Mmaa TTTTTTGTGTGGTTTTTTAAGGTTG AAATCCAATTACAAACAAAATAACTATTCC -14004 
promoter-TSS 
(splice variant) 
240 12 60 
Mrc2 TTGTTTTGTGTTGTTGGAATTTAGA AATATCCCAAAAAACCTACATCATTC -1038 promoter-TSS 267 8 60 
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Msx1 TAGGTTTTGTGGGTAGAGGTGAG TCTCCAAAAAACACAAAAAACTACC -1530 promoter-TSS 234 12 60 
Ndrg3 TTGTAAGTTTGGGTTTTATTTTTAGTA ACCTCAAACACTCAAACTACCACAT 1578 promoter-TSS 352 4 60 
Niacr1 AAGTGGTTTTGTTTGTTTATGAGGA AACAACAAATTACACAAAAACCTCC -98 promoter-TSS 235 7 60 
Npas1 TTTTTTTGGGGTTTTAGGATAATAGA TCACAAATAAAAAAACCATACACACA 3492 intergenic 356 11 60 
Nr1h3 GTTGGGAATATAGGTTGGGGTTTA AAACTAACTCCTCCCCAAACAAC 1335 promoter-TSS 297 13 60 
PTEN TTGTTGAGGTTTGAGATAGATTTGA ATCTCCAAACAAACACTAACAAAAAATA 61027 intron (7 of 8) 460 10 58 
Rbm42 TTGGTTTGGAGTTTAGGTATGAAAT ATAATCCCAACACTTAAAAACCTAC -524 promoter-TSS 229 7 60 
Rita TGTTGGGTTGTTAAATAGGGTTTTA TAACTCACTCTAACCCTCCAAAAAA -851 promoter-TSS 206 7 60 
Rnf8 GGTTTTTAGGTGTTGGTATAGGTGG TCCCTACAAACCTACAAAAAACTCA 2202 intron (1 of 7) 287 7 60 
Sall3 GTTTATTAGGGTTATTTGGTTG TAACACAATTCTCACAAAATAC 151 promoter-TSS 169 7 60 
Shroom2 TGTTTGGTATGTATATGGTGTTTAGA AAAATAACTACAAACCAACCCCTTC -714 promoter-TSS 500 12 60 
Sirt4 TGAGTATTGTATTAGGGGGTATGAA AACTAACCTCAATTCTCCTCTCACC 2223 intron (2 of 4) 404 9 60 
St3gal4 GGAAGGTTTAAGAGTAGGTTTGTT CAAACAATTACATTACAATAACAACATCA 138471 intron (4 of 15) 432 13 60 
Thy1 GTGTTGGTTTTTTGAGTTGTTGTTA TTAAACCCCATCAAATTAAAACCTT -113190 intergenic 437 8 60 
Tlr3 TATGGTTAGAGGTTTGGGATTGTAA CCCCATTTATTTCTAAAAATTCCCT 258 promoter-TSS 271 7 60 
Wap TGTGAGTTTTGTTTTTGGTAGTTTGG AAAAATATCCTTTTATTCCTTATCTCC 3 promoter-TSS 385 7 58 
Wif1 GAAAGGGGAAGATAATTTTTTAGAGT AAATCCTAACCTCCTAAAACACTCC 38674 intron (2 of 9) 436 10 58 
Zfp507 AAATTTTTTAGTTGGGGTTTATAGAGA TACAACCTCCTCCCCTAATACTACC -1902 promoter-TSS 400 10 60 
Additionally added to left primer: 10 mer tag (AGGAAGAGAG) and to right primer: T7 R&DNA polymerase primer tag (CAGTAATACGACTCACTATAGGGAGAAGGCT). 
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3.1.3.2 Primers for genome-wide methylation profiling 
Method  Name Primer sequence TM[°C] 
MCIp Mest Left GCCATCCCCGATCCTGTACC 60 
 
Mest Right GGCCGCATTATCCCATGCC 60 
 
MCct Left1 (Spike in) GGTTCTCTGCTGCCTTGC 60 
 
MCct Right1 (Spike in) ACCCTCACCCTCAACACCAC 60 
 
MCct Left2 (Spike in) GCCCATGAGGCCAGTTAAT 60 
 
MCct Right2 (Spike in) AGGCGCGCCATGAGCTC 60 
RRBS PPC Left AATGATACGGCGACCACCGAGATCTACAC 60 
 
PPC Right CAAGCAGAAGACGGCATACGAGAT 60 
 
TruSeq Universal Adapter  AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT  
 
TruSeq Indexed Adapter  GATCGGAAGAGCACACGTCTGAACTCCAGTCAC‐nnnnnn‐ATCTCGTATGCCGTCTTCTGCTTG  
3. Material and Methods  33 
3.1.3.3 Roche UPL qPCR primers 
Name UPL Probe Left  Right TM[°C] 
Aldh1L1 20 CATGTCCATCCAGACCTTCC GTGGCACCCTGGATCTTATC 60 
Arpp21 1 CCTATAAGAAAAGACAGCTCTTTCG TTGGAGCTGTCAGAATCTGTG 60 
C3 116 TCATCCAGACAGACAAGACCA TCCACAGTGAAGATCCGATAGA 60 
Cdh1 13 CATGCTCTCTGTGGTCAAGC TCATTCTCCACTTTGATCAGCA 60 
DNMT1 16 AACGGTGTTGTCTACCGACTG GCTGGCCATTTTGATGTTG 60 
DNMT3a 1 CAGAAGTGCCGAAACATCG GCACATTCCACCAATGAAGA 60 
DNMT3b 21 GCGATGGCAAGTTTTCTGAG GGTGGCCAGATTAAAGTGCT 60 
Esr1 120 CCCTCCCGCCTTCTACAG TCCTTGGCAGACTCCATGAT 60 
Esr2 3 TCTGGGTGATTGCGAAGAGT TTCCATGCCCTTGTTACTGA 60 
Extl1 111 GCAGGTGGCGTATTACAACC TGGGAAGTATCTCTCCTGGGTAG 60 
Foxa1 114 GAAAGGCTAGCCAGCTAGAGG GATGAAGAAGCTGGAGACTTCAA 60 
Fxyd2 73 CGGAGAATCCCTTCGAGTATG TCTTACTGCCCCCACAGC 60 
Gadd45b 101 CGGCCAAACTGATGAATGT TTGGATCAGGGTGAAGTGAA 60 
Gata3 66 CTATGTGCCCGAGTACAGCTC ACATCCGAACCCGGTAGG 60 
Greb1   120 CGTGCTATCAAAGGGACCTC GGCAAAGAGCAGAGGATTGT 60 
Gsn 77 CCCAAAGTCGGGTGTCTG CTTCCCTGCCTTCAGGAAT 60 
Hprt 22 GGTCCATTCCTATGACTGTAGATTTT CAATCAAGACGTTCTTTCCAGTT 60 
Hprt 95 GACCGGTTCTGTCATGTCG ACCTGGTTCATCATCACTAATCAC 60 
Krt8 67 CAACAAGTTCGCCTCTTTCA GTTGCAGCAAGCTCCATTT 60 
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Krt5 120 CCCTGGATGTGGAGATCG ACTCAGCCTGCACTCCTGTC 60 
Ki67 110 AGATTCAGATTGTCCAGAAGTAAGC TCAGACTCAAACTCCACAAAGG 60 
Mrc2 46 CAGGGCACTGCAGAGGAG AGGATGGGCTATGCCATGT 60 
Ndrg3 62 GTGTTCTACTTTACTGGTGGTTGG TAGGGTCGAGGCGAGAATTA 60 
Niacr1 82 CAAACACAACGTGAGGAACTG GTGGTGAAGAAGGCCAAGTC 60 
PCNA 41 ACCTCACCAGCATGTCCAA CATAGTCTGAAACTTTCTCTTGATTTG 60 
Pgr 20 CGCCCTACCTCAACTACCTG GGTAAGGAATCAAAGCCATATTGT 60 
PTEN 109 CGATACTTCTCTCCAAATTTTAAGGT TCTATAATGATCAGGTTCATTGTCACT 60 
Rnf8 101 AGCAGCTGGAGAAGACGTTC TCCTTGCTCTTTCTCCAAACC 60 
SMA 25 CCCAGCACCATGAAGATCA CGCCGATCCAGACAGAAT 60 
β-actin 64 CCAACCGCGAGAAGATGA CCAGAGGCGTACAGGGATAG 60 
ST3gal4 128 CATGACCAGCAAATCTCACTG TCTCGGAGACGGGAAAATAA 60 
TBP 129 CCCACCAGCAGTTCAGTAGC CAATTCTGGGTTTGATCATTCTG 60 
Tet1 67 CGCCAGTTGCTTATCAAAATC GCCCCTCTTCATTACCAAGTC 60 
Thy1  40 CCACAAGCTCCAATAAAACTATCAA AGCAGCCAGGAAGTGTTTTG 60 
TP63 74 CAGCACACGATCGAGACG AGACTGAGACTGCATCGAGGT 60 
Wap 120 CCACACCCAAATTCTGAGC CCACAGGAACGACACCAGA 60 
Wif1 68 GGCTCTGGAGCATCCTACCT CCCTCCGAGACAATCAGAAT 60 
Zfp507 108 CCAATGTAAGCAGTGCAAAGAA AAGGTGTTGGGCATGCAG 60 
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3.2 Methods 
3.2.1 Experimental diets, animal subjects and study design 
In order to investigate the impact of IF on DNA methylation in vivo two intervention studies were 
performed by our cooperation partners in the IsoCross Project as described below. In the first study, 
Wistar rats were exposed to dietary IF at different doses for various time periods, while the second 
study focused on the impact of a lifelong dietary IF on the kinetics of DNA methylation changes in 
MGs and on cancer preventive efficacy in the ACI rat model of E2-induced mammary carcinogenesis. 
3.2.2 Soy isoflavone enriched diets 
The studies were performed using a commercially available soy bean extract NovaSoy650® which 
was characterized in detail at the Max Rubner Institute in Karlsruhe by the group of Prof. Dr. Sabine 
Kulling (for details see [160]) (Table 1). 
Table 1: Diets and soy extract applied in the Wistar and ACI rat experiments. 
Name Manufacturer 
NovaSoy650® ADM, Decatur, IL, USA 
R/M-H low-phytoestrogen complete-feed Ssniff GmbH, Soest, Germany 
SM R-Z protein-reduced complete feed Ssniff GmbH, Soest, Germany 
 
The diets investigated comprised (summarized in Table 2): 
1) an IF-depleted diet (control (C)) purchased from Ssniff (R/M-H low-phytoestrogen complete-feed) 
which was free of any soy or alfalfa as protein or fat sources and contained approximately 3 ppm of 
IF aglycone equivalents.  
2) a standard IF-containing diet (IF-medium (M) purchased from Ssniff (SM R-Z protein-reduced 
complete feed) which contained soybean meal and full fat soybeans as protein and fat source, 
resulting in approximately 232 ppm of IF aglycone equivalents.  
3) specific IF-enriched diets. IF-low (L) and IF-high (H) diets were manufactured by adding 
NovaSoy650® at the amount of 0.131 g/kg (L) or 1.05 g/kg (H) to the control diet. These diets 
contained approximately 68 and 503 ppm of IF aglycone equivalents, respectively. 
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Table 2: Diet groups investigated in Wistar and ACI rat experiments. 
Abbreviation Diet name 
IF aglycone 
equivalents [ppm] 
NovaSoy650® 
[g/kg] 
Ssniff complete feed  
C Control 3 - R/M-H low-phytoestrogen  
L Low 68 0.131 R/M-H low-phytoestrogen  
M Medium 232 - SM R-Z protein-reduced  
H High 503 1.05 R/M-H low-phytoestrogen  
 
3.2.3 Rat uterotrophy assay in Wistar rats 
Animal experiments were performed with Wistar rats at the German Sports University in Cologne by 
the group of Prof. Dr. Dr. Patrick Diel. For a summary of experimental outlines see Figure 8. 
Adult female Wistar rats were obtained from Janvier Laboratories and were used for 
experimentation after two weeks of acclimatization (Table 3). These rats were maintained by Janvier 
Laboratories on a standard SM R-Z protein-reduced IF-containing diet (M) and were exposed to 
medium levels of IF. On PND 80 all females were ovariectomized and randomly split into two 
treatment groups. At PND 94 after 14 days of endogenous hormonal decline one group of the 
animals was subcutaneously treated for three consecutive days with E2 (4 µg/kg bw/day). Detailed 
information on animal handling, experimental conditions and E2-treatment is published in [160]. In 
order to mimic the postmenopausal situation with a short but high dose IF exposure scenario, rats 
were subjected to a diet switch to IF-high diet (MH group) or receiving control diet (MC group) during 
the hormonal decline period from PND 80 until PND 97. In order to control for effects due to the 
medium lifelong IF exposure until OVX in this intervention scenario, a second group of Wistar rat 
were subjected to the same diet swap protocol after ovariectomy (OVX) and hormonal decline until 
PND 97. Here dams and offspring were maintained on the control C diet and were not exposed to 
any IF prior to the post OVX IF-high diet (CH group).  
 
Table 3: Experimental animals. 
Name Manufacturer 
Wistar rats Janvier Laboratories, Le Genest-St-Isle, France 
August Copenhagen Irish (ACI/segHsd) rats Harlan, Eystrup, Germany 
 
For a lifelong IF intervention protocol, Wistar rats were obtained from Janvier Laboratories and were 
randomly assigned to control C or specific IF-enriched L and H diets prior to mating. Dams were kept 
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on allocated diets, thus female offspring were exposed to IF during conception, the fetal in utero 
period, as well as through weaning, and adolescence until the end of the experimental period in 
adulthood after OVX (PND 97, groups LL and HH). 
The pubertal period as the major period of postnatal MG development beside pregnancy is a critical 
time window for epigenetic reprogramming [144]. Pregnant dams were kept on control diet C and 
offspring received the IF-high diet solely during the specific period from PND 21 until PND 50 (CHC 
group). 
In total 14 experimental treatment groups (n=6-12 animals/group) were available to study the 
impact of IF on estrogen sensitivity and DNA methylation changes in MGs of healthy Wistar rats.  
A full list of all experimental animals, interventions and methods used can be found in Table 4 as well 
as in Table 5. 
3.2.4 August Copenhagen Irish rats 
A second animal experiment was performed with August Copenhagen Irish (ACI/segHsd) rats at the 
Technical University in Dresden by the group of Prof. Dr. Günter Vollmer. 
This rat strain represents an animal model susceptible to develop MG tumors solely after prolonged 
exposure to pregnancy levels of exogenous E2 [161]. Recently, Shull et al. developed a novel animal 
model based on the ACI rat and exhibit the same susceptibility towards breast cancer but promising 
less co-morbidity associated with pituitary hyperplasia [162]. The use of this rat strain can 
compromise longer studies focusing on breast tumor development and might be of first choice for 
future research on mammary cancer prevention. For tumor promotion both ovarian steroids, E2 and 
progesterone have to be present, since OVX completely abolishes mammary carcinogenesis in ACI rat 
[163]. Treatment with tamoxifen also reduced the ability of E2 to induce tumors in ACI rats indicating 
the driving role of E2 in this model of breast carcinogenesis [164, 165]. Distinct quantitative trait loci, 
i.e., estrogen-induced mammary cancer (Emca) underlie the breast cancer susceptibility of these rats 
[166]. Four Emca loci are orthologous to human loci that have been associated with higher 
mammographic breast density and map to genes involved in cell cycle control and DNA Repair (e.g., 
Cdkn2 and Rad51), as well as in proliferation (Myc), and drug resistance (MRPs) [167]. In addition, 
arising tumors show expression of both ERα and Pgr which further supports and emphasizes the 
close connection of this model to human types of breast cancer. 
For the lifelong IF intervention protocols, ACI rats were obtained from Harlan and were randomly 
assigned to control C or H diets prior to mating (Table 3). In the kinetic arm of the experiment, 
pregnant dams were kept on allocated diets, thus female offspring were exposed to IF during all 
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developmental windows of fetal and neonatal, as well as pubertal, and adolescent development until 
the end of the experimental period (Figure 26). In order to better understand the impact of IF on the 
kinetics of DNA methylation changes during normal MG development, rats were sacrificed before 
and after puberty at PND 21 and PND 50±1, during adolescence at PND 81±2, and PND 97±2, as well 
as in adulthood at PND 180±3. 
In the carcinogenesis arm of the study, female ACI rats were randomly divided into two different 
treatment groups (n=10) in order to monitor the impact of IF on MG carcinogenesis (Figure 47). At 
PND 45, when the number of TEB is the highest, one group of ACI rats was implanted with a 4 mg E2-
containing silicon tube to initiate the tumorigenic process. A second tube was implanted at PND 175 
to ensure a consistent E2-release during the experiment, since it has been reported that withdrawal 
of the promoting agent lead to regression and re-differentiation of the pre-neoplastic lesions [168]. 
Tumor development was monitored by palpation. At the termination of the experiment, tumors 
were excised, tumor multiplicity was monitored, and tumor size and weights were recorded. Detailed 
information on animal handling, experimental conditions, and E2-releasing implants is published in 
Möller et al. 2016 (under revision). 
A full list of all experimental animals, interventions and methods used can be found in Table 4 as well 
as in Table 5. 
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Table 4: Summary of all experimental animals, interventions and methods used. 
Rat strain Diet Birth Dissection -E2 [n] +E2 [n] 
Start of E2 
treatment 
[PND] 
Duration 
of E2 treat- 
ment [d] 
Sampling 
[PND] 
Genome 
wide 
method 
Candidate 
gene 
approach 
Gene 
expression 
Protein 
expression 
Wistar CC 03/ 2012 06/ 2012 8 9 94 3 97 - MA RT-qPCR
a
 IHC
b
 
Wistar CHC 03/ 2014 06/ 2014 7 7 94 3 97 - MA RT-qPCR
a
  
Wistar CHC 05/ 2013 08/ 2013 6 9 94 3 97 - MA RT-qPCR
a
  
Wistar LL 01/ 2012 04/ 2012 6 7 94 3 97 - MA RT-qPCR
a
 IHC
b
 
Wistar MC 10/ 2011 11/ 2011 6 6 94 3 97 MCIp-Seq MA RT-qPCR
a
 IHC
b
 
Wistar MH 10/ 2011 11/ 2011 12 12 94 3 97 MCIp-Seq MA RT-qPCR
a
 IHC
b
 
Wistar HH 11/ 2011 02/ 2012 6 7 94 3 97 - MA RT-qPCR
a
 IHC
b
 
           
 
ACI C, H 07/ 2013 04/ 2014 20 20 45 240 285 RRBS MA RT-qPCR
a
 IHC
c
 
ACI C, H 11/ 2011 05/ 2012 12 - - - 180 - MA RT-qPCR
a
 IHC
c
 
ACI C, H 11/ 2011 03/ 2012 12 - - - 97 - MA RT-qPCR
a
 IHC
c
 
ACI C, H 11/ 2011 02/ 2012 12 - - - 81 - MA RT-qPCR
a
 IHC
c
 
ACI C, H 01/ 2012 03/ 2012 12 - - - 50 RRBS MA RT-qPCR
a
 IHC
c
 
ACI C, H 01/ 2012 02/ 2012 12 - - - 21 RRBS MA RT-qPCR
a
 IHC
c
 
C: control diet, L, M and H: Isoflavone enriched diets (68, 232 and 503 ppm), PND: post natal day, RRBS: Reduced representation bisulfite sequencing, MA: MassARRAY,  
RT-qPCR: Real time quantitative PCR, IHC: Immunohistochemistry 
a
: performed by Karin Klimo, technician in the group of Dr. Clarissa Gerhäuser, DKFZ Heidelberg, 
b: 
performed by the group of Prof. Dr. Dr. Patrick Diel, DSHS Cologne, 
c
: performed by the group of Prof. Dr. Günter Vollmer, TU Dresden. 
3. Material and Methods   40 
Table 5: Summary of ACI rats and obtained tissues from E2-induced MG carcinogenesis (PND 285), interventions and methods used. 
Tissue Diet Birth Dissection [n] 
Start of E2 
treatment 
[PND] 
Duration of 
E2 treat- 
ment [d] 
Sampling 
[PND] 
Genome-wide 
method 
Candidate 
gene 
approach 
Gene/Protein 
Expression 
Epithelial 
enrichment 
MG C, H 07/13 04/14 20 - - 285 RRBS MA RT-qPCR
a
, IHC
b
  - 
MG/T C, H 07/13 04/14 17 45 240 285 - MA RT-qPCR
a
, IHC
b
  - 
T C, H 07/13 04/14 24 45 240 285 RRBS MA RT-qPCR
a
, IHC
b
 - 
MG C, H 10/11 06/12 12 - - 240 - MA - LCM 
DCIS C 10/11 06/12 3 60 180 240 - MA - LCM 
MG: mammary gland, MG/T: Mammary gland with no palpable tumor, T: Tumor, DCIS: Ductal carcinoma in situ, C: control diet, L, M and H: Isoflavone enriched diets (68, 
232 and 503 ppm), PND: post natal day, RRBS: Reduced representation bisulfite sequencing, MA: MassARRAY, RT-qPCR: Real time quantitative PCR, IHC: 
Immunohistochemistry, LCM: laser capture microdissection 
a
: performed by Karin Klimo, technician in the group of Dr. Clarissa Gerhäuser, DKFZ Heidelberg, 
b
: performed by the group of Prof. Dr. Günter Vollmer, TU Dresden. 
3. Material and Methods  41 
3.2.5 DNA, RNA and protein isolation 
Material  
Name Manufacturer 
Agilent RNA 6000 nano kit  
 
Agilent Technologies, Palo Alto, USA 
AllPrep RNA/DNA Mini Kit  Qiagen, Hilden, Germany 
Isopropanol Sigma-Aldrich, Taufkirchen, Germany 
Chloroform Sigma-Aldrich, Taufkirchen, Germany 
Ethidium bromide  Sigma-Aldrich, Taufkirchen, Germany 
Lambda DNA/HindIII Marker Thermo Fischer Scientific, Waltham, USA  
 
Proteinase K solution  Qiagen, Hilden, Germany 
RNase A  Sequenom, San Diego, USA 
RNase-free DNase Set  Qiagen, Hilden, Germany 
RWT Buffer Qiagen, Hilden, Germany 
Qubit® RNA 6000 Nano Kit 
 
Invitrogen, Life Technologies, Carlsbad, USA 
Qubit® dsDNA HS Assay Kit Invitrogen, Life Technologies, Carlsbad, USA 
TRIzol reagent  Sigma-Aldrich, Taufkirchen, Germany 
β-mercapto-ethanol AppliChem, Darmstadt, Germany 
 
Non standard instruments  
Name Manufacturer 
Agilent 2100 BioAnalyzer Agilent Technologies, Palo Alto, USA 
Micro-Dismembrator S Sartorius, Göttingen, Germany 
Nanodrop spectrophotometer (ND1000)  PeqLab, Erlangen, Germany 
Qubit® 2.0 Fluorometer Invitrogen, Life Technologies, Carlsbad, USA 
 
DNA, RNA, and protein was isolated from fresh frozen tissue using the Qiagen AllPrep DNA/RNA kit 
and TRIzol reagent. The manufacturers’ protocol was modified in order to increase DNA/RNA yield 
and quality as well as fitting the requirements of the usage of TRIzol. All used buffers were obtained 
from Qiagen. 
3.2.5.1 Tissue processing 
Fresh frozen tumors and MG were pulverized using the Sartorius Micro-Dismembrator S while 
shaking flasks were cooled with liquid nitrogen whenever possible. For isolation 20–50 mg of tissue 
powder were lyzed with 1 ml RLT Plus buffer, supplied with 10 µl β-mercapto-ethanol (β-ME). After 
complete lysis of tissue, samples were centrifuged for 3 min at 10,000 rpm in order to remove non-
soluble material. For DNA binding residual liquid was transferred to an AllPrep DNA spin column in 
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500 µl portions and flow through was collected. The AllPrep DNA spin column was washed with 
500 µl buffer AW1 in order to remove β-ME, and DNA isolation was carried out as described in the 
DNA isolation section (see 3.2.5.2).Flow through was further processed by adding of 1 ml TRIzol 
reagent and vortexed. After incubation for 5 min at room temperature, 200 µl chloroform were 
added followed by vortexing and incubation for 15 min at room temperature. Phase separation was 
achieved by centrifugation for 15 min and 13,000 rpm at 4 °C. The colorless, aqueous phase, 
containing the RNA, was transferred to a new 2 ml reaction tube, mixed with 500 µl isopropanol, and 
stored at -20 °C overnight. RNA isolation was performed as described in the RNA isolation section 
(see 3.2.5.3). The red, organic phase was used for protein isolation as described in the protein 
isolation section (see 3.2.5.4). 
3.2.5.2 DNA isolation 
DNA was bound to AllPrep DNA spin columns as described in the tissue processing section. DNA was 
eluted in 40 µl PBS and 10 µl RNase A was added. RNA was digested for 30 min at 37 °C, and the 
eluate was transferred to the AllPrep DNA spin column again, following RNase A on-column digestion 
for additional 15 min at 37 °C. Columns were washed using buffer AW1 and flow through was 
pipetted on the columns again to ensure complete DNA binding. In order to remove proteins, 20 µl 
proteinase K solution was added to 60 µl buffer AW1 and protein digestion was carried out on-
column for 30 min at room temperature. Proteins were washed away with buffer AW1 twice 
followed by two final washing steps with buffer AW2. In order to remove residual contaminates from 
buffer AW1 columns were inverted during AW2 washing steps. Columns were dried of residual 
ethanol by centrifugation for 5 min and 13,000 rpm and DNA was eluted using 50 µl buffer EB. The 
eluate was pipetted back on the column in a second elution step in order to concentrate DNA.  
Quantification of DNA was done using spectrophotometry at 260 nm and additionally by Qubit® 
dsDNA BR Assay Kit. DNA quality was checked by loading 200 ng DNA and 3 µl Lambda DNA/HindIII 
Marker onto a 0.8 % TBE agarose gel containing 4µl/100ml ethidium bromide for visualization (120 V, 
90 min).  
3.2.5.3 RNA isolation 
The RNA containing aqueous phase was stored at -20 °C overnight as described in the tissue 
processing section. Protein digestion was achieved by adding 80 µl proteinase K solution and 
incubation for 30 min at room temperature. In order to ensure RNA and especially miRNA binding to 
columns, 400 µl buffer RWT was added and mixed briefly by inverting the tubes. The entire solution 
was transferred to an AllPrep RNA spin column in 700 µl portions. After washing the columns with 
400 µl buffer RWT, remaining DNA was digested on-column using 10 µl DNase I in 70 µl buffer RDD 
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(RNase-free DNase Set) for 14 min at room temperature. Columns were washed using 500 µl buffer 
RWT and flow through was pipetted on the AllPrep RNA spin columns in order to ensure complete 
RNA binding. Columns were washed twice with buffer RPE. Columns were inverted in both washing 
steps in order to remove residual contaminates from buffer RWT. Columns were centrifuged dry 
(5 min, 13000 rpm) and RNA was eluted using 30 µl RNase-free water. The eluate was pipetted back 
on the column in a second elution step in order to concentrate RNA. All centrifugation steps were 
carried out at 4 °C. 
RNA quality was checked on an Agilent RNA 6000 nano chip and the concentration was measured by 
spectrometry at 260 nm. Purity was estimated from 260/230 nm and 260/280 nm ratios. 
3.2.5.4 Protein isolation 
Protein was precipitated from the red, organic phase as described in the tissue processing section by 
adding 1 ml isopropanol and incubation for 1 h at room temperature. Protein was pelleted by 
centrifugation for 10 min and 13,000 rpm at 4 °C. Protein pellets were washed twice using 2 ml wash 
solution (0.3 M guanidine hydrochloride in 95 % ethanol) for 20 min. Between washing steps, 
washing solution and protein pellets were centrifuged for 5 min and 13,000 rpm at 4 °C. After the 
final washing step, protein pellets were stored in 100 % ethanol at -20 °C. 
3.2.6 Methyl-CpG Immunoprecipitation and Next generation Sequencing  
Material  
Name Manufacturer 
Agilent high sensitivity DNA kit Agilent Technologies, Palo Alto, USA 
EDTA  Sigma-Aldrich, Taufkirchen, Germany  
MgCl2  Sigma-Aldrich, Taufkirchen, Germany  
MinElute Purification Kit  Qiagen, Hilden, Germany 
NaCl Sigma-Aldrich, Taufkirchen, Germany  
NP-40  Genaxxon Bioscience, Ulm, Germany  
QuantiTect SYBR Green PCR kit  Qiagen, Hilden, Germany  
Qubit® dsDNA HS Assay Kits  Life Technologies, Carlsbad, USA 
Tris-HCl Sigma-Aldrich, Taufkirchen, Germany  
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Non standard equipment  
Name Manufacturer 
12 x 24mm round-bottom glass tubes 
& caps 
Covaris, Woburn USA 
Agilent 2100 BioAnalyzer Agilent Technologies, Palo Alto, USA 
BioFuge Fresco centrifuge  Heraeus, Hanau, Germany  
DiaMag protein A-coated magnetic 
beads  
Diagenode, Liège, Belgium 
H raeus Megafuge 1.0R centrifuge  Thermo Scientific, Rockford, USA  
LightCycler480  Roche, Penzberg, Germany 
S220 Focused-ultrasonicator Covaris, Woburn USA 
SX-8G IP-Star® Automated System Diagenode, Liège, Belgium 
Qubit® 2.0 Fluorometer Invitrogen, Life Technologies, Carlsbad, USA 
 
3.2.6.1 High salt and single fraction elution protocol 
In order to detect differentially methylated regions (DMRs) in normal mammary tissue of healthy 
adult female Wistar rats, MCIp experiments were performed as described previously [169, 170] with 
minor modifications. 2-5 µg high quality genomic DNA was ultrasonicated for 9 min at 4 °C, 10 % duty 
cycle, intensity 5 and 200 cycles/burst to fragment sizes of roughly 150 bp. Selective binding of 
methylated DNA to the methyl binding domain of the MBD2-Fc protein bound to magnetic protein A-
coated beads enabled the separation of low, moderate and highly methylated DNA. Therefore, 60 µg 
MBD2-Fc protein and 40 µl of magnetic beads were washed in buffer A (300 mM NaCl, 0.1 % NP-40, 
20 mM Tris-HCl pH 8.0, 2 mM MgCl2, 0.5 mM EDTA) and mixed with 2-5 µg sonicated DNA.  
An engineered protocol for the Robot SX-8G IP-Star enabled an automatic washing, bead incubation, 
and DNA fragment separation according to their methylation status by sequential elution with 
increasing NaCl concentrations using buffers B-F (buffer B: 400, C: 500, D: 550 and F: 1000 mM NaCl, 
with remaining components as for buffer A). For the high salt elution protocol (HS) the high affinity 
fraction eluted with highest salt concentration F was used for subsequent library preparation 
followed by NGS. This fraction was enriched for highly methylated DNA fragments of CpG-dense 
regions and CGIs. 
In order to enrich for medium and high methylated DNA fragments, a single fraction elution protocol 
(SF) was used. DNA was washed with low salt buffer B to remove non- and low-methylated DNA 
fragments from MBD2-Fc protein and the magnetic beads. A second elution with buffer F containing 
the highest NaCl concentration eluted all DNA fragments from MBD2-Fc protein. Therefore, SF was 
enriched for high and less CpG-dense regions with a medium and high degree of DNA methylation 
[81, 85]. 
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Eluates were desalted using the MinElute Purification Kit according to manufacturer’s instructions. 
DNA elution with 10 µl EB twice led to a final volume of 20 µl enriched DNA. For size confirmation, 
final library quality was checked for unwanted products on an Agilent high sensitivity DNA chip and 
double-stranded DNA concentration was determined by the Qubit® dsDNA HS Assay. 
3.2.6.2 Control for enrichment of methylated DNA by qPCR 
In order to check for effective enrichment, 2 µl of spike-in DNA was added to the ultrasonicated DNA. 
This control DNA was derived from Arabidopsis thaliana and was artificially methylated using M.SssI 
before it was mixed in an equimolar ratio with unmethylated control (1 pg/µl). Elution profiles of the 
internal controls as well as for the imprinted gene Mest were measured by real time quantitative PCR 
(RT-qPCR). For primer sequences see 3.1.3.2. 
The Lightcycler 480 system and the QuantiTect SYBR Green PCR Kit were used for qPCR. In brief, the 
following protocol was used: 1.4 µl DNA from the different fractions + 7 µl qPCR Master Mix (3.5 µl 
Quantitect SYBR Green 2x, 0.2 µl forward primer (10 µM), 0.2 µl reverse primer (10 µM) and 1.7 µl 
nuclease-free water) were analyzed with the following program: 15 min initial denaturation at 95 °C, 
45 cycles of 15 s at 94 °C, 30 s at 60 °C. Analyses were always run in duplicates. Serial dilutions of 
ultrasonicated but non fractioned DNA (1:10, 1:50, 1:100 and 1:1000) were used as basis for a 
standard curve and enrichment profile calculation. Samples were submitted for sequencing (50 bp, 
single-end reads) on a HiSeq 2000 instrument (Illumina Inc., San Diego, USA). Using the NebNext 
chemistry (NEB, Ipswich, USA) sequencing libraries were prepared according to the manufacturer´s 
protocols by the DKFZ Genomics and Proteomics Core facility.  
3.2.6.3 Bioinformatics data mining 
Raw sequencing reads of all animals per diet group were pooled and aligned to the reference 
genome (rn5, http://genome.ucsc.edu) using the BWA aligner [128]. Duplicates and low quality reads 
(MAQ score of <20) were filtered out using SAMtools [171]. The MEDIPs package of R was used to 
measure the read coverage of each individual CpG enriched by MCIp. Read counts were normalized 
to 1 million reads. DMRs (200bp) were generated and annotated using the Homer suite of tools 
[172]. Promoter regions (2kb upstream and 500 bp downstream of TSS) were downloaded from the 
UCSC genome browser. Additionally, gene expression data from the gene expression omnibus 
(GSE38060) was used to further evaluate the candidate list for biological relevance [173]. Putative 
DMRs were selected for high coverage, high fold change and low q-values. Hyper- and 
hypomethylated DMRs refer to the comparison of MH intervention groups with the MC control 
group. Data processing was performed by a set of Perl (http://www.perl.org/) and R (http://www.r-
project.org/) scripts customized by Dr. Lei Gu and Dr. Manuela Zucknick. 
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3.2.7 Reduced representation bisulfite sequencing - Library preparation 
Material  
Name Manufacturer 
5 M NaCl Sigma-Aldrich, Taufkirchen, Germany 
Agilent high sensitivity DNA kit Agilent Technologies, Palo Alto, USA 
dNTP set, 100 mM each NEB, Ipswich, USA 
EB buffer Qiagen, Hilden, Germany 
EZ DNA Methylation-Direct™ Kit Zymo Research, Irvine, USA 
GoTaq qPCR Master Mix  Promega, Mannheim, Germany 
Klenow exo-polymerase NEB, Ipswich, USA 
Methylated and unmethylated control oligos Christoph Bock, CEMM, Vienna, Austria 
MspI NEB, Ipswich, USA 
NEB Buffer #2 NEB, Ipswich, USA 
PEG 8000 Sigma-Aldrich, Taufkirchen, Germany 
Pfu Turbo Cx hotstart DNA polymerase Agilent Technologies, Palo Alto, USA 
Qubit® dsDNA HS Assay Kit Life Technologies, Carlsbad, USA 
Quick ligase NEB, Ipswich, USA 
SPRI AMPure XP magnetic beads Beckman Coulter, Krefeld, Germany 
TruSeq DNA Sample Preparation LT Kit Illumina Inc., San Diego, USA. 
 
Non standard equipment  
Name Manufacturer 
Agilent 2100 BioAnalyzer Agilent Technologies, Palo Alto, USA 
MagnetoPURE-Micro Chemicell, Berlin, Germany 
Qubit® 2.0 Fluorometer Invitrogen, Life Technologies, Carlsbad, USA 
 
3.2.7.1 MspI digest, end repair and A-Tailing 
In order to generate a reduced representation of the rat genome, MspI, a restriction endonuclease 
(C↓CGG) which is insensitive to CpG methylation, was used to generate a predictable number of 
DNA fragments with at least one analyzable CG in each fragment, including highly redundant 
fragments from microsatellite DNA. Therefore, 100 ng genomic DNA was digested using 20 U MspI 
and 3 µl 10x NEB Buffer #2 in a total volume of 30 µl for 14 h at 37°C. 
The digestion reaction was mixed with 5 U Klenow exo- polymerase, 1 µl dNTP mix (10 mM dATP, 
1 mM dCTP and 1 mM dGTP) and 0.1 ng unmethylated and methylated control oligos. Incubation for 
20 min at 30 °C filled in the 3’- and 5'-overhangs of the MspI-digestion fragments. A further 
incubation for 20 min at 37°C was used to add a single A nucleotide to the 3'-terminal ends which 
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prevents the fragments from ligating to one another and is required for the subsequent adapter 
ligation. The reaction was inactivated by heating to 75°C for 20 min. Addition of unmethylated and 
methylated control oligos facilitates subsequent calculations of bisulfite conversion rates. 
3.2.7.2 Adapter Ligation 
The addition of adapters is a basic principle of sequencing random DNA fragments. These short 
sequences allow hybridization of the DNA fragments onto a flow cell and enable barcoding of 
samples to mix multiple DNA libraries together into one sequencing lane. The universal and the 
indexed adapter have a very short complementary sequence which is composed of twelve 
nucleotides only, followed by a number of nucleotides which are hanging off [174]. Illumina standard 
adapters were prepared in 1:50 dilutions in resuspension buffer (provided in the TruSeq DNA Sample 
Preparation LT Kit) and were forwarded for denaturation at 95 °C for 15 min. A subsequent cool 
down to 70 °C for 15 min and a step wise cooling protocol to 25 °C over a period of 25 min allowed 
complementary oligos to anneal and to form “floppy” overhangs. A single T nucleotide on the 3'-
terminal end of the adapters serves as a complementary overhang for the A-tailed DNA fragments. 
2.5 µl adapters were ligated for 20 min at 25 °C using 1 µl Quick ligase and 37.5 µl Quick Ligase 
buffer, followed by an inactivation step at 65 °C for 10 min. 
3.2.7.3 Cleaning up using SPRI Beads 
Adapter ligated fragments were then cleaned by AMPure XP magnetic beads recovering fragments 
between 150 bp and 1000 bp in length. AMPure XP beads were removed from 4 °C storage at least 
30 min prior to usage and were vortexed until they were well dispersed. As total DNA amount was 
below 100 ng, beads were diluted 1:5 with crowding reagent (25 ml 5 M NaCl, 20 ml 50 % w/v 
polyethylene glycol 8000, 5 ml nuclease-free water).  
0.75 volumes of beads were added to the reaction and mixed gently by pipetting up and down 10 
times until beads were resuspended homogeneously. Excessive foaming was prevented by pipetting 
2/3 of the volume, only. The mixture was incubated at room temperature to allow binding to the 
beads and then placed on a magnetic stand for 15 min each. Aspiration of the cleared solution and 
washing of the beads twice with 200 µl freshly prepared 80 % ethanol removed all residual 
contaminants, i.e., primers, dNTPs and unbound DNA fragments. Beads were removed from the 
magnetic stand and were air-dried at room temperature. Over-drying of beads was avoided by 
adding 25 µl EB for DNA elution as soon as remaining ethanol was fully evaporated. Again, beads 
were gently resuspended by pipetting up and down 10 times, incubated at room temperature and 
then placed on a magnetic stand for 15 min each. Eluates, containing the RRBS libraries were 
transferred into a new tube and stored at 4 °C for further analysis or at -20 °C for long term storage. 
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3.2.7.4 Quality control qPCR 
In order to ensure that end repair and adapter ligation were efficient, a semi-quantitative PCR was 
performed as quality control. Obtained Ct-values were used for quantifying RRBS libraries to enable 
homogenous multiplexing of six samples into one sequencing library.  
The Lightcycler 480 system and GoTaq qPCR Master Mix were used for qPCR. In brief, the following 
protocol was used: 1 µl undiluted library + 19 µl qPCR Master Mix (10 µl Master Mix 2x, 2 µl PCR 
primer cocktail (PPC, 25 mM each), 7 µl nuclease-free water) were analyzed with the following 
program: 3 min initial denaturation at 98 °C, 25 cycles of 15 s at 95 °C, 30 s at 60 °C, 30 s at 72 °C and 
a subsequent elongation step for 5 min at 72 °C. Analyses were always run in duplicates. Ct-values, 
calculated with the Roche Lightcycler Software Release 1.5.0 using the Abs quant/2nd derivative max 
option served both as a quality control (Ct <14) and to calculate the volumes for library pooling.  
First, all libraries were sorted by Ct-values in ascending order and six consecutive samples were 
pooled. The volume of the sample used for pooling with maximum Ct-value (Ctmax) was 17 µl. 
Difference in Ct-values (ΔCt) and fielding volumes (vsample) for pooling for the residual five sample 
were calculated using the following equations (see example below): 
 
                –           
                             
 
Samples were pooled in combinations of six according to the calculated volumes in a 2 ml Eppendorf 
tube (Table 6). Libraries with identical adapter numbers in one pool were switched into the next 
pool, since adapters were used for identification of a particular library. The total volume of the 
pooled library was adjusted to 33 µl by adding 2.5 volumes AMPure XP beads and subsequent clean 
up as described before. 
 
Table 6: Library sorting according to Ct values for multiplexed sequencing. 
Library Ct1 Ct2 Ctaverage ΔCt VSample [µl] 
1 8.94 8.75 8.85 0.71 10.4 
2 8.95 8.93 8.94 0.62 11.1 
3 9.26 9.15 9.21 0.35 13.3 
4 9.44 9.18 9.31 0.25 14.3 
5 9.61 9.33 9.47 0.09 16.0 
6 9.56 9.55 9.56 0.00 17.0 
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3.2.7.5 Bisulfite conversion 
In order to maintain methylation information, DNA samples were subjected to bisulfite conversion 
using the DNA Methylation Direct Kit according to manufacturer`s recommendation with major 
modification. Starting the protocol at section II, the pool of 6 libraries was incubated with 117 µl of 
CT Conversion Reagent in an Eppendorf Mastercycler for 20 cycles of 1 min at 95 °C and 10 min at 60 
°C with a subsequent cooling step for 10 min at 4 °C. Trouble shooting and sequencing of several 
bisulfite conversion protocols revealed that 16 cycles of 15 sec at 95°C and 60 min at 50°C using he 
standard Zymo Research methylation Kit increased bisulfite conversion rate und should be used in 
future analyses (see Figure 34). 
For desulphonation, 600 µl of M-Binding Buffer was added to a Zymo-Spin™ IC Column. Bisulfite-
converted library pools were loaded onto a Zymo-Spin™ IC Column and were mixed by inverting the 
column several times. All Zymo-Spin™ IC Columns were washed with 100 µl M-Wash Buffer in order 
to remove denaturating detergences. 200 µl M-Desulphonation buffer was added to the columns and 
library pools were incubated for 30 min at room temperature. Columns were washed twice using 200 
µl M-Wash Buffer before bisulfite converted RRBS libraries were finally eluted by adding 20 µl of M-
Elution Buffer to the column’s membrane. The eluate was pipetted back on the column in a second 
elution step in order to concentrate DNA for immediate enrichment PCR. 
Bisulfite treatment of DNA leads to a chemical deamination of unmethylated cytosines (C) to uracil 
(U). In subsequent PCR reactions, all uracils (from unmethylated Cs) are amplified as thymines, 
whereas only methylated Cs are amplified as cytosines, allowing discrimination of unmethylated and 
methylated Cs at single CpG resolution. Achieving a consistent C to U conversion of unmethylated 
DNA is crucial for obtaining reliable quantitative methylation data. 
3.2.7.6 Enrichment PCR 
The bisulfite-converted DNA was then enriched by PCR amplification using the Pfu Turbo Cx Hotstart 
DNA polymerase, a proof-reading PCR enzyme that does not stall when it encounters uracil.  
To minimize the bias caused by amplification, a semi-quantitative PCR was performed prior to the 
enrichment PCR to determine the lowest possible number of PCR cycles for enrichment. The 
Lightcycler 480 system and GoTaq qPCR Master Mix were used for qPCR. In brief, the following 
protocol was used: 1 µl undiluted bisulfite converted library pool + 19 µl qPCR Master Mix (10 µl 
Master Mix 2x, 2 µl PPC (25 mM each), 7 µl nuclease-free water) were amplified with the following 
program: 3 min initial denaturation at 98 °C, 25 cycles of 15 s at 95 °C, 30 s at 60 °C, 30 s at 72 °C and 
a subsequent elongation step for 5 min at 72 °C. Analyses were always run in duplicates. Ct-values, 
calculated with the Roche Lightcycler Software Release 1.5.0 using the Abs quant/2nd derivative max 
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option served both as a control (Ct <18) and to calculate the optimal cycle number for enrichment 
which is typically Ct-value minus 1. 
For one enrichment reaction, 20 µl of bisulfite converted RRBS library was incubated with 10 U Pfu 
Turbo Cx hotstart DNA polymerase, 20 µl 10× Pfu Turbo Cx reaction buffer, 20 µl PPC (25 mM each) 
and 2 µl dNTP mix (25 mM each dATP, dGTP, dCTP and dTTP) and was adjusted to a total of 200 µl by 
using nuclease-free water. For enrichment of each library pool the reaction was split into eight 
aliquots of 25 µl each and was incubated in a thermocycler according to the following program: 2 min 
initial denaturation at 95 °C, Ct – 1 cycles of 30 s at 95 °C, 30 s at 60 °C, 45 s at 72 °C and a 
subsequent elongation step for 7 min at 72 °C. Analyses were always run in duplicates. 
From now on, all steps were performed in post-PCR environment to control for contamination with 
amplified RRBS libraries. 
PCR-amplified library aliquots were combined into one 2 ml DNA LoBind tube and cleaned by 2 
volumes of undiluted AMPure XP magnetic beads as described before. Pfu Turbo Cx reaction buffer is 
highly viscose and often disturbs subsequent library quality control. Therefore, libraries were washed 
three times with 1 ml freshly prepared 80 % ethanol to ensure a complete removal of the Pfu Turbo 
Cx reaction buffer and were then eluted into a 1.5 ml DNA LoBind tube using 20 µl EB. 
Between all steps of library preparation, samples were kept on ice. 
For size confirmation, final library quality was checked for unwanted products on an Agilent high 
sensitivity DNA chip and double-stranded DNA concentration was determined by the Qubit® dsDNA 
HS Assay. Each library was sequenced on one (ACI rats PND 21-50, see paragraph 4.3.3) or two lanes 
(ACI rats PND 285, see paragraph 4.3.5.2) of an Illumina HighSeq2000 machine (50-base single-end 
reads) and sequencing results are summarized in Supplemental table 3 and Supplemental table 5. 
3.2.7.7 Bioinformatics analysis 
Raw sequencing reads were aligned to the rat genome sequence using BSMAP [175]. Data processing 
was performed by custom Python (http://python.org/) and R (http://www.r-project.org/) scripts 
[176]. A validated software tool called RnBeads [177] was used for bioinformatic RRBS data mining. 
This tool presents quantitative methylation data at single CpG site, CGI and promoter level, allows 
pair- or group-wise statistical comparison of intervention groups for efficient detection of 
differentially methylated sites (DMS) or DMRs, generates graphical reports of results, and provides 
an overview of enriched gene ontologies representing the DMRs [177]. 
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3.2.8 Quantitative DNA Methylation analysis by EpiTYPER technology 
Material  
Name Manufacturer 
EZ DNA Methylation™ Kit  Zymo Research, Irvine, USA 
“T” Cleavage MassCLEAVE reagent kit  Sequenom, San Diego, USA 
dATP, dCTP, dGTP, dTTP Fermentas, St. Leon-Rot, Germany 
DNeasy Kit Qiagen, Hilden, Germany 
HotStar Taq DNA polymerase Qiagen, Hilden, Germany 
HotStarTaq DNA Polymerase kit  Qiagen, Hilden, Germany 
M.SssI Fermentas, St. Leon-Rot, Germany 
REPLI-g Mini Kit Qiagen, Hilden, Germany 
RNase A  Sequenom, San Diego, USA 
Shrimp Alkaline Phosphatase SAP  Sequenom, San Diego, USA 
 
Non standard equipment  
Name Manufacturer 
Mastercycler 384  Eppendorf, Hamburg, Germany 
MALDI-TOF Mass Spectrometry  Sequenom, San Diego, USA 
MassARRAY Nanodispenser Sequenom, San Diego, USA 
Sequenom EpiTYPER software 1.2  Sequenom, San Diego, USA 
 
Methylation of interesting candidate regions were quantitatively analyzed using MALDI-TOF Mass 
spectrometry. The method includes amplification by PCR, SAP treatment, in vitro transcription, and 
base-specific cleavage of nucleic acids, as well as separation of fragments according to their mass to 
charge ratio (m/z). 
The principal of the assay is the conversion of unmethylated C to U by bisulfite conversion and 
subsequently to adenines during an in vitro transcription. Methylated cytosines are unaffected and 
transcribed into guanines. The exchange of guanine to adenine introduces a mass shift of 16 Da for a 
single CpG site or 32, 48, 60, 72 Da etc. for several CpG sites in one CpG-unit and results in a unique 
spectra signal in the MALDI-TOF Mass spectrometry distinguishing methylated and unmethylated Cs. 
Using this system, methylation differences >5 % are detectable by quantifying median methylation of 
single CpGs or two or more CpGs together (CpG units) (also see section 1.2.2.4). 
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3.2.8.1 Bisulfite conversion 
Bisulfite conversion or bisulfite treatment of genomic DNA is used to maintain methylation 
information for downstream applications and is considered as the gold standard for quantitative 
methylome analyses. 
500 ng high quality genomic DNA isolated from the Wistar rats were subjected to sodium bisulfite 
treatment using the EZ DNA Methylation™ Kit, according to the manufacturers’ instructions. In brief, 
5 µl M-Dilution Buffer was added to the DNA and the total volume was adjusted to 50 µl with 
nuclease-free water. After an initial incubation step for 15 min at 37 °C, 100 µl of prepared CT 
Conversion Reagent was added and samples were incubated using the following program: 16 cycles 
of 15 s at 95 °C, 60 min at 50 °C and a subsequent cooling step for 10 min at 4 °C (Protocol 2, see 
Figure 34). For desulphonation, 400 µl of M-Binding Buffer was added to a Zymo-Spin™ IC Column. 
Bisulfite-converted DNA was loaded onto a Zymo-Spin™ IC Column and was mixed by inverting the 
column several times. All Zymo-Spin™ IC Columns were washed with 100 µl M-Wash Buffer in order 
to remove denaturating detergents. 200 µl M-Desulphonation buffer was added to the columns and 
was incubated for 20 min at room temperature. Columns were washed twice using 200 µl M-Wash 
Buffer before bisulfite converted DNA was eluted twice in 30 µl M-Elution buffer, 1:2 diluted using 
nuclease-free water and stored at -20 °C. 
Genomic DNA isolated from ACI rats was subjected to sodium bisulfite treatment using the DNA 
Methylation Direct Kit (Zymo Research) as described for library pools in the RRBS section 3.2.7.5. 
In order to check for efficient conversion, a subsequent PCR was performed. Primers were designed 
to bind to the Sall3 gene, a CG-dense region with many putative C conversions  in non-CpG contexts. 
For one reaction, 1 µl bisulfite converted DNA was incubated with 0.2 U µl HotStar Taq DNA 
polymerase, 0.5 µl 10x HotStar Taq buffer, 0.1 µl 10 µM Forward-Reverse primer mix and 0.1 µl dNTP 
mix (2.5 mM each dATP, dGTP, dCTP and dTTP) and was adjusted to a total of 5 µl by using nuclease-
free water. Reactions were incubated in a thermocycler according to the following program: 15 min 
initial activation at 94 °C, 48 cycles of 30 s at 95 °C, 1 min at 60 °C, 1 min at 72 °C and a subsequent 
elongation step for 5 min at 72 °C. Good quality bisulfite converted DNA served as positive and 
genomic DNA as well as water as negative controls. For visualization the PCR products were loaded 
onto 2 % TBE agarose gel (120 V, 50 min). Primers annealed, if all unmethylated Cs were fully 
converted to Us, resulting in an amplification of the Sall3 region and clearly visible DNA bands at 
around 170 bp. 
3. Material and Methods  53 
3.2.8.2 Primer design and optimization 
For quantitative DNA methylation analysis, primers were designed to bind specifically bisulfite 
converted templates by using the EpiDesigner tool from Sequenom. Basically, primers were designed 
with an annealing temperature ranging from 56 °C to 64 °C with an optimum at 60 °C. Ideally, primer 
length was between 20 and 30 bp and poly-thymine stretches of 6 or more were avoided. Finally 
both strands could serve as template since hemimethylation is a negligible and transient event, 
which exists either during de novo methylation when DNMT3a and 3b establish a new methylation 
pattern or after DNA replication, shortly before DNMT1 is maintaining the parental methylation 
signal. Finally, primers should amplify a product with a length between 100 and 500 bp, with an 
optimal length of 300 bp for high quality input DNA. The RSeqMeth package of R was used to analyze 
amplicons in silico for fragmentation patterns and molecular weights. Primers that generated 
amplicons with an appropriate number of separately analyzable CpGs were selected for PCR 
amplification. In order to adapt primers for the MassARRAY protocol, reverse primers were tagged 
with a T7-promoter and 10mer tags were added to the forward primers to counterbalance the 
melting temperature. 
Primers were tested in a PCR in order to find the optimal annealing temperature to reduce off-target 
amplification and primer-dimer formation. For one reaction, 1 µl template DNA was incubated with 
0.2 U µl HotStar Taq DNA polymerase, 0.5 µl 10x Hot Star Taq buffer, 0.1 µl 10 µM Forward-Reverse 
primer mix and 0.1 µl dNTP mix (2.5 mM each dATP, dGTP, dCTP and dTTP) and was adjusted to a 
total of 5 µl by using nuclease-free water. Each primer pair was tested at four different annealing 
temperatures (56 °C, 58 °C, 60 °C and 62 °C) using good quality bisulfite converted DNA as positive 
and genomic DNA as well as water as negative templates. Reactions were incubated in a 
thermocycler according to the following program: 15 min initial activation at 94 °C, 48 cycles of 30 s 
at 95 °C, 1 min at 56 °C, 58 °C, 60 °C or 62 °C, 1 min at 72 °C and a subsequent elongation step for 
5 min at 72 °C. For visualization, the PCR products were loaded onto a 2 % TBE agarose gel (120 V, 
50 min). Annealing temperatures showing no off-targets in bisulfite converted or genomic DNA were 
used for quantitative methylation analysis. For a summary of all MassARRAY primers see section 
3.1.3.1.  
3.2.8.3 Preparation of methylated and unmethylated standard 
In order to test whether the designed primers are able to amplify DNA within a dynamic range, 
standards reflecting different degrees of methylation were included for each PCR amplification. 
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For methylated control DNA, 15 µg genomic DNA was incubated with 10 µl M.SssI, 13 µl 50x SAM as 
well as 65 µl 10x buffer and was adjusted to a total volume of 650 µl using nuclease-free water. After 
1 h at 37 °C, the methylation reaction was stopped by placing the tubes at 4 °C. 
The bacterial CpG Methyltransferase M.SssI is able to methylate all cytosine-residues in 
unmethylated and hemimethylated DNA in a CpG-context. However, 5fC and 5caC, intermediates of 
active demethylation are not recognized by M.SssI and will be deaminated in a subsequent bisulfite 
conversion. This chemical transmission from cytosine to thymine as well as spontaneous deamination 
of methylcytosine over evolutionary time is measured as unmethylated cytosines and affects the 
standard DNA that we will not be able to measure 100 % methylation. 
Whole genome amplification (WGA) was used to prepare unmethylated control DNA using the REPLI-
g Mini Kit. Amplification was performed for 8 reactions in parallel. Denaturation buffer was prepared 
by adding 35.5 µl nuclease-free water to 10 µl reconstituted buffer DLB. 30 ng genomic DNA was 
mixed with 5 µl denaturation buffer and was incubated at room temperature for 3 min. 
Neutralization buffer was prepared by adding 85 µl nuclease-free water to 15 µl stop solution and 
10 µl were added to stop the denaturation process. The WGA master mix was composed of 250 µl 
REPLI-g Mini Reaction Buffer and 8.3 µl REPLI-g Mini DNA Polymerase. Each reaction was mixed with 
30 µl master mix and incubated for 10-16 h at 30 °C. Amplification was stopped by a subsequent heat 
inactivation for 3 min at 65 °C and tubes were stored at 4 °C for further analysis. 
M.SssI-methylated and unmethylated WGA DNA was purified using the DNeasy Blood & Tissue Kit 
from Qiagen. Briefly, 50 µl DNA was mixed with 150 µl nuclease-free water before 200 µl buffer AL 
and 200 µl ethanol (96-100 %) were added. DNA was bound to DNeasy Mini spin columns by loading 
the whole mixture onto a column. In total, three samples (50 µl methylated or unmethylated DNA) 
were loaded onto one column for purification. Columns were washed by adding 500 µL buffer AW1 
and 500 µl buffer AW2. In order to remove residual contaminates from buffer AW1, columns were 
inverted during AW2 washing steps. Columns were dried of residual ethanol by centrifugation for 5 
min and 13,000 rpm and DNA was eluted using 2x 70 µl buffer EB. Quantification of DNA was done 
using spectrophotometry at 260 nm. 
In order to prepare a six-point DNA methylation standard, methylated and unmethylated DNA was 
mixed to obtain a DNA methylation gradient ranging from 0, 20, 40, 60, 80 and 100 % methylation 
(Table 7). The accuracy of the gradient is dependent on the precise determination of DNA 
concentration (25 ng/µl). Standard DNA was stored at 4 °C and was subjected to bisulfite conversion 
within four weeks. 
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Table 7: Ratios to obtain a 6-point methylation standard. 
methylation 0 % 20 % 40 % 60 % 80 % 100 % 
unmethylated DNA [µl] 40 32 24 16 8 0 
methylated DNA [µl] 0 8 16 24 32 40 
 
3.2.8.4 PCR amplification 
The region of interest was subjected to PCR amplification using a specific designed primer set and 
bisulfite converted DNA. For one reaction, 1 µl template DNA was incubated with 0.2 U µl HotStar 
Taq DNA polymerase, 0.5 µl 10x Hot Star Taq buffer, 0.1 µl 10 µM Forward-Reverse primer mix and 
0.1 µl dNTP mix (2.5 mM each dATP, dGTP, dCTP and dTTP) in a 384-well plate and was adjusted to a 
total of 5 µl by using nuclease-free water. Reactions were incubated in a thermocycler according to 
the following program: 15 min initial activation at 94 °C, 48 cycles of 30 s at 95 °C, 1 min at optimal 
TM, 1 min at 72 °C and a subsequent elongation step for 5 min at 72 °C. For visualization, 1 µl of the 
PCR-product were loaded onto 2 % TBE agarose gel (120 V, 50 min). Sequences of all EpiTYPER 
primers used can be found are listed in 3.1.3.1. 
3.2.8.5 SAP treatment, in vitro transcription and desalting 
In order to degrade all remaining unincorporated dNTPs, PCR amplified products were subjected to 
shrimp alkaline phosphatase (SAP) treatment. 0.3 U SAP (1 U/µl) and 1.7 µl nuclease-water was 
added to each reaction and was incubated for 20 min at 37 °C followed by an heat inactivation step 
for 10 min at 85 °C. 
In a subsequent in vitro transcription, PCR amplified DNA was transcribed into single stranded RNA 
starting from the T7-promoter tag on the reverse strand. Simultaneously, RNase A cleaves the 
phosphodiester bond at the 3' end of pyrimidine ribonucleotides enabling a U- or C-specific cleavage 
of the just transcribed RNA fragment. Since ribo-cytosines were replaced by desoxyribo-cytosines in 
the in vitro transcription reaction RNase A cleavage induced a U-specific cleavage pattern of the RNA 
fragments, only. 
For in vitro transcription and base-specific cleavage the MassCLEAVE T7 Kit from Sequenom was 
used. For one reaction, 2 µl SAP treated DNA was incubated with 22 U µl T7 RNA&DNA Polymerase, 
0.89 µl 5x T7 Polymerase buffer, 0.22 µl T Cleavage Mix (contains dCTP, rUTP, rGTP, and rATP), 
0.22 µl DTT (100 mM) and 0.06 µg RNase A (10 mg/ml) and was adjusted to a total of 7 µl by using 
nuclease-free water. Reactions were incubated for 3 h at 37 °C. 
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For desalting, 20 µl nuclease-free water and 6 mg resin were added to each sample and the 384-well 
plate was incubated under rotation for 45 min at room temperature. Using the Sequenom 
Nanodispenser robot, 15 nl of the cleavage products were dispensed on a silicon chip preloaded with 
matrix and were subjected to MALDI-TOF mass spectrometry analysis.  
3.2.8.6 Analysis of quantitative methylation data 
Methylation spectra from 1,500-7,000 Da were analyzed using the EpiTYPER software in the 
recalibrated spectra view. Uncertainty threshold was set to 0.1 and signals were excluded from the 
analysis, if i: CpG units had a low intensity with less than 100 between signal and noise, ii: CpG units 
showed silent peaks in the methylated or unmethylated peak, iii: CpG units had salt peaks, 
overlapping or duplicate peaks, iv: CpG units were uninformative in more than 50 % of the samples, 
and if v: CpG units showed unexpected values of the corresponding methylation standard. Median 
amplicon methylation was used to calculate median methylation differences between control and 
intervention groups. 
3.2.9 Quantification of nucleic acids using real time quantitative PCR (RT-qPCR) 
Material  
Name Manufacturer 
dNTPs Fermentas, St. Leon-Rot, Germany 
Primers Sigma-Aldrich, Taufkirchen, Germany 
random hexamer primers Life Technologies, Paisley, UK 
Roche Universal Probe Library Roche Diagnostics, Mannheim, Germany 
Roche Universal Probes master mix Roche Diagnostics, Mannheim, Germany 
Superscript III Reverse Transcriptase Invitrogen, Life Technologies, Paislay, UK 
 
Non standard equipment  
Name Manufacturer 
Heraeus Megafuge 1.0R centrifuge  Thermo Scientific, Rockford, USA  
Lightcycler 480 system Roche Diagnostics, Mannheim, Germany 
Roche Lightcycler Software Release 1.5.0 Roche Diagnostics, Mannheim, Germany 
 
RT-qPCR was performed by Karin Klimo. 
3.2.9.1 cDNA synthesis 
1.5 µg isolated RNA was subjected to reverse transcription (RT) with 1 µl 10 mM dNTPs and 250 ng 
random hexamers using 200 units of Superscript III Reverse Transcriptase per reaction according to 
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the cycling conditions in the manufacturer’s protocol. After heat inactivation of the transcriptase, 
cDNA was directly diluted 1:10 with water for qPCR analysis.  
3.2.9.2 Real time quantitative PCR 
Probe-compatible RT-qPCR primers were designed with the Roche Universal Probe Library Assay 
Design tool. Whenever possible, intron-spanning primers were preferred to exclude amplification of 
residual genomic DNA in the samples for mRNA quantification. UPL primer sequences are 
summarized in 3.1.3.3. 
The Lightcycler 480 system and Probes master mix were used for qPCR. In brief, the following 
protocol was used for a 384-well plate: 2.5 µl diluted cDNA, 3.5 µl Probes Master, 1 µl 10 µM 
Forward-Reverse primer mix, 0.05 µl universal probe with the following program: 10 min initial 
denaturation at 95 °C, 45 cycles of 10 s at 95 °C, 20 s at 55 °C, 1 s at 72 °C. Ct-values were calculated 
with the Roche Lightcycler Software Release 1.5.0 using the Abs quant/2nd derivative max option. All 
primers were checked for PCR-efficiencies above 1.94, calculated relative to a cDNA standard ranging 
from 1:10, 1:50, 1:100, and 1:1000 dilutions.  
For cDNA transcript quantification, expression of target nucleic acids was calculated relative to the 
housekeeping genes Hypoxanthine-guanine phosphoribosyltransferase (Hprt), TATA box binding 
protein (TBP) and β-actin using the ΔΔCT-method [178]. 
Statistical analysis was performed as described in section 3.2.12. 
3.2.10 Laser capture microdissection (LCM) 
Material  
Name Manufacturer 
500 µl AdhesiveCap, opaque adhesive filling Zeiss, München, Germany 
MembraneSlide 1.0 PEN  Zeiss, München, Germany 
QIAamp DNA Micro Kit Roche Diagnostics, Mannheim, Germany 
 
Non standard equipment  
Name Manufacturer 
ZEISS P.A.L.M. MicroBeam (Zeiss, München, Germany) 
P.A.L.M. Robo V4 software (Zeiss, München, Germany) 
Qubit® dsDNA HS Assay Kit Agilent Technologies, Palo Alto, USA 
 
58  3. Material and Methods 
MGs were dissected from ACI rats at PND 180 at the TU Dresden by the group of Prof. Dr. Günter 
Vollmer (see section 3.2.1). Cryosections were collected on PEN-membrane covered slides and 
stained with hematoxylin and eosin (H&E) in a standard operating procedure at TU Dresden by the 
group of Prof. Dr. Michael Muders.  
In order to enrich for mammary epithelial cells from the cell mix present in a bulk MG, non-contact 
LCM was performed using the ZEISS P.A.L.M. MicroBeam system. This two-step procedure consists of 
cold ablation and catapulting of the area of choice into adhesive cap tubes without any contact to 
the specimen and against gravity. Focus and laser energy were optimized for each process using a 
pulsed UV laser (355 nm, 2 ns, max. 100 Hz) with an energy output at the outlet opening (objective) 
<20 μJ (2 mW). Mammary epithelial cells were focused using an upright widefield microscope (Axio 
Imager.Z1) and a ZEISS FLUAR 5x/0,25 Air objective lens. The check point function of the Robo V4 
software was used to control for correct catapulting and the cutting area was calculated in terms of 
mm2. For healthy MG between 3-5 mm2 and roughly 1 mm2 from DCIS samples were used for DNA 
isolation.  
Genomic DNA from healthy animals was isolated using the QIAamp DNA Micro Kit according to the 
manufacturer`s recommendations with minor modifications. Briefly, 15 µl Buffer ATL and 10 µl 
Proteinase K were mixed and added to the collected laser microdissected sample in the adhesive cap. 
For protein digestion, samples were incubated upside down for >12 h at 56 °C before tubes were 
centrifuged and 25 µl of additional Buffer ATL was added. For DNA binding, 50 µl of Buffer AL as well 
as 50 µl ethanol (96-100 %) were added, mixed and the liquid was transferred to a QIAamp MinElute 
column. Columns were washed by adding 500 µl buffer AW1 and 500 µl buffer AW2. In order to 
remove residual contaminates from buffer AW1 columns were inverted during AW2 washing steps. 
Columns were dried of residual ethanol by centrifugation for 3 min and 13,000 rpm and DNA was 
eluted using 20 µl buffer EB. The eluate was pipetted back on the column in a second elution step in 
order to concentrate DNA. Quantification of DNA was done using Qubit® dsDNA HS Assay Kit. 
Bisulfite conversion for MGs was performed as described in section 3.2.7.5. 
Laser captured specimens from tumors were directly subjected to bisulfite conversion using the DNA 
Methylation Direct Kit (Zymo Research) according to the manufacturer's instructions with minor 
modification. Briefly, samples were incubated with Proteinase K for >12 h at 56 °C and bisulfite 
conversion was directly performed using the cell lysate as described in 3.2.7.5. 
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3.2.11 Immunohistochemistry (IHC) 
Protein expression of proliferating cell nuclear antigen (PCNA) and progesterone receptor (Pgr) MGs 
of Wistar rats was performed using IHC by the group of Prof. Dr. Dr. Patrick Diel at the German Sports 
University Cologne as previously described [179] (see section 4.3.1.3). 
Protein expression of marker of proliferation Ki67 and Pgr in MGs of ACI rats was performed by the 
group of Prof. Dr. Günter Vollmer at the TU Dresden as previously described [180] (see sections 
4.3.1.3 and 4.3.5.1). 
3.2.12 Statistical analysis 
3.2.12.1 Wistar rats and developmental effects in ACI rats 
Methylation values were analyzed as median amplicon methylation. Spearman correlation coefficient 
rho was calculated to assess pairwise correlation of methylation levels between genes. Beta-
regression was used to compare methylation levels between diet and ER groups. Likelihood-ratio test 
was used to test for global differences between multiple groups. Contrast tests based on the beta-
regression model were used to make pairwise group comparisons. Interaction term was tested to 
identify E2-dependent group effects. Spearman correlation coefficient rho was calculated to assess 
correlation between methylation and gene expression levels. Corresponding 95 % confidence 
intervals based on Fisher’s z-transformation were calculated. For group comparisons, gene 
expression values were log2-transformed if beneficial. Linear regression was used to compare 
expression levels between groups. F-test was used to test for global differences between multiple 
groups. Contrast tests based on the linear regression model were used to make pairwise group 
comparisons. Interaction term was tested to identify E2-dependent group effects. 
3.2.12.2 E2-induced breast carcinogenesis in ACI rats 
A linear mixed model was used to assess differences in DNA methylation and mRNA expression levels 
between diets and tissue types. A random rat effect was included to account for multiple 
tumor/tissue samples from the same animal. A model with diet and tissue effect was fitted. In a 
second model interaction term between diet and tissue was included and tested. P-values were 
adjusted for multiple testing across genes using Benjamini-Hochberg correction in order to control 
the false discovery rate. Calculations were performed with R package nlme. 
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4. Results 
The aim of the present project was to investigate the impact of IF on DNA methylation and estrogen 
responsiveness in vivo. A short-term rat uterotrophic assay was conducted to characterize the E2-
modulating ability of different IF exposure scenarios. Furthermore, a long-term E2-induced rat 
mammary carcinogenesis experiment was performed to investigate the mammary cancer preventive 
potential of IF in a daily dietary intervention protocol. 
4.1 Effects of IF exposure on hormone responsivity in healthy Wistar rats 
Previous studies have demonstrated the potential effects of IF on several endocrinological 
parameters and a variety of cellular signaling pathways. In order to examine the impact of IF-
intervention on DNA methylation, we investigated MG tissue of rats that were maintained for distinct 
time periods on different diets containing IF at increasing doses (Figure 8). 
 
 
After OVX at PND 80 and decline of endogenous hormones for two weeks, a three-day rat 
uterotrophic assay was conducted to analyze whether the IF intervention modulated E2 sensitivity of 
the adult MG. Effects regarding proliferation, ER-dependent and -independent gene expression as 
well as DNA methylation were investigated at the day of sacrifice. Additionally, onset of puberty and 
uterine wet weights (UWW) were monitored as a measure of hormone responsivity. Main results for 
groups CC, LL and HH have recently been published, including further parameters [160]. 
Figure 8: Experimental outline of the rat 
uterotrophic assay in Wistar rats. 
Periods of exposure to IF-free control diet C (3 ppm 
IF) are indicated by grey lines, exposure to IF-
enriched diets (low (L), medium (M), and high (H) IF 
diets containing 68, 232 and 503 ppm IF aglycone 
equivalent, respectively) are indicated by different 
shades of blue. All animals were OVX at PND 80, 
stimulated with either E2 or vehicle from PND 94 for 
three days and sacrificed at PND 97. Group names 
indicate dietary IF exposure before and after OVX. 
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4.1.1 Onset of puberty and rat uterotrophic assay (Results provided by Blei/Diel, DSHS Cologne) 
For the rat uterotrophic assay the soy extract was added to an IF-depleted control diet (C, 3 ppm IF) 
leading to average IF aglycone equivalents of 68 ppm for IF-low diet (L) and 503 ppm for IF-high diet 
(H). Overall intake of the C, L and H diets resulted in a average daily exposure to IF aglycone 
equivalents of 0.2 mg/kg bw, 4.9 mg/kg bw and 36.6 mg/kg bw, respectively (for details see [160]). 
Lifelong IF exposure at low or high concentrations (LL, HH), but also when started at PND 21 (CHC) 
significantly influenced the onset of puberty as specified by an earlier vaginal opening by about 1.5 
days (p=0.0073, one way ANOVA) (Figure 9). IF intervention without E2 stimulation had no effect on 
UWW, independent of the time point of exposure and dose. However, treatment with E2 led to a 
significant increase of UWW in all diet groups (p<0.0001). Interestingly, animals exposed to high IF 
levels only during the period of hormonal decline (after OVX, group CH) were more sensitive to E2 
than animals on control diet (CC) and UWW increased by 12-fold, whereas exposure to H diet only 
during puberty (group CHC) slightly reduced responsivity and increased UWW by only 5-fold, 
suggesting a preventive effect of early IF exposure (not significant). Notably, lifelong low, medium 
and high levels of dietary IF slightly increased E2-induced UWW compared to the control group. This 
effect was not observed when subsequently to OVX animals were exposed to H diet (group MH), 
which lead to a less sensitive response to E2 stimulation and resulting in slightly lower UWW (not 
significant). 
 
 
Figure 9: Effects of IF intervention on vaginal opening and uterus responsivity to E2 stimulation. 
Each dot in the scatter plots represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-97) 
for vaginal opening (VO) and uterus responsivity to E2 stimulation measured by uterus wet weight (UWW). Median values 
per group are indicated by a horizontal line, vertical lines indicate interquartile range. Group names indicate dietary IF 
exposure relative to pre and post OVX (IF-free control diet (C), low (L), medium (M), and high (H) IF diets). 
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4.1.2 Estrogenic and proliferative response measured by reference genes (Results provided by 
Karin Klimo) 
In order to investigate the effects of the three day E2 challenge on the MG, we determined the 
estrogenic response by measuring changes in mRNA expression of selected reference genes for E2 
responsiveness (i.e., Pgr, Greb1 and C3), for proliferation (i.e., Ki67 and PCNA), for TFs involved in E2 
signaling (i.e., Gata3 and FoxA1), as well as hormone receptors (i.e., AR, Esr1, Esr2 and Vdr) and Krt8 
as a marker for epithelial cells (Figure 10 and for statistical analysis Table 8). Gene expression levels 
were measured in all dietary groups except for MC and MH, for which no RNA was available.  
As expected, expression of Pgr, as a prototypical estrogen responsive gene, was low in normal MGs 
and got massively upregulated upon post OVX E2 challenge (Figure 10A). This E2-induced effect was 
not as pronounced for C3 and Greb1. Here, mRNA expression was significantly modified by the 
different IF treatments particularly due to the CH and HH diet. For C3 the post OVX IF intervention 
(CH group) induced C3 expression to levels observed after E2 treatment, whereas, lifelong high IF 
levels (HH) showed a rather anti-estrogenic response and prevented C3 expression. Significant 
interactive effects of lifelong IF levels and E2 exposure further increased gene expression for Greb1 
in a dose-dependent manner and suggested an estrogenic mode of action. 
Similarly, the proliferation marker PCNA illustrated an E2 response leading to increased mRNA 
expression (borderline significant p=0.0549) although IF intervention alone as well as in combination 
with E2 treatment affected mRNA expression of Ki67 and PCNA to a greater extent (Figure 10B and 
Table 8). Interestingly, short term exposure to high IF levels strongly modified estrogen response in 
the proliferation markers in an opposing manner. For PCNA, estrogenic response was increased by 
pubertal (CHC) and post OVX (CH) high IF dose whereas mRNA expression levels for Ki67 were 
reduced. 
Although effects were not as pronounced, expression of hormone receptors Vdr and Esr1 was clearly 
affected by E2 treatment (for Esr1 borderline significant p=0.0577) (Figure 10C). Esr1 was massively 
upregulated after a short term post OVX IF exposure (CH) and Vdr was additionally affected by a 
pubertal IF exposure (CHC), increasing mRNA expression of the non E2-treated group to levels 
observed after E2 treatment. Notably, E2 responsive gene expression was enhanced after both 
pubertal and short term post OVX high IF exposure.  
GATA3, a TF involved in E2 signaling and an important regulator for luminal differentiation did not 
show a pronounced E2 response but interesting expression patterns due to different IF exposures 
(Figure 10D).  
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Figure 10: Estrogenic and proliferative response detected by reference gene expression in Wistar rats 
For markers of A: E2 responsiveness, B: proliferation, C: hormone receptors and D: for TFs involved in E2 signaling, as well as E: Krt8, as a marker for epithelial cells. Each dot in 
the aligned dot plots represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-97). Median expression per group is indicated by a horizontal line, 
with vertical lines indicating interquartile range. The median expression level of the control group is indicated by a dashed line. For statistical analysis see Table 8. Group names 
indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), low (L), medium (M), and high (H) IF diets). 
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While a lifelong IF intervention (group HH) reduced GATA3 mRNA expression, short term high level of 
IF increased GATA3 expression independent of timing of exposure to OVX (groups CHC and CH).  
Krt8 as a marker for epithelial cells was not significant modified by the E2 challenge (Figure 10E). 
However, the expression pattern resembled the IF-induced estrogenic pro-proliferative effects by the 
short term high IF exposure as seen for, e.g., PCNA, Gata3 and Esr1, as well as the preventive E2-
repressive action as observed for C3, Gata3 and Vdr, induced by a lifelong IF intervention which was 
attained in a dose dependent manner (groups LL and HH). Ar, Esr2 and Foxa1 were not affected by 
any treatment. 
 
Table 8: Statistical analysis of the estrogenic and proliferative response of Wistar rats. 
 Source of 
Variation 
E2 treatment 
[p value] 
IF intervention 
[p value] 
Interaction 
[p value] 
 
 
    
 
 Ar 0.4546 0.7364 0.4373  
 C3 0.7713 0.0002 0.4949  
 Esr1 0.0577 < 0.0001 0.2205  
 Esr2 0.4669 0.3701 0.1136  
 Foxa1 0.414 0.8242 0.2386  
 Gata3 0.5696 < 0.001 0.1365  
 Greb1 0.4108 0.0351 0.0024  
 Ki67 0.5689 0.0101 0.0222  
 Krt8 0.4517 0.0020 0.2251  
 PCNA 0.0549 < 0.0001 0.0430  
 Pgr < 0.0001 0.3133 0.2817  
 Vdr 0.0275 0.0018 0.2815  
      Statistical significance of differences was calculated for all reference genes using two way ANOVA with the factors: E2 
treatment, IF intervention and interaction between E2 treatment and IF intervention across the dietary groups available 
(CC, CHC, CH, LL, HH). 
 
4.1.3 IHC in mammary gland tissue (Results provided by Blei/Diel, DSHS Cologne) 
In order to evaluate the influence of IF on the estrogenic and proliferative response of MG epithelia 
cells, protein expression of Pgr (PR) as a sensitive marker for E2 responsiveness and of PCNA a well-
established proliferation marker was determined by IHC (Figure 11). This technique enables a 
quantitative assessment of PR and PCNA protein expression in mammary epithelial cells independent 
of the bulk of cell types by which they are surrounded.  
As previously observed for PR gene expression (see section 4.1.2), no signal for positively labeled 
nuclei for PR was detected in all groups without E2 stimulation. However, treatment with E2 
significantly increased the percentage of positively labeled nuclei to up to 27 % in the LL diet group. A 
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highly statistical significant effect of the combination of diet and E2 could be observed. Interestingly, 
low IF levels in diet (group LL) increased the percentage of positively labeled nuclei after E2 
treatment by an additional 6 % when compared to the control group CC (21 %), whereas lifelong 
exposure to high IF levels in diet (group HH) prevented the increase in PR expression and resulted in 
10 % positively labeled nuclei.  
 
 
Figure 11: PR and PCNA protein expression levels in response to IF and E2 exposure in Wistar rats. 
Protein expression of the E2-responsive PR and the proliferation marker PCNA in the MG determined by IHC. Each dot in 
the scatter plot represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-97). Median 
values per group are indicated by a horizontal line, vertical lines indicate interquartile range. The median expression level of 
the control group is indicated by a dashed line. Statistical significance of differences was calculated using Two-way ANOVA 
with the factors: E2 treatment, IF intervention and interaction between E2 treatment and IF intervention. n.d. not detected. 
Group names indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), low (L), medium (M), and 
high (H) IF diets). 
 
Interestingly, medium levels of dietary IF pre OVX (group MC) reduced the E2-induced PR protein 
expression by about one third compared to the control group. This effect was not observed when 
subsequently to OVX animals were exposed to H diet (MH), which lead to a more sensitive response 
to E2 stimulation and upregulation of PR protein expression to levels of the control group. Thus, high 
IF exposure after OVX abolished the preventive effect of a medium pre OVX IF dose, but not of a 
lifelong high IF dose.  
Treatment with E2 and IF alone as well as the combination of both significantly increased the 
proliferation index in the MG from 0 % in the CC group up to 50 % positively labeled nuclei for PCNA 
in the LL group. Interestingly, low IF levels in the diet (group LL) elevated PCNA expression also in the 
absence of E2 (~10 % positively labeled nuclei) whereas high IF levels (group HH) prevented the 
increase in PCNA expression in response to E2 treatment by two thirds compared to control diet to 
only 15 % nuclei positively labeled for PCNA. Notably, for PCNA we could observe a similar effect in 
the MC and MH groups as for PR protein expression. Medium levels of IF prior OVX (MC) reduced 
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PCNA protein expression to only 30 % positively labeled nuclei. This was reversed when animals were 
exposed post OVX to H diet (MH), which lead to an increase in PCNA protein expression comparable 
to levels of the control group. For further details see Blei et al. [160]. 
Results for both proteins are in line with the relative mRNA expression of these two genes obtained 
by RT-qPCR (Figure 10). 
Overall, these data indicated that dependent on the timing and/or on the dose, exposure to IF quite 
differentially affected hormone responsivity of the adult MG in Wistar rats.  
4.2 DNA methylome mining in normal mammary glands of Wistar rats 
4.2.1 Enrichment of high and medium methylated DNA for MCIp-Seq 
In order to investigate IF-induced changes in DNA methylation on a genome-wide scale, animals of 
the MC and MH groups were analyzed. These two groups were selected for the analyses because the 
tissue samples were the first to be available. Methyl-CpG Immunoprecipitation (MCIp) was used to 
enrich for medium and highly methylated DNA fragments, followed by next generation NGS (Figure 
12). 
 
 
Figure 12: Flowchart of MCIp-Seq. 
 HS, High salt elution; SF, single fraction elution; NaCl, sodium chloride; (pictures partly provided by 
http://www.illumina.com). 
 
Briefly, for enrichment of methylated fragments DNA from groups MC and MH was ultrasonicated 
and fractionated according to CpG density and methylation status by sequential elution with 
increasing sodium chloride concentrations. It has been suggested that highly methylated CGIs might 
be more resistant to demethylation than regions with intermediate levels of methylation [181]. 
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Therefore, we performed two MCIp experiments, enriching for either highly methylated DNA 
fragments only, using the highest salt containing fraction (HS) or for medium and high methylated 
fragments using a single fraction elution protocol (SF) [75]. 
4.2.2 Identification of IF-induced differential methylated regions 
Raw sequencing reads for samples of all animals per diet group were pooled and aligned to the 
reference rat genome (release rn5, March 2012). Duplicates and low quality reads were filtered out. 
Read coverage of each individual CpG and the overall genomic coverage were measured.  
4.2.3  Genomic coverage 
In total, 17.5 to 18.3 M reads were mapped from the HS elution protocol which covered 24-28 % of 
all available CpGs in the rat genome at least once (Figure 13). For the SF elution, additionally 
containing medium methylated fragments, we obtained 45.4 to 71.7 M reads per group which 
covered 76-85 % of all CpGs. 
 
 
Figure 13: Genomic coverage of MCIp-Seq. 
Coverage depth per single CpG for A: high salt (HS) and B: single fraction (SF) elution. Data processing was the performed 
using the MEDIPs working package of R. 
  
Since reads were distributed over more CpGs, the coverage depth per single CpG was lower than in 
the HS evaluation (saturation correlation 0.98 vs. 0.92) and the number of reads per CpG were lower. 
Read counts were normalized to 10 M reads. IF-induced DMRs were generated and annotated using 
the Homer suite of tools [172]. Data processing was performed by a set of custom Perl and R scripts. 
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4.2.3.1 Relative genomic distribution 
Bioinformatics comparison of genome-wide methylation profiles of the MC and MH groups revealed 
that exposure to distinct IF-containing diets after OVX led to relatively few methylation changes 
(Figure 14A). Overall, we observed more pronounced hypo- than hypermethylation in HS (3,014 vs. 
2,077 DMRs) and slightly more hypermethylation for the SF (296 vs. 1,062 DMRs). The relative 
genomic distribution of the DMRs was very similar in the HS and SF experiment and for hypo- and 
hypermethylation, with less than 1 % mapping to regulatory regions (promoters, CpG islands or 
5’ UTRs), 3-4 % located in exons, and about 90 % accounting for intronic regions, repetitive 
sequences (LINE, SINE, LTRs, simple repeats and satellites) and intergenic regions. 
When comparing hypo- and hypermethylated DMRs identified for HS and SF elution, we detected 
distinct sets of DMRs with just little overlap between different elution protocols as shown in the 
Venn diagrams (Figure 14B). This might be partially explained by the lower coverage in the SF 
experiment and the small number of DMRs.  
 
 
Figure 14: Genomic distribution of DMRs obtained by MCIp-Seq. 
A: Relative genomic distribution of hypo- and hypermethylated DMRs identified between the MC and MH groups. B: Venn 
diagrams for overlapping DMRs between HS and SF experiment. (light grey, HS, high salt elution; dark grey, SF, single 
fraction elution, circles, hypermethylated DMR, squares, hypomethylated DMRs)  
 
4.2.3.2 Overlap and TF motif enrichment 
In order to find TF binding sites that might be enriched in the DMRs identified between the MC and 
MH groups, a de novo TF binding motif discovery as well as an enrichment analysis of known TF 
binding motifs was performed using the Homer suite of tools [172] (Figure 15). 
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Figure 15: Enrichment of TF binding sites in IF-induced DMRs obtained by MCIp-Seq. 
Heatmap showing motif enrichment in hypo- and hypermethylated DMRs detected by high salt (HS) and single fraction 
elution (SF) of MC vs. MH group. Different shades of grey indicate the negative decadal logarithm of the enrichment P-value 
ranging from 0 (light grey) to 20 (dark grey). Enrichment scores are depicted as numbers in squares and are calculated by 
dividing the percentage of targets in a given sequence with the percentage of the targets found in background sequences. 
Only significant motifs in at least one of the four DMR sets are shown. 
 
 
Distinct results were obtained when analyzing motif enrichment for both datasets, as only little 
overlap between enriched motifs was detectable between HS and SF. Enrichment was predominantly 
found for basic leucine zipper (bZIP)-domain TFs (i.e., Atf3, Fosl2 and MafK) in hypomethylated DMRs 
and motifs of E26 transformation-specific (ETS)-domain TF family members (i.e., ERG, SpiB and Ets1) 
in hypermethylated DMRs. Both families have been implicated to play important roles in tissue 
development and cancer progression. 
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4.2.4 Confirmation of IF-induced DMRs obtained from MCIp-Seq using MassARRAY 
For validation of DMRs between the MC and MH group observed in the genome-wide methylation 
analysis by MCIp-Seq, quantitative analysis of DNA methylation was performed using mass 
spectrometry-based EpiTYPER MassARRAY technology. Using this system, methylation differences ≥5 
% are detectable by quantifying median methylation of CpG units. 
We selected 14 DMRs with 4-fold enrichment difference between the MC and MH groups, mainly 
located in gene promoter regions or close to the TSS from both MCIp experiments to quantify 
methylation in all experimental groups (Supplemental table 2). 
DMR-associated genes are involved in energy homeostasis and metabolism (Niacr1, Sirt4), DNA 
repair (Gadd45b), cell cycle regulation (Cdh13), cell signaling and cell proliferation (Wap), cell-cell 
communication (Cldn4), cell structure (Gsn), estrogen (Esr1 and Cyp2c6v1) and one-carbon 
metabolism (Aldh1L1) and function as TSGs (PTEN and Wif1) or are frequently down regulated in 
mammary tumors (Arpp21). Extl1 is highly inducible by E2 in rats [173] but its role in human MG 
development has not yet been investigated.  
For most of the candidate regions we were not able to confirm IF-induced methylation changes 
between groups MC and MH detected by MCIp-Seq which is an enrichment-based methylome 
profiling technique. MassARRAY analysis revealed median methylation differences below 10 % (for 
detailed group wise comparisons see Supplemental figure 2) with high interindividual variation in 
methylation levels within dietary groups. Solely for Gadd45b and Cyp2C6v1 we were able to identify 
a statistical significant effect of the post OVX H IF diet on DNA methylation (Figure 16). 
 
 
Figure 16: Median methylation differences between MC and MH groups. 
Each dot in the aligned dot plot represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-
97). Median values per group are indicated by a horizontal line, vertical lines indicate interquartile range. Median 
methylation of the CC group is indicated as horizontal dashed line and summarized Supplemental table 2. For group wise 
comparisons of median DNA methylation for all 14 analyzed candidate genes across all dietary groups see Supplemental 
figure 2. Group names indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), medium (M), and 
high (H) IF diets). 
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A summarizing figure for median DNA methylation differences in the MC and MH groups relative to 
the control CC for the other candidate genes can be found in the Supplemental figure 1. 
4.2.5 Response to dietary IF is dependent on dose and timing of exposure 
In order to investigate rats that were maintained for distinct time periods and diets containing IF at 
increasing doses, we further assessed DNA methylation in IF-induced DMRs identified by MCIp-Seq, 
in MG tissues of the remaining experimental groups using MassARRAY technology (Figure 8). 
4.2.5.1 Critical time windows 
Generally, lifelong exposure rather than a short term treatment regimen is reported to be related to 
beneficial effects to soy IF. Therefore, we were interested whether the observed effects in DNA 
methylation were mainly introduced by the pre OVX IF exposure or whether the short term post OVX 
treatment was the changing trigger. 
In order to asses this question, methylation data across several groups were compared dependent on 
their dietary regime before and after OVX. In principal, groups receiving the same IF dose before OVX 
were combined and the effects of different IF doses prior to OVX were assessed (Figure 17A). The 
same approach was used for post OVX comparison. Here, the dietary groups that were exposed to 
high IF levels after OVX were considered to have the same treatment regime and were compared to 
groups not receiving any IF post OVX (Figure 17B).  
 
 
Figure 17: Statistical outline to assess the timing effects of a pre vs. post OVX IF intervention. 
Group names indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), low (L), medium (M), and 
high (H) IF diets). Periods of exposure to C diet are indicated by grey lines, exposure to IF-enriched diets is indicated by 
different shades of blue. Comparison groups are combined according to their A: pre or B: post OVX dietary regime and are 
highlighted in rectangles (dark orange: combined control group, light orange: combined group for comparison).  
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In general, three different comparison groups were defined for the pre OVX effects, receiving either 
M or H diet before OVX or swapped to H during pubertal phase only (CH). For post OVX comparison a 
single comparison group was available since either C or H diet was administered after OVX. 
Following our statistical analysis more than 75 % of the investigated regions (11 out of 14), DNA 
methylation changes were already present prior to OVX independent whether a medium or high IF 
dose was administered, with three regions (Gadd45, Gsn and Sirt4) affected by either M or H diet 
(Figure 18A).  
 
 
Figure 18: Effects of a pre vs. post OVX IF intervention on DNA methylation. 
Statistical analysis across several experimental groups according to their pre and post OVX dietary regime (for 
details see Figure 17). Likelihood-ratio test was used to test for global differences in DNA methylation 
between multiple groups. Different shades of grey indicate the negative decadal logarithm of the three distinct 
significance levels (from light to dark: p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, white = not significant). Text in boxes 
corresponds to methylation change compared to the combined control group (Hyper: increase and Hypo: 
decrease of methylation; A: without and B: with subsequent E2 treatment after hormonal decline (PND 94).  
 
Interestingly, in more than 90 % of all comparisons early and lifelong exposure to IF increased DNA 
methylation when compared with the combined control group. Solely the promoter region of PTEN 
and Cyp2C6v1 showed a significant effect of the additional post OVX treatment using a high IF dose. 
Here, a clear hypomethylation of the candidate region could be detected.  
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In general, effects of pre and post OVX IF treatment were less pronounced when rats were 
challenged with E2 subsequently after OVX. Although tendencies were less significant, methylation 
was rather increased due to an early and lifelong exposure to IF and predominantly decreased when 
IF was applied only or for an additional period during hormonal decline after OVX (Figure 18B). 
Exposure to high IF only during the pubertal phase (group CHC) does not seem to be responsible for 
the effects on DNA methylation seen due to lifelong and early IF exposure. Only Extl1 and Aldh1L1 
showed a significant change in promoter methylation. However, no clear picture of the direction of 
DNA methylation changes could be drawn by pubertal exposure to IF. Methylation was either slightly 
increased or decreased when compared to the combined control group (not significant) and often 
did not follow any tendency of methylation changes induced by lifelong exposure (Figure 18). 
4.2.5.2 Dose aspects of IF intervention 
In order to address the question whether the observed timing effects were additional affected by the 
different doses of IF, we had a look at dose-effect relationships. First, we looked at all groups 
exposed to high IF levels post OVX and compared the trends of the different IF doses administered 
pre OVX. Three different IF diets namely CH, MH and HH were available for comparison with the 
control group CC. Interestingly, exposure to high IF levels only after OVX (CH group) lowered 
methylation levels of many of the analyzed regions in comparison to CC and all other dietary groups 
(Figure 19). With increasing dietary IF to medium and high levels pre OVX, methylation often 
increased relative to the control group CC, resulting in significant methylation differences between 
the CH, MH and the HH groups, e.g., for Niacr1, Cldn4, Extl1, Wap, Gsn, and PTEN, as well as Esr1, 
Gadd45, and Sirt4, with less pronounced effects after E2 treatment (for a summary of statistical 
analyses see Supplemental figure 2). For Aldh1L1, we observed an anti-correlated pattern. Here, we 
observed strongly decreased DNA methylation in the promoter region in the HH group and increased 
methylation in the CH group. 
When comparing the ability of different pre OVX IF doses to introduce alterations in DNA 
methylation, we were able to detect significant differences between the CH, MH and HH diet. In 10 
out of 14 regions pre OVX methylation changes were induced dose-dependently with a linear trend 
towards hypermethylation in 8 out of the 10 affected genes (Figure 20A left panel). Only Gadd45 and 
Sirt4 showing a bell-shape-like methylation pattern with the medium IF levels increasing methylation 
and higher levels decreasing methylation to values comparable with the control group (Figure 19B). 
We observed a major impact of a medium and high pre OVX IF exposure on DNA methylation with 
alterations up to 18 % (Wap). No significant effects of different pre OVX IF-containing diets were 
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detected for Arpp21, Cyp2C6v1, Wif1 and Cdh13, although the last was identified as being affected 
by a pre OVX medium and high IF treatment, previously (Figure 18). 
 
Figure 19: Trends of different pre OVX IF doses (CH, M and H) on median methylation differences. 
Each dot in the aligned dot plot represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-
97), summarizing A: linear and B: U or bell-shape like alterations in DNA methylation. Median values per group are 
indicated by a horizontal line, vertical lines indicate interquartile range. Median methylation of the CC group is indicated as 
horizontal dashed lines and summarized in Supplemental table 2.For group wise comparison and statistical calculations of 
dose-trend-relationships see Supplemental figure 2 and Figure 20, respectively. Group names indicate dietary IF exposure 
relative to pre and post OVX (IF-free control diet (C), medium (M), and high (H) IF diets). 
 
Next, we were interested whether a lifelong low dose IF treatment (group LL) would be sufficient to 
induce the effects obtained with medium and high IF diets. We compared the groups LL and HH, two 
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treatment regimens with a constant lifelong IF exposure, to group CC with no IF exposure. As already 
described above, lifelong HH diet increased methylation of several genes compared to CC, i.e., Cldn4, 
Extl1, Wap and Niacr1. Notably, low IF levels exhibited opposite effects. Promoter regions were 
hypomethylated in MGs of rats exposed to LL diet when compared to CC and HH groups and led to a 
significantly altered DNA methylation profile in a U-shape like dose-dependent manner (Figure 20A 
right panel and Figure 21A). Exclusively, Extl1, Niacr1 and Wap gained methylation at the 
corresponding promoter regions due to the low IF exposure and a more linear trend towards 
hypermethylation could be detected (Figure 21B). Neither lifelong low nor high IF levels modified 
Arpp21, Cdh13, Esr1, Gadd45b, and Sirt4 methylation levels significantly.  
Overall, there seems to be a critical IF concentration leading to distinct biological effects since the 
lower IF concentrations rather oppose the effects observed with high dietary IF levels.  
 
 
Figure 20: Summary of significant alterations of DNA methylation and gene expression by different IF doses. 
Statistical analysis across several experimental groups according to their dosage regime for A: DNA methylation and B: gene 
expression changes. Different shades of grey indicate the negative decadal logarithm of the three distinct significance levels 
(from light to dark: p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, white = not significant). Shapes in boxes correspond to changes in 
median methylation (A) and relative mRNA expression (B) compared to the control group (/: increase, \: decrease, ᴗ or ᴖ: U 
or bell shaped) with and without subsequent E2 treatment after hormonal decline (PND 94). n.d.: not determined. Group 
names indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), low (L), medium (M), and high (H) 
IF diets). 
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Figure 21: Dose dependent effects of a lifelong IF exposure on median methylation differences. 
Each dot in the aligned dot plot represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-
97), summarizing A: U- or bell-shape like and B: linear alterations in DNA methylation. Median values per group are 
indicated by a horizontal line, vertical lines indicate interquartile range. Median methylation of CC groups are indicated as 
horizontal dashed lines and are summarized in Supplemental table 2. For group wise comparison and statistical calculations 
of dose-trend-relationships see Supplemental figure 2 and Figure 20, respectively. Group names indicate dietary IF 
exposure relative to pre and post OVX (IF-free control diet (C), low (L), and high (H) IF diets). 
 
As expected, E2 treatment had little impact on DNA methylation of the investigated regions since we 
selected particularly IF affected DMRs for quantitative analysis. However, in certain regions a lifelong 
pre OVX exposure to high IF levels altered the susceptibility to E2 treatment which is depicted as a 
decrease (i.e., Cldn4, Extl1 and Wap) or increase (Wif1) in median promoter methylation (Figure 21, 
Supplemental figure 4). For Gsn, promoter hypomethylation was achieved rather by a post OVX H 
diet (MH, HH). On the other site, a prevention of the estrogenic response towards loss of 
methylation (i.e., PTEN, Gsn) or increase in methylation (i.e., Niacr1, Extl1) due to the lifelong pre 
OVX M or H diet was detected. Principally, there was only a minor impact of the IF exposure on the 
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estrogen responsiveness and in more than 70 % this effect was exclusively achieved in the HH group. 
A summarizing figure for median methylation differences across all experimental groups can be 
found in the Supplements (Supplemental figure 5). 
4.2.6 Effects of an IF intervention are reflected in gene expression patterns (analyses performed by 
Karin Klimo) 
In order to determine whether changes in DNA methylation might be correlated with changes in 
gene expression, RT-qPCR was performed. Gene expression levels were measured in all dietary 
groups except for MC and MH, for which no RNA was available. Spearman correlation coefficient rho 
was computed for the comparison of promoter methylation and gene expression.  
Methylation levels of 6 out of 14 genes significantly correlated with expression levels, with 
correlation coefficient rho in the range of -0.34 to -0.52 for negative correlation of Extl1, Cldn4, Wap, 
and Esr1 (higher methylation leads to reduced expression) and 0.29 to 0.33 for Gsn and Wif1 with 
weak positive correlation (Figure 22). 
 
 
Figure 22: Correlations between DNA methylation and gene expression levels in candidate genes obtained by MCIp-Seq. 
Each dot represents one sample. Spearman correlation coefficient rho was computed for the comparison of promoter 
methylation and gene expression. Corresponding 95 % confidence intervals based on Fisher’s z-transformation were 
calculated (grey area). rho: correlation coefficient. 
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Interestingly, all DMRs for which methylation levels correlated with expression levels were annotated 
to promoter regions, emphasizing the relationship between promoter methylation and regulation of 
gene transcription.  
Analysis of gene expression confirmed our observation that timing of IF exposure relative to OVX was 
in many cases a critical determinant for biological effects. Corresponding to the methylation levels, 
gene expression was oppositely affected by pre vs. post OVX H diet. Hypermethylation due to pre 
OVX exposure to high levels of IF mainly lead to transcriptional downregulation whereas 
hypomethylation, predominantly induced by post OVX H diet, increase gene expression (although not 
consistent for all candidate genes) (Figure 23). 
 
 
Figure 23: Effects of a pre vs. post OVX IF intervention on gene expression. 
Statistical analysis across several experimental groups according to their pre and post OVX dietary regime. Different shades 
of grey indicate the negative decadal logarithm of the three distinct significance levels (from light to dark: p ≤ 0.05, p ≤ 0.01 
and p ≤ 0.001, white = not significant). Text in boxes corresponds to methylation changes compared to the combined 
control group (up: increase and down: decrease in gene expression); with (right) and without (left) subsequent E2 
treatment after hormonal decline (PND 94)). Group names indicate dietary IF exposure relative to pre and post OVX (IF-free 
control diet (C) and high (H) IF diets). 
 
Exposure to the high IF dose exclusively during the pubertal period exhibited only minor effects on 
mRNA levels. Consistent with Extl1 hypomethylation, gene expression was significantly up regulated, 
whereas PTEN expression was reduced in the group exposed to E2 after PND 94 (without a change in 
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DNA methylation). These results indicate that pubertal exposure to IF might persistently determine 
transcriptional regulation of these loci. 
Gene expression was significantly affected by a short term post OVX vs. lifelong IF exposure 
detectable between the CH and HH groups (Figure 24). As already indicated in Figure 19, in seven out 
of 14 genes exposure to high IF levels induced alterations in gene expression dependent on the 
exposure time. IF exposure only after OVX downregulated Arpp21, PTEN, and Gadd45, whereas 
Cldn4, Esr1, and Wap mRNA expression levels were induced. For Esr1, PTEN, and Gadd45 IF-induced 
effects were independent of the E2 treatment, since IF-induced gene expression changes were 
persistent also after a three day E2 challenge. 
 
 
 
Figure 24: Trends of short term vs. lifelong high (CH and HH) IF doses  on gene expression. 
Each dot in the aligned dot plot represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-
97). Median rel. mRNA expression to pooled housekeeping genes (HKG: Hprt, TBP and β-actin) is indicated as horizontal 
lines, with vertical lines depicting interquartile range. Median rel. expression of the CC group is indicated as horizontal 
dashed line. For group wise comparison and statistical calculations of dose-trend-relation-ships see Supplemental figure 3 
and Figure 20B, respectively. Group names indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C) 
and high (H) IF diets). 
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For Arpp21, Cldn4, Wap, and Extl1 effects of the high IF diet on mRNA expression was diminished 
when E2 was administered. The animals did not show a difference in Gadd45 gene expression 
without E2 exposure but when challenged with E2 for three consecutive days high lifelong IF levels 
increased the estrogenic response. 
Similarly, lifelong exposure to different IF doses, i.e., CC, LL and HH led to significant group wise 
changes in gene expression (Figure 25). Of the seven regions that were affected by a pre OVX 
exposure (Figure 23), five regions additionally showed dose dependent effects, i.e., Arpp21, PTEN, 
Cldn4, Esr1, and Extl. In agreement with the observed U-or bell-shaped trends in methylation 
changes, relative mRNA expression was affected by lifelong exposure to the low IF dose (group LL) 
(also see Figure 20). 
Comparable to the modifications in DNA methylation, E2 treatment from PND 94 to 97 had nearly no 
impact on the transcriptional regulation of the analyzed candidate genes. Solely for Extl1, exposure 
to high IF levels increased the susceptibility to the estrogen responsiveness, but only if administered 
in a lifelong fashion (Supplemental figure 4). 
A summarizing figure for relative mRNA expression across all experimental groups can be found in 
the supplements (Supplemental figure 6). 
 
 
Figure 25: Dose dependent trends of a lifelong IF exposure (LL and HH) on gene expression. 
Each dot in the aligned dot plot represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-
97) ), summarizing A: bell- or U-shaped and B: linear alterations in gene expression. Median rel. mRNA expression to pooled 
housekeeping genes (HKG: Hprt, TBP and β-actin) is indicated as horizontal lines, with vertical lines depicting interquartile 
range. Median rel. expression of the CC group is indicated as horizontal dashed line. For group wise comparison and 
statistical calculations of dose-trend-relationships see Supplemental figure 3 and Figure 20B, respectively. Group names 
indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), low (L), and high (H) IF diets). 
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4.3 Lifelong exposure to dietary IF affects specific endpoints in ACI rats 
In a second study, we focused on the impact of a lifelong dietary IF exposure on the kinetics of DNA 
methylation changes in MGs of ACI rats during developmentally critical time windows, e.g., 
embryonic/fetal, early postnatal, and pubertal periods, as well as on the cancer preventive efficacy 
during E2-driven carcinogenesis of the MG. 
4.3.1 Kinetics of DNA methylation in the course of normal MG development  
For the lifelong IF intervention protocols, ACI rats were assigned to control C or H diets prior to 
mating. Female offspring in the H diet group was exposed to IF during all developmental windows of 
fetal and neonatal, as well as pubertal and adolescent development. In order to better understand 
the impact of IF on the kinetics of DNA methylation changes during normal MG development, rats 
were sacrificed before and after puberty at PND 21 and PND 50±1, during adolescence at PND 81±2 
and PND 97±2, as well as in adulthood at PND 180±3 (Figure 26). 
 
 
 
4.3.1.1  Onset of puberty and effects on physiological parameters (Results provided by 
Möller/Vollmer TU Dresden). 
In our previous study in Wistar rats, we demonstrated potential effects of IF on several 
endocrinological parameters such as onset of puberty and UWW (Figure 9). 
For comparison, we also analyze ACI rats for IF-induced effects on puberty onset and UWW. Lifelong 
IF exposure resulted in an about 1.5 days earlier vaginal opening compared to the control group C 
Figure 26: Experimental outline to 
study DNA methylation kinetics 
during MG development. 
 
August Copenhagen Irish rats re-
ceived either control (C) or high IF 
diet (H), containing 3 ppm and 
503 ppm IF aglycone equivalents, 
respectively, and were sacrificed 
before and after puberty (PND 21 
and 50), during adolescence (PND 
81 and 97) as well as in adulthood 
(PND 180). PND: post natal day 
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(not significant p=0.3452, Figure 27A). Relative UWW normalized to body weight were not affected 
by dietary exposure to IF (Figure 27B), but we observed significant differences between the age 
groups (p=0.0066) with a pronounced reduction of UWW after puberty at PND 50 and 81 and an 
increase above prepubertal levels at older age.  
 
 
Figure 27: IF-induced effects on vaginal opening and relative uterus wet weight across all developmental windows. 
A: Vaginal opening (VO), B: uterine wet weight (UWW) from PND 21-180. Each dot in the plots represents one animal (light 
grey, control diet and dark grey, IF diet). Horizontal dashed lines indicate median values of the control group (PND 21, C 
diet), vertical lines indicate interquartile range. Statistical significance of differences was calculated using Two-way ANOVA 
with the factors: Time (age), Treatment (IF intervention), and interaction between age and IF intervention. 
 
 
4.3.1.2 Estrogenic and proliferative response of the MG across developmental stages (Results 
provided by Karin Klimo). 
In order to monitor the impact of lifelong IF intervention on MG development, we monitored E2 
responsiveness by determining mRNA expression of selected reference genes for proliferation (e.g., 
Ki67, PCNA) and hormone receptors (e.g., Pgr, Esr1, Esr2), see Figure 28 and Figure 29. 
During normal development of the MG relative mRNA expression of the proliferation marker Ki67 
increased from PND 21 to PND 180 (borderline significant p=0.0671). Interestingly, IF intervention led 
to a significant increase in PCNA mRNA expression at prepubertal phase (p=0.0147) which returned 
to basal levels observed in control groups from post-puberty onwards. No signal for Pgr mRNA 
expression was observed at PND 21 in both diet groups. From puberty onwards, Pgr mRNA 
expression significantly increased, displaying a clear age effect (p=0.0229) which was not affected by 
the dietary IF intervention. However, transcript levels of Esr1 and Esr2 exhibited no significant 
alterations during MG development. 
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Figure 28: Gene expression of E2-responsive genes across all developmental windows. 
Relative Gene expression of A: proliferation markers and B: hormone receptors during all developmental windows from 
PND 21 until PND 180. Each dot in the aligned dot plots represents one animal (light grey, control diet and dark grey, H 
diet). The horizontal dashed line indicates median methylation values from the C group at PND 21. Vertical lines indicated 
interquartile range. Statistical significance of differences was calculated using Two-way ANOVA with the factors: Time (age), 
Treatment (IF intervention), and interaction between age and IF intervention. For comparison between consecutive 
developmental windows see Figure 29. 
 
 
 
 
 
Figure 29: Statistical comparison of gene expression of E2-responsive genes between consecutive developmental 
windows. 
For statistical analysis of pair wise comparison a parametric beta regression model was used to test for significant 
differences in gene expression. Pairwise comparisons were adjusted for multiple testing (Tukey test). Shapes in boxes 
correspond to changes in gene expression /: increase, \: decrease between age groups indicated above. Different shades of 
grey indicate the negative decadal logarithm of three distinct P-values (p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, ranging from light 
to dark grey, white = not significant).  
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4.3.1.3 IHC in mammary gland tissue (Results provided by Möller/Vollmer TU Dresden). 
For comparison with mRNA expression, protein levels of Ki67 and PR were determined in all age 
groups by IHC. The proliferation index (percentage of nuclei stained positive for Ki67) gradually 
increased during normal development of the MG in the control group C, from 10 % and 20 % at PND 
21 and 50, to 37 % at PND 180. Interestingly, lifelong IF intervention increased proliferation indicated 
by Ki67 protein expression at young age (PND 21 and 50) to levels similar to those seen at older age 
(on average 46 % positively labeled nuclei) and even above the level detected in adult ACI rats 
maintained on C diet at PND 180 (Figure 30A). 
 
 
Figure 30: IF-induced effects on Ki67 and PR protein expression during MG development. 
A: Expression of the proliferation marker Ki67 and B: the E2-responsive gene PR in the MG determined by IHC. Each dot in 
the aligned dot plots represents one animal (light grey, control diet and dark grey, H diet). Horizontal dashed lines indicate 
median expression level of the control group (PND 21, C diet), vertical lines indicate the range. Statistical significance of 
differences was calculated using Two-way ANOVA with the factors: Time (age), Treatment (IF intervention), and interaction 
between age and IF intervention. 
 
No signal for PR was observed at PND 21 in the C diet group. From puberty onwards, PR expression in 
MGs significantly increased to 30 % positively labeled nuclei at PND 180, indicating a clear age 
influence (p<0.0001). Dietary IF intervention significantly (p=0.0217) increased the percentage of 
positively labeled nuclei especially in the younger animals (up to 20 % at PND 21). For both, Ki67 and 
PR, we observed a statistically significant effect of the combination of IF intervention and age. 
4.3.2 Implementation of a RRBS library preparation protocol and trouble shooting 
Similar to the investigations in Wistar rats, we intended to perform genome-wide methylation 
analyses to investigate the impact of the IF intervention on DNA methylation in the MG during 
development. We decided to establish the RRBS technology for the ACI rat experiments, since it 
avoids the drawbacks of the enrichment-based MCIp method used in the Wistar study. The 
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advantage of RRBS lies in the fact that this method is not enrichment-based and provides a direct 
quantitative readout of single nucleotide methylation levels for biostatistics comparison of groups. 
In cooperation with Christoph Bock (CeMM, Research Center for Molecular Medicine of the Austrian 
Academy of Sciences, Vienna), we have established a RRBS library preparation pipeline. Next-
generation sequencing of the libraries was performed at CeMM. 
4.3.2.1 RRBS library preparation  
Briefly, genomic DNA is digested with MspI creating fragments with a 5'-CpG at the terminal ends. 
Fragments are end repaired, A-tailed, and ligated to standard Illumina adapters. Libraries are 
multiplexed by six in one library pool and epigenetic methylation marks are converted into genetic 
marks by bisulfite treatment. This information can be read by genomic sequencing using the 
sequencing by synthesis technology provided by Illumina. 
The MspI restriction endonuclease cuts at C↓CGG and is insensitive to CpG methylation. Digestion 
with MspI generates a predictable number of DNA fragments, including highly redundant fragments 
from microsatellite DNA (Figure 31A).  
 
 
Figure 31: Characteristics of a RRBS library preparation. 
A: In silico MspI digest using the rat genome annotation rn5 and B: Final RRBS library using rat specimen visualized on an 
Agilent high sensitivity DNA chip. Peaks at 35 and 10,380 bp are internal markers used for DNA quantification as well as 
adapter dimers. FU: fluorescence units. 
 
Microsatellites are simple sequence repeats of 1 to 4 nucleotide units. These single units are 
repeated for characteristic number of times, therefore microsatellites can be used as genetic 
markers, e.g., for genetic fingerprinting in forensics and as positive controls in DNA library 
preparation. Since all fragments including microsatellite fragments are ligated to Illumina standard 
adapters, after PCR amplification highly redundant microsatellite DNA is clearly visible in final RRBS 
libraries, monitored for size confirmation on a Agilent high sensitivity DNA chip. By adding an extra 
130 bp (adapter size) to the MspI introduced fragment length, we could identify microsatellites at 
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roughly 300, 330 and 500 bp size/migration time with high fluorescence intensity (FU), corresponding 
to their redundancy (Figure 31B). 
4.3.2.2 Library preparation troubleshooting 
RRBS library preparation is multistep process starting from DNA isolation and MspI digestion to End 
repair, A-tailing, and adapter ligation, multiple clean up steps before and after library multiplexing, as 
well as bisulfite conversion, and final enrichment PCR. 
Potentially each of these steps is prone to errors that jeopardize library integrity. 
Loss of fragments 
SPRI beads and the amount of corresponding buffers used to remove adapters, dNTPs, and enzymes 
from the reactions affect the size of fragments eluted from the beads (or that bind in the first place) 
and determine size distribution of the final library. The combination of amount of beads and buffer is 
a crucial step of optimization. Particularly, the concentration of polyethylene glycol defines the 
binding of DNA to the beads. AMPure XP magnetic beads show high affinity to double stranded DNA 
and 1 µl is able to retain more than 1 µg DNA. Since RRBS is a low input technique we used only 
100 ng DNA for library preparation. Therefore, SPRI beads are highly overdosed. To avoid overdosing, 
AMPure XP magnetic beads were purified from the delivered buffer and were diluted 1:5 with a self-
made "crowding reagent". Final fragment binding was controlled for pure and diluted SPRI beads 
showing optimal DNA binding capacity at low DNA input and two different binding regimes (0.75x 
and 1.5x volumes of beads, Figure 32A and B, respectively). As expected, by increasing the ratio of 
SPRI:DNA from 0.75x to 1.5x smaller fragments were bound and eluted from the beads. The overall 
quantity of retained DNA was not affected as detected by identical fluorescence intensities, 
underscoring the high quality DNA binding ability of the beads diluted by the crowing reagent. 
 
 
Figure 32: DNA binding capacity of pure and diluted AMPure XP SPRI beads.  
Determination of DNA binding of pure (blue) and 1:5 diluted (red) AMPure XP SPRI beads by adding A: 0.75x and B: 1.5x 
volume of beads to a Fermentas gene ruler. FU: fluorescence units Peaks at 35 and 1500 bp are internal markers used for 
DNA quantification. 
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For the epigenetic profiling of the kinetics of DNA methylation during normal developmental of MGs 
in ACI rats, we prepared four libraries for 24 samples (MGs of six ACI rats on two diets each, at PND 
21 and 50). Final enrichment PCRs were cleaned up using pure SPRI beads.  
Although pure and diluted beads performed identical in the initial experiment depicted in Figure 32, 
in this library preparation experiment smaller fragments less than 250 bp were not bound to the 
beads and got lost in the final library (Figure 33A). The fragments smaller than 250 bp were not 
retained in the four libraries of the 24 MG samples, with a slightly higher amplification of fragments 
with sizes between 300 bp to 500 bp in the pink library compared to the three other libraries. 
 
 
Figure 33: Troubleshooting: Loss of fragments during RRBS library preparation. 
Final library quality was monitored on Agilent high sensitivity DNA chip, detecting fluorescence units (FU) vs. size/migration 
time. Electropherograms showing loss of fragments with A: sizes less than 250 bp (compare representative library profiles 
with the blue profile of an optimal library) and B: a general loss of amplified DNA and larger than 400 bp (compare profiles 
to the optimal profile in A and decreasing FU per RRBS library). Peaks at 35 and 10,380 bp are internal markers used for 
DNA quantification as well as adapter dimers.  
 
Fragment loss also occurred when specific thermo cyclers were used for the enrichment PCR 
(examples in Figure 33B). Here, particularly longer fragments over 400 bp or even the overall 
amounts of libraries were reduced. Varying ramping rates even of identical cyclers should be taken 
into consideration for library preparation, especially if protocols do not perform well in other hands. 
Therefore, besides fresh and clean consumables, the choice of the cycling machine and the 
corresponding ramping rates should be controlled properly. 
Bisulfite conversion rate 
In order to maintain methylation information during PCR amplification, DNA samples are subjected 
to bisulfite conversion. Bisulfite treatment of DNA leads to a chemical deamination of unmethylated 
cytosines (C) to uracils (U). In subsequent PCR reactions, all uracils (from unmethylated Cs) are 
amplified as thymines, allowing discrimination of unmethylated and methylated Cs at single CpG 
resolution, since only methylated Cs are amplified as cytosines. Achieving a consistent C to U 
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conversion of unmethylated DNA is crucial for obtaining reliable quantitative methylation data. Since 
several bisulfite conversion protocols were available in our lab, RRBS libraries were bisulfite treated 
following three different protocols to determine the procedure leading to highest bisulfite 
conversion rates. 
The Methylation Direct Kit from Zymo Research was used with two different cycling conditions, 
varying in the time the DNA is heated to 95 °C. Protocol 1 (30 s): 16x (30s at 95°C, 10 min at 60°C) 
and Protocol 2 (60 s): 16x (60s at 95°C, 10 min at 60°C). For a third approach, the standard Zymo 
Research methylation Kit was used according to manufacturer`s recommendations; Protocol 3: 16x 
(15s at 95°C, 60 min at 50°C). This protocol runs overnight with longer incubation at a lower 
temperature compared to Protocols 1 and 2. 
In general, all three methods considerably harm the DNA, leading to an overall library loss of >90 % 
as detected by qPCR (data not shown). However, different bisulfite conversion protocols also affect 
the loss of fragments. Particularly, conversion protocols 2 and 3 reduced the overall amount of 
library which can be seen by lower fluorescence intensities using the Agilent high sensitivity DNA chip 
(Figure 34A). However, protocols 2 and 3 showed the most reliable bisulfite treatment with 
conversion rates between 98.5-99 % (Figure 34B). For all the RRBS libraries we used bisulfite 
conversion Protocol 2.  
 
 
Figure 34: Troubleshooting: Bisulfite conversion rate during RRBS library preparation. 
Three different bisulfite conversion protocols of commercially available kits regularly used in our lab were tested for A: loss 
of library fragments monitored on an Agilent high sensitivity DNA chip and B: bisulfite conversion rates calculated based on 
cytosine conversions in a non CpG context. Methylation Direct Kit from Zymo Research was used for Protocol 1: 16x (30s at 
95°C, 10 min at 60°C) in green and Protocol 2: 16x (60s at 95°C, 10 min at 60°C) in blue. For Protocol 3: 16x (15s at 95°C, 
60 min at 50°C) in red, the standard Zymo Research methylation Kit was used according to manufacturer`s 
recommendations. FU: fluorescence units 
 
4.3.3 Epigenetic profiling of developmental effects during puberty 
As outlined above, we subjected 24 MG samples to RRBS library preparation and NGS, in close 
cooperation with Christoph Bock (CeMM, Vienna). After pipeline adjustments for the alignment to 
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the rn5 rat genome, initial bioinformatics analyses of the sequencing data were also performed at 
CeMM.  
Out of 24.7 M CpGs that are present in the rat genome we covered roughly 2.18 M CpG (unique 
aligned motifs) with a general mean coverage of 32x per site. By sequencing our libraries on one lane 
of a Illumina HiSeq2000 machine, we obtained 14-35 M high quality reads per sample with an 
alignment rate ranging from 73–76 %. Calculations with a bisulfite conversion rate of 98.5% yielded 
to a mean global methylation of 64 % at PND 21 and 50. A general summary of the obtained 
sequencing results of pre- and postpubertal ACI rats can be found in Supplemental table 3. 
For the identification of DMS, the RnBeads pipeline was used. For efficient detection of DMS 
resulting from exposure to IF-depleted or -enriched chow within each age group, only CpG sites were 
considered with a minimum coverage of 20 reads in at least 5 of the 6 samples per dietary group, 
reducing the number of sites to roughly 165,000 and 168,000 DMS, respectively (Figure 35).  
 
 
Figure 35: Flowchart for the selection of candidate regions for RRBS confirmation from the puberty study. 
PND: post natal day, TSS: transcriptional start site,  
 
Further filtering of the dataset for significant (p<0.05) methylation changes of >5 %, less than 
10,000 DMS were retained within each age group. Around 7 % of these selected sites were located in 
regulatory regions (promoters, CpG islands or 5’ UTRs). Only 282 DMS were overlapping between 
both age groups, indicating that within each age group a specific set of CpG sites is significantly 
affected by IF exposure (Figure 36). 
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Figure 36: Genomic distribution and overlap of DMS from the puberty study. 
CpGs with a minimum coverage of 20 reads in at least 5 of the 6 samples within each age groups were considered and 
filtered for IF-induced differentially methylated sites (DMS) with significant methylation difference >5 %. A: Genomic 
distribution of DMS and (B) Venn diagram depicting the overlap of DMS between age groups. CpG sites were annotated to 8 
categories (indicated by colors) according to the nearest transcription start site and grouped in % relative to the total 
number of DMS below each chart. PND: post natal day, DMS: differentially methylated site  
 
4.3.3.1 Technical confirmation of quantitative methylation analyses 
Although RRBS provides a direct quantitative read out of single nucleotide methylation levels, the 
validity of the results has to be confirmed by independent methods. Using the mass spectrometry-
based EpiTYPER MassARRAY technology we are able to detect methylation differences ≥5 % by 
quantifying median methylation of CpG units in a high throughput manner. 
Selection of candidate regions for RRBS confirmation 
Candidate site selection from the RRBS data was based on a minimum coverage of 20 reads in at 
least 5 of the 6 samples, with a minimum coverage of 10x for each sample. CpGs selected for 
validation showed a significant methylation difference of >5 % between groups, with two or more 
sites in close proximity <300 bp distance. Since the relationship between DNA methylation and gene 
expression is best understood for promoter regions, we additional filtered our data for DMS located 
between 2 kb upstream and 0.5 kb downstream of a TSS. After applying these settings, IF-induced 
differential methylation was identified for 512 CpGs in 267 gene promoters in MGs of prepubertal 
and for 376 CpGs in 207 gene promoters in MGs of postpubertal ACI rats.  
Ten candidate regions/gene promoters were selected for MassARRAY validation (Figure 35). The 
respective proteins are associated with energy homeostasis and metabolism (Fxyd2, Bpgm, Mmaa 
and Niacr1), cell structure (Shroom2), have been shown to be downregulated during breast 
carcinogenesis (Arrp21) or directly induced tumor growth and stem cell-like phenotype in xenografts 
(Tlr3). Zfp507 is a not further characterized zinc-finger protein, and has not yet been investigated 
with respect to tumor formation or MG development. Rpm42 might affect cell cycle control by 
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binding to p21, and Nr1h3 is involved in homeostasis of cholesterol and metabolism of steroid 
hormones. A summary of all RRBS candidates and EpiTYPER amplicon information can be found in 
Supplemental table 4. 
RRBS confirmation using MassARRAY technology 
Primers for the MassARRAY validation of ten candidate regions were designed and conditions for PCR 
amplification were optimized. Each DMR was represented by at least 2 single CpGs or a CpG unit 
consisting of 2 CpGs.  
The majority of the selected regions were identified in the PND 21 group, except for Shroom2 and 
Niacr1 which showed differential methylation in animals at PND 50. Niacr1, Zfp507, Fxyd2, Arpp21, 
and Mmaa showed high methylation levels around 1 in RRBS that were reduced by intervention with 
IF (Figure 37). For Niacr1, we observed significant methylation differences of 19-24 % by RRBS 
between the dietary groups at PND 50, but not at PND 21. Analyzing the same region with 
MassARRAY technology we could not confirm this IF-induced methylation change. Similarly, for 
Zfp507, Fxyd2, Arpp21, and Mmaa RRBS identified DMS between the C and H group at PND 21 that 
we were not able to confirm by the EpiTYPER technology. However, with the exception of Zfp507 
methylation in the PND 50 group (RRBS had indicated unmethylated CpG sites), we were able to 
validate at least the overall degree of methylation of the selected regions above 50 % absolute 
methylation.  
For Zfp507, but also in general, group wise methylation levels were much more homogeneous when 
determined by MassARRAY in comparison to the RRBS data. This indicates that the methylation 
differences detected by RRBS were at least partly due to technical artifacts. Interestingly, for Arpp21, 
Niacr1, and Fxyd2 we detected by MassARRAY pronounced methylation differences between the 
individual age groups with an overall increase of 25 % in the PND 50 group for Arpp21 and a decrease 
of 10-12 % for Niacr1 and Fxyd2. Since we had access to MG tissue of various age groups (Figure 26), 
we further followed up these observations in section 4.3.3.2.  
For Rpm42, Bpgm, Tlr3, and Nr1h3, we focused on PND 21 only. With RRBS, the selected regions for 
Tlr3, Nr1h3, and Bpgm showed low levels of methylation in the control group, and IF-intervention led 
to a significant gain (Figure 38). Rpm42 methylation levels were in the range of 60-90 % in the control 
group and also were hypermethylated in the H diet group. Differential methylation detected by RRBS 
between C and H diet groups could not be confirmed by MassARRAY, although the level of overall 
methylation was consistent, with the exception of Rpm42.  
For Shroom2, individual methylation values for the CpG sites covered by RRBS reads were not 
obtainable by MassARRAY, therefore a direct comparison was not possible. 
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Figure 37: Technical confirmation of highly methylated DMS by MassARRAY technology from the puberty study. 
Absolute methylation of the DMS analyzed by MassARRAY (left) and RRBS (right). Each dot in the aligned dot plots 
represents one animal (light grey, control diet and dark grey, H diet. Horizontal dashed lines indicate median methylation 
values of the first CpG (PND 21, C diet), vertical lines indicate interquartile range. PND: post natal day.  
 
 
Figure 38: Technical confirmation of lowly methylated DMS by MassARRAY technology from the puberty study. 
Absolute methylation of the DMS analyzed by MassARRAY (left) and RRBS (right). Each dot in the aligned dot plots 
represents one animal (light grey, control diet and dark grey, H diet). Horizontal dashed lines indicate median methylation 
values of the first CpG (PND 21, C diet), vertical lines indicate interquartile range. PND: post natal day. 
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Although we were not able to confirm IF-induced methylation changes by MassARRAY, our results 
indicated that the general methylation levels detected by both technologies were comparable. We 
performed a correlation analysis considering methylation data for the CpGs in the MassARRAY 
amplicon that covered the DMS identified by RRBS. Methylation was measured in a zero-to-one 
scale, and for each of the candidate regions, median methylation was calculated for the selected 
CpGs (Figure 39). In total, 166 values for 24 animals were plotted against each other and showed 
highly significant correlation (Spearman correlation coefficient rho: 0.7038, 95% CI = 0.6149-0.7751 
and p<0.0001). 
 
 
Figure 39: Correlation of quantitative RRBS and MassARRAY data from the puberty study. 
Each dot in the correlation plots represents one median methylation value per animal obtained for 24 animals in nine 
candidate regions (Spearman correlation coefficient rho: 0.7038, 95% CI = 0.6149-0.7751 and p<0.0001). 
 
4.3.3.2 Quantitative analysis of candidate regions across all developmental windows 
Since we had access to MG tissue of various age groups (Figure 26), we were able to follow up age-
induced changes in DNA methylation of Niacr1, Fxyd2, Arpp21, Mmaa, Zfp507, and Shroom2 from 
early development until adolescence and adulthood (PND 21-180). Additionally, we investigated Esr1 
and Extl1 promoter methylation during MG development, two interesting candidate genes obtained 
from the MCIp-Seq approach in Wistar rats (Figure 40). 
For Niacr1 and Fxyd2, methylation levels gradually decreased with advancing age by about 20-30 % in 
comparison with the prepubertal rats at PND 21 (Figure 40A). Temporarily at PND 97, methylation of 
Niacr1 was significantly higher in the H diet when compared to PND 80 or 180 (see Figure 41). For 
Arpp21, Mmaa, and Extl1 methylation levels increased with age (Figure 40B). Methylation of Extl1 
increased up to PND 97 but decreased in older animals to levels below those of prepubertal rats at 
PND 21 (significant for C diet). Notably, lifelong H diet prevented the loss of DNA methylation 
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between PND 97-180. Methylation in the promoter regions of Zfp507, Shroom2 and Esr1 also 
gradually increased significantly by 5-10 % starting at PND 21 or 50 (Figure 40C).  
 
 
Figure 40: Quantitative analysis of candidate regions across all developmental windows. 
Median methylation of selected candidate regions in MGs between PND 21-180, with focus on DMS with confirmed 
differential methylation levels between PND 21 and 50 (see Figure 37). Each dot in the aligned dot plots represents one 
animal (light grey, control diet and dark grey, IF diet). The horizontal dashed line indicates median methylation values from 
the C group at PND 21. Vertical lines indicate interquartile range. For statistical analysis, Two-way ANOVA was used with the 
factors: Time (age), Treatment (F intervention), and interaction between age and IF intervention. For comparison between 
consecutive developmental windows see Figure 41. 
 
In summary, MassARRAY analysis revealed significant age-dependent effects on DNA methylation 
representing the MG methylome before and after puberty (PND 21 and 50), as well as in 
adolescence, and adulthood (PND 81-180) with most pronounced effects during puberty (PND 21-50, 
Figure 41). IF exposure within one age group led to methylation changes of about 5 % which 
however, did not reach statistical significance. 
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Figure 41: Statistical comparison of candidate regions between consecutive developmental windows. 
For statistical analysis of pair wise comparison a parametric beta regression model was used to test for significant 
differences in DNA methylation. Pairwise comparisons were adjusted for multiple testing (Tukey test). Shapes in boxes 
correspond to changes in DNA methylation /: increase, \: decrease between age groups indicated above. Different shades 
of grey indicate the negative decadal logarithm of three distinct P-values (p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, ranging from 
light to dark grey, white = not significant).  
 
4.3.4 Gene expression analyses (performed by Karin Klimo) 
4.3.4.1 Candidate gene expression and correlation with DNA methylation changes 
In order to determine whether changes in DNA methylation might be correlated with changes in 
gene expression, RT-qPCR was performed. Gene expression levels were measured for Niacr1, Fxyd2, 
Arpp21, Extl1, Zfp507, and Esr1. No gene expression data was available for Mmaa and Shroom2 due 
to unsuccessful primer design. We were not able to identify any significant age- or diet-induced gene 
expression changes in the candidate regions obtained by RRBS (Figure 42).  
Consequently, correlation analyses for the comparison of promoter methylation and gene expression 
did not reveal significant correlation. Spearman correlation coefficient rho was in the range of 
-0.01 to -0.04 for negative and 0.02 to 0.23 for positive correlation (data not shown). 
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Figure 42: Gene expression of the candidate regions across all developmental windows. 
Relative gene expression of selected candidate regions in MGs between PND 21-180. Each dot in the aligned dot plots 
represents one animal (light grey, control diet and dark grey, H diet). The horizontal dashed line indicates median gene 
expression values of the C group at PND 21. Vertical lines indicate interquartile range. For statistical analysis, Two-way 
ANOVA was used with the factors: Time (age), Treatment (IF intervention), and interaction between age and IF 
intervention.  
 
4.3.4.2 Gene expression-based pre characterization using cell type marker genes 
Since normal MG development involves a massive reorganization regarding the cytoarchitecture, we 
selected marker genes for epithelial cells (Keratin 8 (Krt8) and E-cadherin (Cdh1)) as well as for 
myoepithelial cells (Keratin 5 (Krt5), smooth muscle actin (SMA), and Tp63) to determine alterations 
in the glandular structure and the cellular composition of the MGs (Figure 43).  
We observed significantly increased transcript levels of both myoepithelial and epithelial cell type 
markers from PND 50 onwards (not significant for Krt5). During MG development strongest up-
regulation of cell marker mRNA levels were observed during the pubertal phase between PND 21 and 
50 (Figure 44). Interestingly, there was a global effect of the lifelong IF intervention on Krt8 mRNA 
expression (p=0.0018) especially in the older rats. Here, Krt8 transcript levels where significantly 
higher than those of animals on the C diet. 
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Figure 43: Gene expression of marker genes for epithelial cells across all developmental windows. 
Relative gene expression for A: myoepithelial and B: epithelial cell type markers during all developmental windows from 
PND 21-180. Each dot in the aligned dot plots represents one animal (light grey, control diet and dark grey, H diet). The 
horizontal dashed line indicates gene expression values from the C group at PND 21. Vertical lines indicated interquartile 
range. For statistical analysis, Two-way ANOVA was used with the factors: Time (age), Treatment (IF intervention), and 
interaction between age and IF intervention. For comparison between consecutive developmental windows see Figure 44. 
 
 
 
Figure 44: Statistical comparison of gene expression of cell type marker genes between consecutive developmental 
windows. 
For pair wise comparison a parametric linear regression model was used to test for statistically significant differences in 
gene expression. Pairwise comparisons were adjusted for multiple testing (Tukey test). Shapes in boxes correspond to 
changes in gene expression /: increase, \: decrease between age groups indicated above. Different shades of grey indicate 
the negative decadal logarithm of three P-values (p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, ranging from light to dark grey, white = 
not significant). 
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4.3.4.3 IF affect gene expression of key epigenetic enzymes 
In order to identify the underlying mechanism of IF and age-induced changes in DNA methylation and 
gene expression during MG development we measured relative mRNA expression of selected 
epigenetic modifying enzymes involved in writing and erasing DNA methylation (e.g., DNMT1, 3a, 3b 
and Tet1).  
The relative mRNA expression of DNA methylation modifying enzymes showed a divers pattern 
(Figure 45). DNMT1 transcript levels increase in the control group with increasing age, whereas 
expression showed a bell-shaped pattern in the H diet group with a maximum at PND 81 (not 
statistically significant). Within the control diet groups, DNMT3a and 3b showed a tendency of lower 
expression at older age. Lifelong IF intervention reversed this tendency, with lower expression levels 
at PND 21 in the H compared to the C group and a steady increase in expression up to PND 180, 
especially for DNMT3b. Tet1 mRNA expression was clearly reduced in the course of MG development 
in both dietary groups. 
 
 
 
Figure 45: Gene expression of epigenetic key enzymes across all developmental windows. 
Relative gene expression of DNA methylation modifying enzymes during all developmental windows from PND 21-180. Each 
dot in the aligned dot plots represents one animal (light grey, control diet and dark grey, H diet). The horizontal dashed line 
indicates gene expression values from the C group at PND 21. Vertical lines indicated interquartile range. For statistical 
analysis, Two-way ANOVA was used with the factors: Time (age), Treatment (IF intervention), and interaction between age 
and IF intervention. For comparison between consecutive developmental windows see Figure 46. 
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Figure 46: Statistical comparison of gene expression of epigenetic key enzymes between consecutive developmental 
windows. 
For statistical analysis of pair wise comparison a parametric linear regression model was used to test for significant 
differences in gene expression. Pairwise comparisons were adjusted for multiple testing (Tukey test). Shapes in boxes 
correspond to changes in gene expression /: increase, \: decrease between age groups indicated above. Different shades of 
grey indicate the negative decadal logarithm of three P-values (p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, ranging from light to dark 
grey, white = not significant). 
 
4.3.5 Epigenetic profiling during E2-induced breast carcinogenesis in ACI rats 
The ACI rat strain is highly susceptible to develop mammary tumors upon prolonged exposure to 
pregnancy levels of exogenous E2 [161]. Six Emca loci determine the breast cancer susceptibility 
which in part have been identified to be orthologous to loci in human. Further, they have been 
associated with various risk markers such as mammographic breast density which emphasizes the 
relevance of the animal model for human breast cancer [166].  
4.3.5.1 E2-induced carcinogenesis in the MG (Results provided by Möller/Vollmer TU Dresden) 
In order to monitor the impact of IF on MG carcinogenesis, female ACI rats were assigned to control 
C or H diets prior to mating and female offspring was exposed to IF during all developmental 
windows of fetal and neonatal, as well as pubertal, and adolescent development (Figure 47). 
Morphological analyses indicated the highest numbers of highly proliferative and susceptible 
structures before PND 50 (TEBs, data not shown), therefore rats were implanted with an E2-
containing silicon tube to initiate the tumorigenic process at PND 45. In order to further promote the 
carcinogenic process, the silicon tubes were renewed at PND 175. Previous studies showed reduced 
numbers of TEBs at PND 50 after exposure to the H diet. Since many processes during early 
development are regulated by epigenetic mechanisms these processes might be targeted by IF, 
affecting normal cell growth and susceptibility to breast cancer [144] (reviewed in [2]). For detailed 
information on animal experimentation see section 3.2.4 as well as Möller et al. 2016 (in revision). 
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Figure 47: Experimental outline of E2-induced MG carcinogenesis in ACI rats. 
August Copenhagen Irish (ACI) rats received either control (C) or high IF diet (H) containing 3 ppm and 503 ppm IF aglycone 
equivalents. For initiation and promotion of the carcinogenic process, E2-releasing tubes were implanted at PND 45 and 
PND 175 in half of the animals. All animals were sacrificed at PND 285 to monitor tumor development. 
 
 
Mammary tumors arose in ACI rats which were implanted with E2-releasing silicon tubes with a 
median tumor multiplicity of 3.5 tumors per animals. Earliest palpable tumors were detected at 
postnatal week 25 and 20 for C and H diet, respectively (p<0.0001, data not shown). Although H diet 
showed a significantly shorter time-to-tumor appearance, tumor multiplicity was reduced by 56 % 
compared to controls (p=0.018). However, tumors that developed in animals exposed lifelong to H 
diet grew to larger size with a median total tumor volume of 19.3 cm3 and wet weights of about 
2.5-fold greater than in control animals (Figure 48).  
Taken together, these results indicate a chemopreventive effect of lifelong IF exposure on tumor 
incidence and multiplicity in ACI rats. However, if tumors escaped the preventive effect, they grew to 
larger sizes (in three out of the six animals), resulting in a higher tumor burden. 
 
 
 
Figure 48: Effects of a high IF diet on tumor characteristics of ACI rats. 
Each dot in the scatter plots represents one animal (light grey: C diet, dark grey: H diet). Median values per group are 
indicated by a horizontal line, vertical lines indicate interquartile range. The horizontal dashed line indicates median values 
from MGs of the C group. For statistical analysis, MG: mammary gland, T: tumor 
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IF treatment affects various physiological parameters (Results provided by Möller/Vollmer TU 
Dresden) 
In order to assess the potential effects of lifelong IF intervention on endocrinological parameters, we 
determined UWW and measured mRNA as well as protein expression of prototypical estrogen 
responsive genes and classical proliferation markers during E2-induced breast carcinogenesis. 
Interestingly, UWW was slightly increased at PND 285 by 15 % in both groups on H diet compared to 
control diet groups, suggesting an estrogenic effect of IF exposure (borderline significant p=0.0508). 
For Ki67 protein staining determined by IHC, E2 treatment significantly increased the proliferation 
index from 0 % to 11 % positively labeled nuclei in MGs of E2-exposed animals not bearing frank 
tumors (MG/T) (p=0.0028). Although IF intervention showed a pro-estrogenic effect in the uterus, no 
significant impact of the lifelong IF diet was observed in healthy and neoplastic MGs in the H group. 
 
 
Figure 49: Uterus wet weight and Ki67 protein expression in MG and tumors. 
A: Uterus wet weight (UWW) and B: IHC of the proliferation marker Ki67 in response to E2 stimulation. Each dot in the 
scatter plots represents one animal (light grey: C diet, dark grey: H diet). Median values per group are indicated by a 
horizontal line, vertical lines indicate interquartile range. The horizontal dashed line indicates median values from the C 
group without estrogen (E2) stimulation. For statistical analysis, Two-way ANOVA was used with the factors: Diet 
intervention, E2 treatment, and interaction between diet intervention and E2 treatment. MG: mammary gland, MG/T: MG 
without detectable tumors 
 
Impact of IF intervention on estrogenic and proliferative response in MGs and E2-induced tumors 
In order to monitor the impact of lifelong IF intervention during E2-induced MG carcinogenesis, we 
determined mRNA expression of selected reference genes for proliferation (e.g., Ki67, PCNA) and 
hormone receptors (e.g., Pgr, Esr1, Esr2) in MGs of untreated animals, as well as in MG and tumor 
tissue of E2-exposed animals (MG/T and T, respectively). Transcripts levels of the proliferation 
markers Ki67 and PCNA increased in tumors independent of the dietary regime and confirmed the 
observations made by IHC (borderline significant for Ki67 p=0.0752). Interestingly, expression of the 
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proliferation markers were lower in MGs of E2-exposed animals not bearing frank tumors (MG/T) 
than in both normal MG and in tumors (Figure 50A). 
Hormone receptors showed interesting gene expression patterns during MG tumorigenesis (Figure 
50B). While Pgr mRNA levels got significantly upregulated by E2 treatment, transcript levels of both, 
Esr1 and Esr2 were downregulated in tumors independent of the diet administered (not statistically 
significant). Expression levels in MG/T ranged between normal untreated MGs and E2-induced 
tumors. Results of the statistical analyses accounting for multiple tissues derived from individual 
animals are summarized in Table 9. 
 
 
Figure 50: Gene expression of E2-responsive genes during MG tumorigenesis. 
Relative gene expression of A: proliferation markers and B: hormone receptors in healthy mammary glands (MGs), MG 
without detectable tumors (MG/T) and tumors (T) at PND 285. Each dot in the scatter plots represents one animal (light 
grey, control diet and dark grey, H diet). The horizontal dashed line indicates median expression levels in MGs in the C 
group. Vertical lines indicated interquartile range.  
 
 
Table 9: Statistical analysis of gene expression during MG tumor development. 
 
Source of 
Variation 
Diet 
[p value] 
Tissue global 
[p value] 
MG+T vs. MG/T 
[p value] 
Interaction 
[p value] 
 
 Ki67 ns 0.0752 ns ns  
 PCNA ns <0.001 <0.01 ns  
 Pgr ns <0.001 <0.001 ns  
 Esr1 ns ns ns ns  
 Esr2 ns ns ns ns  
Statistical significance of differences was calculated for all candidate genes using a linear mixed model. A random rat effect 
was included to account for multiple tumor/tissue samples from the same animal. Models for diet and tissue effects as well 
for interaction were fitted. P-values were adjusted for multiple testing across genes using Benjamini-Hochberg correction. 
Tissue effects were calculated across all tissue types (global: mammary glands (MGs) vs. mammary glands with no palpable 
tumors (MG/T) vs. tumors (T)) as well as MG and tumor compared to MG/T (MG+T vs. MG/T). ns: not statistically 
significant. 
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4.3.5.2 DNA methylome mining during tumor formation 
In the carcinogenesis experiment, 24 samples were subjected for RRBS library preparation (MGs of C 
(n=5) and H (n=6) diet groups, tumor samples of C (n=6) and H (n=7) diet groups). We covered about 
2 M CpGs (unique aligned motifs, Figure 51A). By sequencing libraries on two lanes (instead of one as 
in the previous experiment) we obtained 26-68 M high quality reads per sample with an alignment 
rate ranging from 66-88 % (except for 36 % for one tumor samples with was excluded from further 
analysis). In general, mean coverage was improved from 32x to 71x per site, when compared with 
libraries obtained from pre- and postpubertal ACI rats (see section 4.3.3). Also, average bisulfite 
conversion rate was increased from 98.5 to 99.0 % due to the optimized library preparation. 
Calculation of methylation data from all uniquely aligned motifs for MG and tumor samples of 
animals from PND 285 showed a mean global methylation of 53 %, in comparison to 64 % of the pre- 
and postpubertal ACI rats at PND 21 and 50 (Figure 51B).  
A general summary of the obtained sequencing results of adult ACI rats can be found in 
Supplemental table 5. 
 
 
Figure 51: Summary of RRBS library runs from the puberty and the carcinogenesis study. 
Comparison of RRBS library runs for general sequencing characteristics (A) and global methylation (B). PND 21 and 50: pre- 
and postpubertal ACI rats; PND 285: adult ACI rats, MG: Mammary gland 
 
Genomic Distribution 
For efficient detection of DMS between groups, only sites were considered with a minimum coverage 
of 20 reads in at least 20 out of the 24 samples within the groups, leading to 666,745 overlapping 
CpGs in all diet groups (Figure 52A). 
Looking for significant methylation changes of at least 5 %, more than 40,000 sites were identified as 
differentially methylated as a result of the E2 treatment and the subsequent carcinogenic process in 
both, C and H diets, twice as many sites as due to IF intervention alone. During tumor development 
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(C vs.C+E2 and H vs. H+E2), we observed a genome-wide loss in methylation. Two thirds of the 
identified DMS accounted for hypomethylated sites with half of this sites mapping to repetitive 
genomic regions and might contribute to genome-wide instability [182] (Figure 52B). Gain in 
methylation was most prominent in intergenic and intronic regions (38 % and 20 %, respectively). 
 
 
Figure 52: Flowchart and pie charts of genomic distribution of DMS in MGs and tumors from the carcinogenesis study. 
A: Pipeline defining a series of cutoffs (minimum coverage of 20 reads in at least 20 out of the 24 samples within the four 
groups, p<0.05 for group-wise comparison, methylation difference >5 %) for efficient DMS detection. B: CpG sites were 
annotated to 8 categories (indicated by colors) according to the nearest transcription start site, and grouped in % relative to 
the total number of CpGs above each chart. Sites with loss in methylation are depicted as hypomethylated, sites with gain 
in methylation as hypermethylated DMS.  
 
In contrast, effects of a lifelong IF exposure were less pronounced. In total ~24,000 CpGs were 
affected between the different diets when comparing normal MGs (C vs. H) or tumors (C+E2 vs. 
A 
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H+E2). Here, H diet increased methylation of two thirds of all DMS but distribution of the sites was 
roughly equivalent. In general, less than 10 % of these selected sites were located in regulatory 
regions (promoters, CpG islands or 5’ UTRs), with some overlap between groups as shown in a Venn 
diagram (Figure 53A). 
In each group, more than 50 % of DMS were specifically affected by the particular treatment and 
were not shared with any other groups. The residual sites overlapped with at least one more 
treatment regime. The greatest overlap can be seen between the two tumor comparisons in 
C vs. C +E2 and H vs. H+E2 (blue vs. red) with 7,872 sites. Most of these sites mapped to repeat 
regions and most probably correspond to hypomethylated DMS (site not distinguished here).  
 
 
Figure 53: Venn diagram and genomic distribution of overlapping DMS from the carcinogenesis study. 
A: Venn diagram of overlapping DMS between different group comparisons as indicted by colors. B: Genomic distribution of 
a subset of overlapping DMS. CpG sites were annotated to 8 categories (indicated by colors) according to the nearest 
transcription start site, and grouped in percent relative to the total number of CpGs above each chart.  
 
A pure IF effect can be seen in the overlap between C vs. H and C+E2 vs. H+E2 (yellow vs. green). 
Many sites were shared also with the two other groups, but 737 sites were exclusively induced due 
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to the IF exposure. Interestingly, these sites were summarized in the category "others" where IF 
exposure especially affected methylation of ribosomal RNAs and short cytoplasmic RNAs (data not 
shown). A total of 162 DMS were shared by all groups. These sites might be important during normal 
MG development and are affected by IF and/or E2 intervention. The direction of DNA methylation 
change might vary between the groups and distribution of these sites throughout the genome did 
not show enrichment in a particular category. 
The chemopreventive effects of lifelong IF exposure evolve in distinct biological processes 
In order to understand the underlying mechanisms and the molecular events affected by a lifelong IF 
exposure during tumor development, we used the Core Analysis function included in the Ingenuity 
pathway analysis. DMS distinguishing tumors of the C vs. H diet were investigated to interpret IF 
effects on biological processes, signaling pathways and cell networks (Figure 54). 
 
Figure 54: Functional gene enrichment based on DMS differentially methylated between tumors in the C vs. H diet 
groups. 
Functional pathways with significantly enriched gene sets are ranked according to their p-values obtained with ''Core 
Analysis' function using Ingenuity pathway analysis. 
 
Therefore, the 24,015 IF-induced DMS that distinguish tumors of C and H diets (comparison C+E2 vs. 
H+E2, see Figure 52) were annotated to genomic identifiers and were defined as value parameters 
for the analysis: Hypomethylated genes were assumed to be downregulated and hypomethylated 
genes upregulated by translating methylation values into a -2 to 2 expression scale as Ingenuity 
pathway analysis is not able to work with methylation data directly. Both, hypo- and 
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hypermethylated DMS were filtered for close proximity to the next TSS (5 kb) to postulate a 
functional relationship between DMS and the annotated identifier. In total, 1565 affected genes 
were analyzed for significant enrichment in molecular, cellular and physiological functions as well as 
in diseases and disorders.  
Using this approach, we identified that differentially methylated genes were highly enriched in 
functional pathways such as organismal survival, growth and proliferation, cellular development and 
movement, as well as cell death and survival, and many more with top hypermethylated genes, i.e., 
RAX, SMAD7, MAFK, and Wnt5a as well as top hypomethylated genes, i.e., PIK3R1, Trip11, and 
HOXD3 being involved in several of the observed processes. 
4.3.5.3 Technical confirmation of quantitative methylation levels from RRBS 
By sequencing of bisulfite converted DNA and subsequent bioinformatics analysis, RRBS provided 
quantitative methylation data in single nucleotide resolution. Nevertheless we aimed to confirm 
genome-wide data by using mass spectrometry-based EpiTYPER MassARRAY technology. In the 
previous study in pre- and postpubertal ACI rats, direct confirmation of RRBS-identified DMS was 
impeded by the fact that diet-induced differences were small and interindividual variation was high. 
By applying more stringent cutoff criteria for candidate site selection, we aimed to increase the 
chances to detect true DMS between groups. 
Selection of candidate regions for RRBS confirmation in adult ACI rats 
Candidate site selection from the RRBS data was based on a minimum coverage of 10x in every 
sample with a significant methylation difference of at least 5 %. A summary of our selection criteria is 
summarized in Figure 55.  
Due to the library preparation and sequencing some animals did not meet the initial minimum 
coverage of 20x per CpG and values of these samples were set NA. In the next selection step just one 
NA per group was allowed and DMS for validation should be in close proximity to each other with 
less than 300 bp distance. After applying these settings, differential methylation was identified for 
4,230 CpGs due to IF intervention and 12,816 CpGs as result of the E2 treatment (comparison 1 and 
2, respectively). 
Further E2-induced CpG sites were selected when we observed a concomitant preventive effects of 
the IF intervention (comparison 3). Here 12,816 E2-induced DMS were overlapped with 3,856 DMS 
found between the tumors of different dietary regimes (C+E2 vs. H+E2) resulting in a total of 271 
CpGs that got differentially methylated during tumor development within the C diet but show an 
opposing methylation tendency in tumors of the H diet. These methylation levels might be more like 
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those in normal MGs and may underscore the preventive effect of the H diet in terms of DNA 
methylation changes during tumorigenesis. 
 
 
Figure 55: Flowchart for the selection of candidate regions for RRBS confirmation from the carcinogenesis study. 
Pipeline defining a series of cutoff criteria (max. one NA value (<20x per CpG), min. coverage of at least 10x per CpG in all 
residual samples, p<0.05 for group-wise comparison, methylation difference >5 %) narrowing down the 24.7 M CpGs that 
are present in the rat genome for efficient DMS detection. 
 
 
In order to enable a reasonable selection of candidate genes for conformation, the list of sites was 
further reduced by setting additional criteria. This approach was also used to investigate which 
setting might best identify those CpG sites with true methylation changes that could be confirmed by 
alternative methods. For the IF-induced effects in the MGs and E2-induced effects in the C diet group 
(comparison 1 and 2), regions of interest were narrowed down by the following setting: i) closer 
proximity to the next TSS with less than 5 kb distance and ii) methylation difference of >15 %. These 
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settings retained 147 sites in 59 genes affected by the IF intervention and 57 sites in 25 genes as a 
result of the E2 treatment. Latter sites were also filtered for standard deviation <15 % absolute 
methylation to exclude sites that were identified as DMS as result of individual outlier values. 
In order to select regions that showed a preventive effect of the IF intervention (comparison 3), sites 
were either filtered for a less than 5 kb distance to the next TSS or i) for standard deviation <15 % 
absolute methylation, ii) methylation difference greater than 15 % and iii) mean methylation levels in 
the range of 5-95 %. The third setting was intended to particularly exclude sites which were 
identified as either unmethylated or 100 % methylated. These sites had been identified as false 
positives or negatives in the previous validation experiment in young ACI rats. In total 29 sites in 
14 genes for promoter regions and 42 sites in 19 genes for non-promoter regions were retained. 
Overall, eleven regions containing DMS mainly located in gene promoter regions or close to the TSS 
were selected to verify methylation with EpiTYPER MassARRAY in all experimental groups 
(Supplemental table 4). 
Technical confirmation of RRBS data using MassARRAY for MG and tumor samples of ACI rats  
Candidate regions selected for confirmation by MassARRAY were represented by at least 2 single 
CpGs or a CpG unit consisting of 2 CpGs. Methylation was measured in a zero-to-one scale.  
For Comparison 1 (IF-induced methylation changes, C vs. H diet in MG samples), we did not set very 
stringent cutoff criteria, since evaluation of the RRBS data did not provide large numbers of H diet-
induced DMS (see Figure 55). We selected DMS in the promoter regions of Lect2 (leukocyte cell-
derived chemotaxin 2) and Rita (RBPJ interacting and tubulin associated 1). Lect2 has been linked to 
rheumatoid arthritis and amyloidosis [183]. However, in a recent work from Andres et al. it was 
identified amongst other as important predictor of breast cancer recurrence and mortality among 
smokers [184]. Overexpression of Rita upregulated p53 and reduced cyclinD1 and cyclinE levels, 
favoring apoptosis over cell proliferation in HepG2 cells and might function as a TSG in hepatocellular 
carcinoma [185, 186]. 
Selected candidate sites were often unmethylated (0 % methylation) such as for Lect2, or fully 
methylated (100 % methylation) such as for Rita in the RRBS dataset. These extreme methylation 
values could not be validated by MassARRAY and apparently represent technical and bioinformatics 
artifacts (see Figure 56A). So far, we do not fully understand, how generation of these artifacts can 
be prevented but bioinformatics optimization is ongoing. 
For comparison 2 (carcinogenesis-induced methylation changes in the control group, C vs. C+E2 ), we 
took the information about artifacts into consideration by setting a threshold for standard deviation 
below 15 % methylation (see Figure 55). This filter removes highly variable CpGs with values ranging 
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from 0 to 100 % methylation within one group. We selected promoter regions for three out of 
25 genes passing our thresholds, Npas1 (neuronal PAS domain protein 1), Msx1 (msh homeobox 1), 
and Gbp2 (guanylate binding protein 2, interferon-inducible). 
The exact function of the PAS-family TF Npas1 is unclear, however it may play a role during late 
embryogenesis and postnatal development and has shown copy number variations in ERα-positive 
MCF-7 cells [187]. The homeodomain-containing TF Msx1 possesses repressive control on 
organogenesis and tissue interaction during embryonic development. It has been reported that 
promoter binding of Msx1 influences enrichment of H3K9me2 at repressed targets and redistributes 
the H3K27me3 mark, thereby affecting epigenetic regulation of its target genes [188]. The encoded 
protein of Gbp2 is a GTPase which has been associated with good prognosis in breast cancer [189]. 
RRBS data obtained for MGs and tumors of the C diet group showed significant hypomethylation for 
Gbp2 and considerable hypermethylation for Npas1 and Msx1 (Figure 56). Methylation differences 
between MGs and tumors of the C diet could be clearly validated. As an example, values for Gbp2 
showed great concordance between the two quantitative methods with a slightly overall decrease in 
methylation for CpG 3 in the MassARRAY analysis. Overall, MassARRAY analyses revealed lower 
interindividual variation within the groups, indicating again that some of the more extreme 
methylation values detected by RRBS close to 0 or 100 % methylation might be artifacts.  
In comparison 3, we were interested in carcinogenesis-induced methylation changes that could be 
prevented by intervention with IF (C vs. C+E2 vs. H+E2). Promoter (Figure 56C) and non-promoter 
regions (Figure 56D) were investigated comparing RRBS data for MGs vs. tumors of the C group 
overlapping MGs vs. tumors of H diet group. For comparison of promoter regions, we selected Rnf8 
(ring finger protein 8, E3 ubiquitin protein ligase), Ndrg3 (N-myc downstream regulated gene family 
member 3), Mrc2 (receptor, C type 2), and miR-10a.  
RNF8 plays an important role in histone ubiquitination and chromatin remodeling during DNA 
damage response. Depletion of this protein causes cell growth inhibition and cell cycle arrest. Ndrg3 
is an androgen regulated aberrantly expressed gene in prostate cancer which might serve as a 
prognostic marker, since it is correlated with a shorter recurrence-free survival and shorter overall 
survival [190]. The encoded protein of Mrc2 is a central component in the collagen turnover process 
that directs basement membrane collagen as well as interstitial collagen to lysosomal degradation. 
Modulation of the tumor-surrounding extracellular matrix is a key determinant for cancer invasion, 
thus Mrc1 deregulation has been identified in various malignancies including breast cancer [191]. 
Deregulation of miR-10a has been reported in a number of cancers, including breast cancer and 
expression displayed both onco-miR as well as TSG roles by targeting the PTEN/AKT/ERK pathway. In 
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postmenopausal ERα-positive breast cancer patients, miR-10a upregulation was associated with 
longer relapse-free time following tamoxifen treatment and might rather possess TSG potential in he 
breast [192].  
 
 
Figure 56: Technical confirmation of RRBS data by MassARRAY technology from the carcinogenesis study. 
DMS between A: MGs of the C vs. H diet (comparison 1), B: C vs. C+E2 diet (comparison 2) and C vs. C+E2 diet overlapping H 
vs. H+E2 diet (comparison 3) in C: promoter and D: non promoter regions. Each dot in the aligned dot plots represents one 
animal (light grey, control diet and dark grey, H diet). The horizontal dashed lines indicate median methylation values from 
the MassARRAY analysis of the first CpG of the control group. The vertical lines indicate inter-quartile range. MG: mammary 
gland, T: tumor  
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For the non-promoter comparison, we selected Thy (Thy-1 cell surface antigen), a surface 
glycoprotein expressed on multiple cell types, affecting cell-cell or cell-matrix interactions, as well as 
cellular adhesion and migration. Further, St3gal4 (ST3 beta-galactoside alpha-2,3-sialyltransferase 4 
(siat4c)) passed our selection criteria. Sialylation plays a crucial role in cell adhesion and regulates the 
biological stability of glycoproteins by influencing the hydrophilic character and electronegative 
charge [193]. 
No thresholds were set for standard deviation and consequently intraindividual variation was high 
with up to 30 % absolute methylation difference for Rnf8, Ndrg3, miR-10a, and Mrc2 between the 
RRBS and MassARRAY values. However, methylation differences between MGs and tumors of the C 
diet and the prevention of this alterations by the IF intervention could clearly be confirmed (Figure 
56C). Comparable results were obtained for non-promoter regions of this comparison. Since these 
regions were selected using the most stringent filtering criteria to avoid error-prone data, with 
standard deviation below 15 %, mean methylation between 5 and 95 %, and methylation difference 
>15 % as outlined in Figure 30, methylation data for St3gal4 and Thy1 showed great concordance 
between the two quantitative methods (Figure 56D). 
Overall, we were able to confirm the RRBS data by cutting down the interindividual variation within 
one group by reducing standard deviation or overall mean methylation levels. Since we did not apply 
any of these setting to verify the IF effect in MGs of C vs. H diet (comparison 1), we were not able to 
confirm these findings. Tumorigenesis induced greater methylation changes, and RRBS-identified 
DMS could be confirmed by the independent MassARRAY analysis. In general, variation was the 
greatest in tumors of the H diet independent of the method of analysis, reflecting the individual 
biological response to IF exposure during tumor development. 
Correlation of MassARRAY and RRBS data of MGs and tumors of ACI rats 
Correlation analysis was performed to determine the general consistency of the RRBS and 
MassARRAY data. For comparison, only the specific CpGs in the MassARRAY amplicon that covered 
the differential methylated DMS were considered. For each DMR, median methylation was 
calculated from the selected CpGs and RRBS methylation values were plotted against MassARRAY 
values in a 0 to 1 scale.  
Notably, we could confirm that the 287 quantitative methylation values that were measured by both 
RRBS and MassARRAY significantly correlate (Spearman correlation coefficient rho: 0.7868, 95% CI 
= 0.7368-0.8284 and p<0.0001, Figure 57). This underscores that RRBS is a reliable tool to investigate 
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DNA methylation changes on a genome-wide scale, especially when specific cutoff criteria for 
selection are met (listed in Figure 55). 
 
 
Figure 57: Correlation of RRBS and MassARRAY data generated from the carcinogenesis study.  
Each dot in the correlation plots represents one median methylation values obtained from 24 animals in twelve candidate 
regions. In total, 287 quantitative methylation values measured by RRBS and MassARRAY show a significant correlation with 
a Spearman correlation coefficient rho: 0.7868, 95% CI = 0.7368-0.8284 and p<0.0001. 
 
 
4.3.5.4 Quantitative analysis of candidate regions during MG tumor development 
Next, we were interested to investigate methylation changes of validated candidate regions in the 
course of MG tumorigenesis, therefore we extended our quantitative analysis to all samples available 
from the carcinogenesis study. From C and H diet groups, we analyzed healthy MGs without E2 
challenge (MG; n=20) and tumors from individual animals (T; n=24) as well as MGs from E2-exposed 
animals (MG/T; n=17) (Table 5). 
In all regions investigated, we detected a significant impact of the tumorigenic process on 
methylation levels (Table 10, except for Rita). Gbp2 and Ndrg3, both used as markers for either a 
good prognosis in breast cancer or shorter overall survival in prostate cancer, became gradually 
hypomethylated by up to 25 %. Additionally, methylation levels of Thy, a glycoprotein involved in 
cellular adhesion and St3gal4, regulating glycoprotein stability decreased by up to 31 %. Also Rnf8, an 
E3 ubiquitin protein ligase involved in chromatin remodeling and Lect2, a predictor of breast cancer 
recurrence became hypomethylated during mammary carcinogenesis and methylation levels 
gradually decreased by up to 31 % (Figure 58).  
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Table 10: Statistical analysis of DNA methylation changes of candidate regions during MG tumor development. 
 
Source of 
Variation 
Diet 
[p value] 
Tissue global 
[p value] 
MG+T vs. MG/T 
[p value] 
Interaction 
[p value] 
 
 Gbp ns <0.0001 ns ns  
 Ndrg3 ns <0.01 ns ns  
 St3gal4 ns <0.0001 ns ns  
 Rnf8 ns <0.0001 <0.01 ns  
 Thy1 ns <0.0001 ns ns  
 Lect2 0.0972 <0.0001 ns <0.05  
 miR-10a ns <0.0001 0.0904 ns  
 Npas1 ns <0.0001 0.0864 ns  
 Mrc2 ns <0.0001 ns ns  
 Msx1 ns <0.0001 ns ns  
 Rita ns ns ns ns  
Statistical significance of differences was calculated for all candidate genes using a linear mixed model. A random rat effect 
was included to account for multiple tumor/tissue samples from the same animal. Models for diet and tissue effects as well 
for interaction were fitted. P-values were adjusted for multiple testing across genes using Benjamini-Hochberg correction. 
Tissue effects were calculated across all tissue types (global: mammary glands (MG) vs. mammary glands with no palpable 
tumors (MG/T) vs. tumors (T)) as well as MG and tumor compared to MG/T (MG+T vs. MG/T). 
 
 
Figure 58: DNA hypomethylation of candidate regions during MG tumor development. 
Median methylation in healthy mammary glands (MGs), mammary glands with no palpable tumors (MG/T) and tumors (T) 
from PND 285 analyzed by MassARRAY. Median methylation of MGs of the C diet is indicated by a horizontal dashed line. 
Each dot in the scatter plots represents one animal (light grey, control diet and dark grey, IF diet). For statistical analysis see 
Table 10. 
 
In contrast, promoters of miR-10a, a TSG in breast cancer, the embryonic TF Npas1 and Msx1 as well 
as Mrc2, a gene involved in collagen turnover and often deregulated in breast cancer gained 
methylation, and methylation levels significantly increased by about 15-30 % in the tumor samples of 
the C group (Figure 59).  
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Interestingly, lifelong IF intervention induced Lect2 methylation in MG samples of the H group 
(borderline significant p=0.0972) and prevented the carcinogenesis-mediated loss or gain in 
methylation by 7-14 % for Rnf8, Thy, miR-10a, Npas1, and St3gal4, as well as Lect2. However, 
according to the statistical analysis, most of these preventive effects did not reach statistical 
significance (except for Lect2 p<0.05).  
Particularly interesting are methylation levels of the MG/T samples. Unfortunately, no 
histopathological data is available to estimate the degree to transformation of these samples. By 
analyzing DNA methylation, we found that MG/T samples ranged between normal (untreated) MGs 
and E2-induced tumors, but could not statistically be distinguished from one or the other (except for 
Rnf8 p<0.01, borderline significant for miR-10a and Npas1 with p=0.0904 and 0.0864, respectively). 
However, this data indicates that adjacent MGs without palpable tumors from rats treated with E2 
cannot be considered as normal MGs as they already show tumor-characteristic DNA methylation 
patterns. 
 
 
Figure 59: DNA hypermethylation of candidate regions during MG tumor development. 
Median methylation in healthy mammary glands (MGs), mammary glands with no palpable tumors (MG/T) and tumors (T) 
from PND 285 analyzed by MassARRAY. Median methylation of MG of the C diet is indicated by a horizontal dashed line. 
Each dot in the scatter plots represents one animal (light grey, control diet and dark grey, IF diet). For statistical analysis see 
Table 10. 
 
For Msx1, Mrc2 and St3gal4 we did not detect this gradual development of aberrant methylation. 
MG/T samples rather exhibited methylation patterns similar to healthy MGs. Eventually, epigenetic 
alterations of these regions might be a terminal event during tumor development and are therefore 
not yet visible in MG/T samples. 
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In addition to these regions selected from the RRBS dataset, we were interested whether regions 
selected from the RRBS investigation of pre- and postpubertal ACI rats (see section 4.3.3.2) would 
undergo additional methylation changes during E2-induced carcinogenesis (Figure 60, Table 11). 
 
 
Figure 60: DNA methylation of candidate regions from the puberty study during MG tumor development. 
Median methylation in healthy mammary glands (MG), mammary glands with no palpable tumors (MG/T) and tumors (T) 
from PND 285 analyzed by MassARRAY. Median methylation of MG of the C diet is indicated by a horizontal solid line. Each 
dot in the scatter plots represents one animal (light grey, control diet and dark grey, IF diet). For statistical analysis see 
Table 11. 
 
Out of eight analyzed regions, methylation levels of Niacr1 and Fxyd2, two genes involved in adipose 
tissue maintenance and energy homeostasis, as well as Extl1, an E2-inducible gene further changed 
in the course of carcinogenesis. Promoter methylation of Niacr1 significantly decreased by about 
30 % in both dietary groups. Promoter methylation of Extl1 initially decreased by 5-10 % in MGs of 
E2-treated animals (MG/T) (borderline significant p=0.0989) before the region underwent a 
tumorigenesis-induced gain in methylation to control levels. Similar results have been obtained for 
Esr1 and Fxyd2, methylation levels in MG/T did not change from control but promoter methylation 
increased by 5 % and 30 %, respectively during tumor development. For Arpp21 and Mmaa, we 
focused on MG and T, only. Statistical analysis identified a borderline significant diet-induced 
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hypomethylation in the MGs of Arpp21 promoter (p=0.0751) when compared to control group. 
Notably, median methylation of Mmaa was especially homogeneous in the H group. 
Zfp507 and Shroom2 showed less pronounced alterations and did not show a significant impact of 
either E2 treatment or lifelong IF intervention on promoter methylation levels at PND 285. 
 
Table 11: Statistical analysis of DNA methylation of candidate regions during MG tumor development. 
 
Source of 
Variation 
Diet 
[p value] 
Tissue global 
[p value] 
MG+T vs. MG/T 
[p value] 
Interaction 
[p value] 
 
 Niacr1 ns <0.0001 <0.0001 ns  
 Fxyd2 ns <0.0001 ns ns  
 Zfp507 ns ns ns ns  
 Arpp21 ns 0.0751 ns ns  
 Mmaa ns 0.0705 ns ns  
 Shroom2 ns ns ns ns  
 Esr1 ns 0.07 ns ns  
 Extl1 ns <0.05 0.0989 ns  
Statistical significance of differences was calculated for all candidate regions using a linear mixed model. A random rat 
effect was included to account for multiple tumor/tissue samples from the same animal. Models for diet and tissue effects 
as well for interaction were fitted. P-values were adjusted for multiple testing across genes using Benjamini-Hochberg 
correction. Tissue effects were calculated across all tissue types (global: mammary glands (MG) vs. mammary glands with 
no palpable tumors (MG/T) vs. tumors (T)) as well as MGs and tumors compared to MG/T (MG+T vs. MG/T). 
 
4.3.6 Gene expression analyses (performed by Karin Klimo) 
4.3.6.1 Candidate gene expression and correlation with DNA methylation changes 
Since we had selected candidate regions in the promoter regions of genes, we were interested 
whether changes in DNA methylation might be correlated with changes in gene expression. We 
aimed to analyze candidate genes obtained from the RRBS runs of pre- and postpubertal (Niacr1, 
Fxyd2, Arpp21, Shroom2, Zfp507, Mmaa), adult ACI rats (Ndrg3, Lect2, Mrc2, Npas1, Msx1, Rita, 
Gbp2, Thy1, Rnf8, St3gal4,mirR-10a), as well as two candidates from the Wistar rat study (Esr1, 
Extl1). 
No expression data could be obtained for Mmaa and Shroom2 due to unsuccessful primer design. 
Also, Lect2, Npas1, Msx1, Rita, Gbp2, and miR-10a mRNA levels could not be determined. These 
genes were previously reported as being not expressed in adult ACI rats [194]. 
Gene expression levels were therefore measured for Ndrg3, Mrc2, Thy, Rnf8, St3gl4, Niacr1, Fxyd2, 
Arpp21, Zfp507, Esr1, as well as Extl1, and Spearman correlation coefficient rho was calculated for 
correlation of methylation and gene expression. 
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For six of these eleven genes we detected a significant impact of the tumorigenic process on mRNA 
expression (Table 12). Arpp21, Fxyd2, Rnf8, and Zfp507 mRNA transcript levels decreased during 
mammary carcinogenesis (Figure 61). Gene expression of Mrc2 initially decreased in MG/T before it 
underwent a tumorigenesis-induced upregulation close to control levels (borderline significant 
p=0.077).  
 
Table 12: Statistical analysis of gene expression changes during MG tumor development. 
 
Source of 
Variation 
Diet 
[p value] 
Tissue global 
[p value] 
MG+T vs. MG/T 
[p value] 
Interaction 
[p value] 
 
 Arpp21 <0.05 <0.001 <0.001 ns  
 Fxyd2 0.0898 <0.01 <0.01 ns  
 Rnf8 0.0590 <0.001 ns ns  
 Zfp507 ns <0.05 ns ns  
 Esr1 ns ns ns ns  
 Mrc2 ns 0.0773 ns ns  
 Thy1 ns <0.05 ns <0.05  
 Ndrg3 0.0505 ns ns ns  
 St3gal4 ns <0.001 <0.01 ns  
 Niacr1 ns ns ns ns  
 Extl1 ns ns ns ns  
Statistical significance of differences was calculated for all candidate genes using a linear mixed model. A random rat effect 
was included to account for multiple tumor/tissue samples from the same animal. Models for diet and tissue effects as well 
for interaction were fitted. P-values were adjusted for multiple testing across genes using Benjamini-Hochberg correction. 
Tissue effects were calculated across all tissue types (global: mammary glands (MG) vs. MGs with no palpable tumors 
(MG/T) vs. tumors (T)), as well as MGs and tumors compared to MG/T (MG+T vs. MG/T). 
 
Thy expression was significantly induced by IF intervention during the carcinogenic process, with 
mRNA levels being significantly higher in the tumor samples of the H group than of the C group 
(Figure 62). Interestingly, St3gal4 mRNA expression was highest in MG/T without palpable tumors 
independent of the dietary regime. 
Lifelong IF intervention led to increased transcript levels of Arpp21, Fxyd2, Rnf8 (Figure 61), and 
Ndrg3 (Figure 62), borderline significant for Fxyd2, Rnf8, and Ndrg3 p=0.0505-0.0898) in healthy MG 
of the H group. Expression levels in MG/T ranged between normal untreated MGs and E2-induced 
tumors but were distinct from MGs and tumors for Arpp21, Fxyd2 (Figure 61), and St3gal4 mRNA.  
In six out of eleven candidate genes, methylation levels correlated with expression levels, with 
Spearman correlation coefficients rho in the range of 0.09 to 0.48 for positive correlation (St3gal4, 
Esr1 and Niacr1) and -0.36 to -0.37 for negative correlation (Ndrg3, Arpp21, Fxyd2) with higher 
methylation leading to reduced gene expression (Figure 63). Correlation was weak for Esr1, since no 
significant methylation changes were identified during carcinogenesis. Correlations for Niacr1 and 
Fxyd2 were border line significant (p=0.0809 and p=0.0710, respectively).  
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Figure 61: Expression of candidate genes decreasing during MG tumor development. 
Relative mRNA expression to pooled housekeeping genes (HKG: Hprt, TBP and β-actin) in healthy mammary glands (MGs), 
MGs with no palpable tumors (MG/T) and tumors (T) from PND 285 of candidate regions obtained by RRBS. Each dot in the 
scatter plots represents one animal (light grey, control diet and dark grey, H diet). The horizontal dashed line indicates 
median expression level of the MGs of the C diet. Vertical lines indicated interquartile range. For statistical analysis see 
Table 12. 
 
 
Figure 62: Gene expression changes during MG tumor development. 
Relative mRNA expression to pooled housekeeping genes (HKG: Hprt, TBP and β-actin) in healthy mammary glands (MGs), 
MGs with no palpable tumors (MG/T) and tumors (T) from PND 285 of candidate regions obtained by RRBS. Each dot in the 
scatter plots represents one animal (light grey, control diet and dark grey, H diet). The horizontal dashed line indicates 
median expression level of the MGs of the C diet. Vertical lines indicated interquartile range. For statistical analysis see 
Table 12. 
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Interestingly, all DMRs for which methylation levels correlated with expression levels were annotated 
to promoter regions. Indeed, DNA methylation might be responsible for gene silencing in these 
regions by either recruiting MBD proteins and HDACs, leading to subsequent chromatin compaction, 
or by inhibiting methylation-sensitive TF binding to the promoter regions. Also positive correlations 
with higher methylation leading to enhanced gene expression have been frequently reported. It has 
been proposed that the H3K36me3 mark which is associated with transcriptional elongation actively 
recruits DNMTs thus consequently increase methylation status, although is effect has been mainly 
limited to the intragenic regions [195]. 
 
 
Figure 63: Correlation of DNA methylation levels and gene expression from the carcinogenesis study. 
Each dot represents one sample. Spearman correlation coefficient rho was computed for the comparison of promoter 
methylation and gene expression. 
 
4.3.6.2 Gene expression-based cell type characterization using reference markers 
Both, methylation as well as gene expression analyses were performed with homogenates of whole 
organs/tumors representing a mix of cell types. Therefore, we characterized the cellular composition 
of healthy MGs, MGs without palpable tumors and tumors to be able to better interpret differential 
expression patterns, observed in normal MGs and MG tumorigenesis. We determined relative 
transcript levels for selected marker genes for epithelial cells (Krt8 and Cdh1) and myoepithelial cells 
(Krt5, SMA and Tp63). 
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Due to the breast carcinogenic process, markers of epithelial cell differentiation, i.e., Krt8 and Cdh1 
got massively upregulated while myoepithelial markers, i.e., Krt5, SMA and TP63 were down-
regulated (nonsignificant for Krt5), indicating the enormous clonal expansion of luminal cells in 
mammary tumors (Figure 64, Table 13).  
 
Figure 64: Gene expression of cell type markers during MG tumor development. 
Relative mRNA expression to pooled housekeeping genes (HKG: Hprt, TBP and β-actin) in healthy mammary glands (MGs), 
MGs with no palpable tumors (MG/T) and tumors (T) from PND 285 of candidate regions obtained by RRBS. Each dot in the 
scatter plots represents one animal (light grey, control diet and dark grey, H diet). The horizontal dashed line indicates 
median expression level of the MGs of the C diet. Vertical lines indicated interquartile range. For statistical comparison see 
Table 13. 
 
Table 13: Statistical analysis of gene expression of cell type markers during MG tumor development. 
 
Source of 
Variation 
Diet 
[p value] 
Tissue global 
[p value] 
MG+T vs. MG/T 
[p value] 
Interaction 
[p value] 
 
 Krt5 ns ns ns ns  
 SMA ns <0.01 <0.05 ns  
 TP63 ns <0.05 0.0538 ns  
 Krt8 ns <0.01 ns ns  
 Cdh1 ns <0.01 ns ns  
Statistical significance of differences was calculated for all candidate genes using a linear mixed model. A random rat effect 
was included to account for multiple tumor/tissue samples from the same animal. Models for diet and tissue effects as well 
for interaction were fitted. P-values were adjusted for multiple testing across genes using Benjamini-Hochberg correction.  
Tissue effects were calculated across all tissue types (global: mammary glands (MGs) vs. MGs with no palpable tumors 
(MG/T) vs. tumors (T)), as well as MGs and tumors compared to MG/T (MG+T vs. MG/T). 
 
Again, expression levels of mammary gland without palpable tumors range between normal 
untreated MG and E2-induced tumors but were distinct from MG and tumor for SMA and TP63 
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(borderline significant for TP63 p=0.0538). Gene expression of Cdh1 initially decreased in MG/T 
before it underwent a tumorigenesis-induced upregulation above control levels.  
No effect of the lifelong IF intervention was observed for the transcript levels of any cell marker. 
4.3.6.3 IF affect gene expression of key epigenetic enzymes 
In order to identify the underlying mechanism of IF and age-induced DNA methylation and gene 
expression changes during MG development, we measured relative mRNA expression of selected 
epigenetic modifying enzymes involved in writing and erasing DNA methylation (e.g., DNMT1, 3a, 3b 
and Tet1) (Figure 65 and Table 14).  
 
Figure 65: Gene expression of epigenetic key enzymes during MG tumor development. 
Relative mRNA expression to pooled housekeeping genes (HKG: Hprt, TBP and β-actin) of epigenetic key enzymes in healthy 
mammary glands (MGs), mammary glands with no palpable tumors (MG/T) and tumors (T) from PND 285. Each dot in the 
scatter plots represents one animal (light grey, control diet and dark grey, H diet). The horizontal dashed line indicates 
median expression level of the MG of the C diet. Vertical lines indicated interquartile range. For statistical comparison see 
Table 14. 
 
Similarly to the developmental effects, relative mRNA expression of DNA methylation modifying 
enzymes showed a divers pattern. DNMT3a and DNMT3b mRNA levels were not significantly affected 
during tumor formation. Transcripts levels of DNMT1 and Tet1 showed opposing alterations in mRNA 
expression. While DNMT1 mRNA levels were upregulated in tumors, especially in the C diet group, 
Tet1 expression was decreased, with most pronounced reductions in MGs without palpable tumors 
(MG/T) independent of the dietary group. Interestingly, lifelong IF exposure significantly reduced 
mRNA levels of DNMT1 in healthy MGs of the H group as well as in MG/T and T and prevented the 
E2-induced upregulation of DNMT1 mRNA during tumor formation.  
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Table 14: Statistical analysis of gene expression of epigenetic key enzymes during MG tumor development. 
 
Source of 
Variation 
Diet 
[p value] 
Tissue global 
[p value] 
MG+T vs. MG/T 
[p value] 
Interaction 
[p value] 
 
 DNMT1 <0.05 <0.05 ns ns  
 DNMT3a ns ns ns ns  
 DNMT3b ns ns ns ns  
 Tet1 ns <0.001 <0.001 ns  
Statistical significance of differences was calculated for all candidate genes using a linear mixed model. A random rat effect 
was included to account for multiple tumor/tissue samples from the same animal. Models for diet and tissue effects as well 
for interaction were fitted. P-values were adjusted for multiple testing across genes using Benjamini-Hochberg correction.  
Tissue effects were calculated across all tissue types (global: mammary glands (MGs) vs. mammary glands with no palpable 
tumors (MG/T) vs. tumors (T)), as well as MGs and tumors compared to MG/T (MG+T vs. MG/T). 
 
4.3.7 DNA methylation changes of enriched MG epithelial cells obtained by LCM 
Since MGs are composed of multiple cell types, i.e., ductal epithelial cells, adipocytes, stromal cells, 
immunological cells, and others, differences in methylation might reflect differences in cell 
composition between samples rather than alterations in methylation levels. 
We assumed that methylation differences within mammary epithelial cells were “diluted” by the 
contribution of all cell types to an average methylation level as we used whole MG tissue for our 
quantitative analyses. In order to enrich for mammary epithelial cells from the cell mix present in a 
bulk MG, non-contact laser capture microdissection (LCM) was performed from MGs (n=6) of the C 
and H diets as well as DCIS (n=3) of the control group (Table 5). A two-step process of cutting the 
specimen and catapulting into adhesive cap tubes, without any contact and against gravity enabled 
an enrichment of the area of choice (Figure 66). For healthy MGs between 3-5 mm2 and roughly 
1 mm2 from DCIS samples were used for DNA isolation. 
In order to gain a clear insight into the DNA methylation levels of enriched MG epithelial cells, we 
analyzed candidate regions identified by RRBS analyses of pre- and postpubertal ACI rats as well as 
during ACI carcinogenesis by MassARRAY. 
Due to limited amounts of DNA (mostly less than 30 ng), no PCR product was obtained for Niacr1, 
Arpp21, Fxyd2, and Mmaa. Interestingly, Extl1, Ndrg3, Thy, and in part Esr1, and Zfp507 showed 
relative homogenous methylation levels within one dietary group, reflecting the observed median 
methylation when analyzing the whole MGs (Figure 67). With an exception of Thy and Zfp507, 
methylation levels determined for the LCM-samples was increased when compared to the non-
dissected counterparts (with high variation for Zfp507 in the H diet) suggesting that the epithelial-
surrounded cell types indeed are able to influence DNA methylation analysis. 
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In contrast to our expectations, interindividual DNA methylation was often greater in the LCM 
samples when compared to samples obtained from the MG bulk of cells. Especially miR-10a, Mrc2, 
Rnf8, St3gal4, and Npas1 showed massive divergence within one diet group which did not enable a 
clear insight into epithelial DNA methylation changes unbiased by other cell subtypes. 
 
 
Figure 66: Non-contact laser capture microdissection to enrich for MG epithelial cells. 
The overview consist of 24 individual snapshots under 5x magnification. A: MGs were dissected from ACI rats and 
cryosections were collected on PEN-membrane covered slides, stained with hematoxylin and eosin and viewed to locate the 
MG epithelium. B: View of the specimen after cutting and catapulting of the target regions. 
 
Methylation data for MG samples containing DCIS was obtained for Msx1, Gbp2, and Npas1. Msx1 
and Gbp2 methylation showed less interindividual variation than for Npas1 and resembled 
methylation of the corresponding bulk MG samples (Figure 68).  
In total, with the exception of Thy1 and Zfp507, all epithelial cell samples obtained from LCM mostly 
confirmed median methylation obtained from the mix of all cell types within the MG samples, 
although the high variation often complicated concrete comparisons. Thy and Zfp507 clearly 
exemplified that analysis of a mixture of various cell types, which the MG is comprised of, might 
affect median methylation levels of a given specimen. 
 
 
 
A 
B 
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Figure 67: Quantitative analysis of candidate regions of enriched MG epithelial cells. 
Median methylation in healthy mammary glands (MGs), enriched mammary gland epithelial cells obtained by LCM (MG-
LCM) from PND 240 analyzed by MassARRAY. Each dot in the scatter plots represents one animal (light grey, control diet 
and dark grey, IF diet). 
 
 
 
Figure 68: Quantitative analysis of candidate regions of enriched MG epithelial cells with DCIS. 
Median methylation in healthy mammary glands (MGs), enriched mammary gland epithelial cells obtained by LCM (MG-
LCM), mammary glands with no palpable tumors (MG/T) and ductal carcinoma in situ (DCIS) enriched by LCM from PND 240 
analyzed by MassARRAY. Each dot in the scatter plots represents one animal (light grey, control diet and dark grey, IF diet). 
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5. Discussion 
Numerous studies indicate that lifestyle and environmental factors, such as dietary habits, essentially 
affect international incidences of certain cancer types [124, 125]. Notably, hormone-dependent 
cancer rates are particularly low in populations following a traditional Asian diet rich in soy and soy 
products. IF have attracted much attention regarding their chemopreventive potential with several 
investigations providing evidence of IF targeting the epigenome. 
In the present thesis, two sequencing-based methodologies for methylation profiling, i.e., MCIp-Seq 
and RRBS were established and implemented to analyze the impact of IF on epigenetic mechanisms 
in breast cancer prevention. Genome-wide DNA methylation profiles of MGs of healthy rats and 
during E2-induced mammary carcinogenesis were analyzed by means of bioinformatics evaluation 
and quantitative confirmation by MassARRAY technology. Additionally, IF-induced epigenetic effects 
culminated in gene expression changes of candidate genes involved in E2-responsive signaling and 
epigenetic mechanisms.  
Dose-response aspects, critical time windows and the influence on carcinogenesis will be discussed. 
5.1 Method establishment 
5.1.1 MCIp-Seq in Wistar rats 
The impact of IF on DNA methylation on a genome-wide scale was investigated using Methyl-CpG 
Immunoprecipitation (MCIp) followed by next generation sequencing (NGS, Seq). Since animals of 
the MC and MH groups were the first samples available, we selected those for genome-wide DNA 
methylation profiling. 
Affinity enrichment-based methods such as MCIp have been used in combination with promoter, 
CGI, or tiling arrays as well as with NGS. Array-based data analysis was routinely used in the division 
and provided straightforward bioinformatics analysis, although biased for preselected genomic 
regions covered by the array. However, technical support was discontinued for the rat genome at the 
DKFZ, therefore NGS-based detection was applied. We used MCIp enrichment for medium and highly 
methylated DNA fragments by adjusting the amount of salt in the washing buffer, we were able to 
enrich DNA fragments according to their degree of methylation.  
A stepwise elution of fragments from the MBD protein with increasing amounts of salt results in 
enrichment of fractions with increasing DNA methylation levels and density. By using high salt (HS) 
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eluted fractions or by applying a single fraction (SF) elution protocol to elute all methylated fractions, 
high or moderately-to-high methylated DNA fragments, respectively, can be enriched. 
5.1.1.1 HS elution: enriching for highly methylated DNA 
Firstly, we focused our analysis on the highly methylated regions obtained by the HS protocol. 
Sequencing the high CpG density regions, we obtained roughly 20 M reads per group and covered 
24-28 % of all available CpGs in the rat genome at least once with a good overall genomic coverage 
(saturation correlation 0.98). Enrichment profiles generated by MCIp-Seq were used to identify DMRs 
between animals on standard IF-containing diet which were swapped to control diet (MC) or high IF 
diet (MH) during the hormonal decline period after ovariectomy. MCIp-Seq does not provide precise 
quantification of methylation levels. Rather, differences between samples are measured as 
enrichment scores of DNA fragments. The Homer suite of tools was used for analysis of MCIp-Seq 
data. After bioinformatics comparison, we identified relatively few methylation changes between MC 
and MH group throughout the genome. With 4-fold difference in read counts between both diet 
groups, and at least 10 reads per region in one group as selection criteria, we observed an increase of 
hypo- over hypermethylated regions (3,014 vs. 2,077 DMRs) due to the post-OVX IF intervention. 
Annotation of the DMRs according to genomic regions showed that the majority of changes in DNA 
methylation occurred outside of regulatory regions (promoters, CpG islands or 5’ UTRs). In fact, more 
than 90 % mapped to intronic and intergenic regions, as well as to repetitive sequences (LINE, SINE, 
LTRs, simple repeats and satellites) introducing changes of DNA methylation within these regions.  
The precise function of DNA methylation changes in introns, exons or intergenic regions has not been 
clarified in detail, but recent investigations suggest that they play a role in transcriptional regulation, 
alternative splicing and promoter usage as well as in expression of coding and non-coding transcripts 
[195]. Further, it has been reported that DNA methylation outside of promoter regions might play a 
role in controlling the distribution of repressive chromatin marks such as H3K27me3 around the 
border of active core promoters and therefore counteracting their propagation [196]. However, 
some of the identified DMRs presumably overlap with enhancers and other distal regulatory regions 
which regulate gene expression in a cell type-specific manner [197]. Different from the human and 
mouse genome, the exact mapping of enhancers is, however, not well known for the rat genome and 
will be a focus of future investigations. 
5.1.1.2 SF elution: enriching for moderate and highly methylated DNA 
Since it has been suggested that highly methylated CpG-dense regions might be resistant to 
demethylation [181], we were interested in the IF-induced effects on moderately methylated and 
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probably less CpG-dense regions. Therefore, we performed a second MCIp-Seq approach applying 
the SF elution protocol and sequenced all methylated fractions, including fragments with moderate-
to-high methylated DNA and intermediate-to-high CpG density. 
Sequencing of medium-to-high methylated DNA fragments after applying SF revealed a number of 
novel insights about IF-responsive regulatory modules. Comparing HS and SF enrichment techniques 
both revealed a different representation and coverage of the genome. HS favors high CpG density 
regions and covered 24-28 % of all available CpGs in the rat genome at least once. 8-9 % of all CpGs 
showed more than 10x coverage. In contrast, the SF protocol covered 76-85 % of all available CpGs 
with 23-32 % of all CpGs showed more than 10x coverage.  
In total, SF obtained 45-71 M reads per group, which accounts for 2.5 to 4-fold more reads than the 
HS elution. This difference might be explained by the slightly higher number of animals sequenced. 
Since these reads were distributed over more CpGs, coverage depth per single CpG was lower than in 
the HS (saturation correlation 0.92 vs. 0.98). We observed that only few CpGs showed a high read 
depth with more than 100 reads per site, whereas a high percentage of the CpGs in the SF elution 
experiment was sequenced to a lower depth which subsequently hampered the identification of 
significant DMRs. In contrast, the number of highly covered CpGs was higher with the HS elution 
protocol. These sites are located in CpG-dense regions which were highly enriched and subsequently 
sequenced to a greater depth, resulting in higher power to detect significant changes. 
Bioinformatics comparison of the MC and MH group identified less methylation changes in the SF 
study than in the HS protocol (1,062 hyper- and 296 hypomethylated DMRs), with a similar relative 
genomic distribution. However, DMRs showed relatively little overlap between groups, reflecting 
that both elution protocols cover specific sets of CpG sites due to the differences in genomic 
coverage.  
We required a 4-fold difference in enrichment/reads between two groups to call a region 
“differentially methylated”. To avoid detection of DMRs with low coverage, we set stringent cutoff 
criteria of at least 10x coverage per region in one group. Therefore, more than half of the newly 
covered CpGs using SF elution had to be discarded due to insufficient coverage but with the 
advantage to detect biological meaningful significant changes.  
In future experiments, it will be necessary to increase the number of reads per sample by additional 
sequencing or by decreasing the number of samples per lane, to successfully cover this broader 
range of CpG-densities. It should then be considered that the required sequencing effort would 
increase overall experimental cost. Also, it has to be taken into consideration that enrichment-based 
methods only provide indirect DNA methylation information which has to be validated by 
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quantitative methods, e.g., clonal bisulfite sequencing, pyrosequencing or by MassARRAY technology 
[94, 198]. 
5.1.1.3 Confirmation of MCIp-Seq data 
For validation of differential methylated regions observed in the genome-wide methylation analysis 
by MCIp-Seq, quantitative analysis of DNA methylation was performed using the mass spectrometry-
based EpiTYPER MassARRAY technology. This technique represents a candidate region approach and 
is able to provide accurate quantitative methylation data with a technical detection limit of 5 % 
methylation difference, by quantifying median methylation of CpG units of candidate regions. 
We selected 14 IF-induced DMRs of both MCIp experiments mainly located in gene promoter regions 
or close to the TSS to quantify methylation levels in the experimental groups. For most of the 
candidate regions, we were not able to confirm IF-induced methylation changes observed by MCIp-
Seq. Median methylation differences of less than 10 % between the MC and MH groups were 
observed with high interindividual variation within the dietary groups. The high interindividual 
variation might be attributed to the fact that the Wistar rat strain is an outbred stain, and therefore 
individual response to ovariectomy and IF intervention might be variable.  
Overall, we were able to identify a statistically significant effect of the post OVX high IF diet on DNA 
methylation in two regions (Gadd45b and Cyp2C6v1).  
A possibly explanation for the discordance between the results obtained by MCIp enrichment and 
EpiTYPER MassARRAY might be the composition of the MG samples we used. Histologically, lobules 
and ducts are organized in single layers of luminal epithelial and contractile myoepithelial cells which 
are surrounded by the ECM, fibroblasts, immune cells, and adipocytes, as well as blood vessels, and 
others. MCIp is an enrichment-based methylome profiling technique. Consequently, differences in 
read counts between groups might reflect an enrichment of highly methylated DNA derived from a 
subpopulation of cells. Confirmation of differences by MassARRAY relies on the quantitative analysis 
of methylation derived from all cells in one sample. Therefore, the methylation differences of a 
particular subpopulation will be “diluted” by the average methylation levels of the bulk of 
contributing cell types. Differences in read counts in MCIp-Seq experiments might also reflect 
differences the glandular structure or the cellular composition of the MG between samples, rather 
than alterations in methylation levels [75].  
Furthermore, it is not known whether affinity-based methods distinguish 5mC and 5hmC which 
might lead to validation problems, since quantification by MassARRAY relies on bisulfite conversion 
which does not discriminate these chemical modifications [53]. 
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Additionally, dietary and environmental factors have been shown to induce rather small changes in 
DNA methylation in non-neoplastic specimen which is in sharp contrast to the massive methylation 
changes in cancerous samples compared to normal tissue [199], reviewed in [200, 201]. Here the 
pathological process entirely disrupts the physiology of the cells, and, therefore, it is not unusual to 
detect large differences in DNA methylation [83]. 
In our project, the study with the MC and MH groups provided the first DNA samples available for 
genome-wide profiling. In fact, if soy IF lead to developmental reprogramming during early life by 
engagement of the epigenomic machinery, reflected in modified methylation profiles, it is 
reasonable that we did not detected major methylation differences between these two groups. The 
MCIp technology has been successfully used previously to detect methylation changes in cancer 
studies [83, 169, 202]. Since it does not provide quantitative data it might be not optimally suited to 
identify subtle diet-induced methylation changes. Nevertheless, we found interesting regions 
susceptible to IF-induced alterations in methylation. 
In order to allow a more accurate assessment of the potential of IF on DNA methylation in further 
studies, we decided to establish RRBS for genome-wide methylation profiling, as it avoids the 
drawbacks of the enrichment-based MCIp-Seq method and enables a quantitative assessment of 
small-scale methylation differences of a large fraction of the genome at reasonable costs. 
5.1.2 RRBS in ACI rats 
Similar to the investigations in Wistar rats, we intended to perform genome-wide methylation 
analyses to investigate the impact of a lifelong dietary IF exposure on DNA methylation changes in 
MGs of ACI rats. In the kinetics arm of the project, we planned to focus on developmentally critical 
time windows, whereas in the carcinogenesis arm, we were interested in cancer preventive efficacy 
during E2-driven mammary carcinogenesis.  
In order to overcome the limitations of the enrichment-based MCIp-Seq technology that we had 
used in the Wistar study, we decided to implement RRBS in the division for our methylome screen in 
the ACI rat experiments. The advantage of RRBS lies in the fact that this method provides single 
nucleotide methylation information for about 10 % of all CpGs in a genome, with enhanced coverage 
of regions, with moderate to high CpG density, including CGIs, promoters and enhancers [88, 203]. 
Methods other than RRBS that assess DNA methylation on a single nucleotide basis and a genome-
wide scale either rely on high bioinformatics and financial effort (e.g., WGBS) or on a reference 
methylome available on BeadChips arrays (e.g., Illumina 450k). 
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In cooperation with Christoph Bock (CeMM, Vienna), we have established a RRBS library preparation 
pipeline. We started to analyzed DNA from pre- and postpubertal ACI rats, since the main changes of 
MG development and differentiation are initiated at puberty [108]. In the second part of the study, 
we continued with adult MG and tumor samples. 
5.1.2.1 Genome-wide methylation screen during puberty 
In order to understand the potential of IF on DNA methylation during the early epigenetic 
programming of the MG, we subjected 24 MG from pre- and postpubertal ACI rats to RRBS library 
preparation. Sequencing was done on 6 multiplexed libraries on one lane. We roughly covered 
2.18 M out of the 24.7 M CpGs in the rat genome, with roughly 1 M CpGs being uniquely aligned per 
sample. In total, 14-35 M high quality reads were obtained per sample with an alignment rate of 
73-76% and a mean bisulfite conversion rate of 98.5 %. This is in line with results that have been 
published by others [204-207]. To our knowledge, there is no reference rat methylome of the MG 
available. Several studies investigated DNA methylation in rat on a genome-wide scale but focused 
on different tissue such as liver, kidney, placenta, or neurological tissues [204, 206, 208]. Methylation 
patterns have been shown to serve as a specific cellular memory and are therefore highly cell type 
specific. For example, embryonic stem cells have very low levels of DNA methylation which is 
increasing by de novo methylation determining somatic methylation patterns with up to 80 % global 
methylation [209]. Therefore, we could not use these available data sets for comparison and to 
investigate the impact of IF on the MG methylome.  
In total, we determined a global DNA methylation of 64 % in healthy pre- and postpubertal MGs of 
ACI rats. In order to detect CpGs that responded to environmental perturbations, i.e., dietary IF 
intervention, we first applied filtering criteria in an attempt to increase the reliability of data being 
analyzed at a given CpG and limit the occurrence of false-positives. We required high sequencing 
read depth per CpG per sample, filtering out loci with lower than 20x coverage in at least 10 out of 
the 12 animals per age group, enabling a detection limit of at least 5 % absolute methylation 
differences. Comparing rats of individual dietary regimes (C vs. H group), we observed modest 
differences in methylation with less than 10,000 DMS. 
In order to gain potential insight into functional and mechanistic characteristics of DMS, we assessed 
the overlap with various genomic features with respect to 5' UTRs, promoters, and CGIs, as well as 
introns, exons, intergenic and repeat annotations. In agreement with the results obtained by MCIp-
Seq in the healthy adolescent Wistar rats, IF-induced changes in DNA methylation predominantly 
occurred outside of regulatory regions (promoters, CpG islands or 5’ UTRs). Similarly, more than 90 % 
mapped to introns, and intergenic regions, as well as to repetitive sequences (LINE, SINE, LTRs, 
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simple repeats and satellite regions). However, DMS showed relatively little overlap between groups, 
indicating a specific set of CpG sites that is significantly affected by IF exposure in each age group.  
These results support the observations from the MCIp-Seq analysis that IF-induced DNA methylation 
might regulate gene expression not only by affecting gene promoters but also by modulating distal 
regulatory regions such as enhancers or non-coding RNAs. This might be achieved by engaging 
chromatin-modifying enzymes that influence transcriptional regulation and cellular health. Sandovici 
et al. investigated the Hnf-4α locus, a TF involved in glucose homeostasis and development of type 2 
diabetes and demonstrated the impact of maternal diet on promoter-enhancer regulation during 
fetal and early postnatal life in pancreatic islets of rats [210]. Low protein intake of the dams resulted 
in a modest increase in DNA methylation and concomitant changes in histone marks (loss of 
H3K4me1, gain of H3K9me2). The introduced epigenetic changes mapped outside the core promoter 
region and decreased the long-range interaction of the distal Hnf-4α promoter with the enhancer 
region, leading to profound silencing of the TF and loss of glucose tolerance [210]. Therefore, 
promoter-enhancer interaction might be a frequent but hitherto underestimated target of nutritional 
modification such as early dietary IF exposure. 
5.1.2.2 Methylome profiling during E2-induced breast carcinogenesis 
Additionally, we mined the DNA methylome of ACI rats during E2-driven carcinogenesis of the MG, in 
order to assess the influence of a lifelong IF exposure on DNA methylation and potential cancer 
preventive effects. 
After we optimized our RRBS library preparation protocol for the adult rat study and sequenced 
libraries on two lanes (instead of one as in the puberty study), we were able to increase the 
qualitative as well as quantitative results of the sequencing run. With an increase in the bisulfite 
conversion rate to 99 % and an alignment rate of 73-76 %, we covered around 2.27 M of the 24.7 M 
CpGs of the rat genome. In total, the number of aligned reads increased by roughly 2-fold to 45-68 M 
high quality reads per sample. Concomitantly, distribution of the reads throughout the genome 
enhanced the extent of uniquely aligned reads from 1 M to 1.5 M. Also, read depth was increased 
from 30x to roughly 70x mean coverage per individual CpG.  
Overall, we determined a global methylation of 53 % in MG and tumor DNA of adult rats indepen-
dent of the state of disease. This represents a loss of global methylation in course of MG 
development of 11 % when compared to 64 % methylation in MGs of the puberty study. This is in line 
with Heyn et al. who proposed age-specific demethylation in healthy normal tissues and were able to 
determine the biological age solely by means of DNA methylation [211].  
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Similar to the approach in the puberty study, we applied filtering criteria in an attempt to increase 
the reliability of the data at a given CpG, responsive to diet and E2-treatment. In sharp contrast to 
array-based analyses with defined sites at preselected genomic positions, CpG sites in RRBS runs that 
pass the selection criteria are not necessarily identical in all samples of one experiment, depending 
on the quality of the sequenced library. Consequently, the number of overlapping sites that meet 
certain quality criteria such as coverage or false discover rate might vary substantially. Since we 
wanted to compare several intervention groups within the carcinogenesis study, we required high 
sequencing read depth per CpG in all samples. Therefore, we filtered out loci with lower than 20x 
coverage in at least 20 out of the 24 sequenced animals leading to 666,745 overlapping CpGs 
between all groups. 
Looking for significant methylation changes of at least 5 %, we observed an increase of IF-induced 
methylation changes by 2-fold compared to the puberty study. These DMS represent accumulated 
changes of the MG, which eventually putting a cell at a heightened risk for damage or might reduce 
susceptibility towards a certain disease. We identified roughly 24,000 diet-induced DMS in adult rats 
analyzed in normal MGs (C vs. H group) as well as in tumors (C+E2 vs. H+E2 group). By far the 
greatest impact on the methylome was seen during tumor formation with roughly 43,000 to 49,000 
E2-induced DMS (H vs. H+E2 and C vs. C+E2 groups, respectively). 
During tumor development (C vs. C+E2 and H vs. H+E2), we observed a genome-wide loss in 
methylation with two-thirds of the identified DMS accounting for hypomethylated sites. This finding 
is supported by previous studies on E2-induced MG tumors in ACI rats that measure global DNA 
methylation by the use of a HpaII-based radio-labeled [3H]-dCTP extension assay. HpaII cleaves 
unmethylated CCGG sites and leaves an overhang that is subsequently radio-labeled with [3H]-dCTP. 
E2-induced a global loss of DNA methylation which was detectable starting from mild to moderate 
and severe hyperplasia at PND 75, 100, 140 and 180. Due to the methodology used, no information 
on candidate regions was available [168, 212]. 
Annotation of the DMS to genomic features with respect to 5' UTRs, promoters, and CGIs, as well as 
exon/intron, intergenic and repeat annotations revealed that DMS identified during E2-induced 
tumorigenesis showed a significantly loss of methylation in repetitive elements. Methylation in these 
regions contributes to limiting DNA accessibility, and transcriptional activation of repetitive elements 
has been associated with chromosomal instability [213]. Thus, increasing hypomethylation weakens 
the defense mechanisms against transposition of mobile elements. A recent study has shown that 
one endogenous retrovirus (ERV) class, i.e., ERV-K-type family contributes to genome variability in 
inbred rat strains. Therefore, such a defense mechanism is important for rodents who harbor active 
ERV within their genomes [214]. 
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Although, RRBS tends to cover regions with high CpG density such as promoters and CGIs, less than 
15 % of the identified DMS in our data mapped to regulatory regions (5' UTRs, promoter, CGIs). This 
is comparable to recently published RRBS data sets with less than 20 % of the DMS cover promoter 
regions [206]. Since we used the Homer suite of tools for annotating the DMS, identified promoter 
regions are defined as 1 kb around the TSS by default. Standard promoter definition consider 2 kb 
upstream and 0.5-2 kb downstream of a TSS; therefore, many putative promoter CpGs might have 
been considered to map to intergenic regions or to exons and introns, explaining the lower number 
of mappable CpGs at promoter regions. 
Notably, we observed a significant enrichment of hypermethylated DMRs in introns, and exons. as 
well as in regions close to TSS which, in addition to potential roles for general transcriptional 
regulation, could indicate effects on gene splicing and isoform-specific regulation. Sati et al. observed 
that specifically intron-exon-intron junction are marked by DNA methylation in rat liver, emphasizing 
the role of DNA methylation in distinguishing exons from introns [215]. There is also evidence that 
gene body methylation, particularly in CGIs, could highlight non-canonical TSS and tissue-specific 
gene regulation as well as dynamically target alternative splicing of cassette exons (skipping or 
inclusion) and intron retention in the final transcript [216, 217]. 
DNA methylation and consequently transcriptional regulation of imprinted genes is often affected 
during cancer development, since these regions require tight control to maintain paternal- or 
maternal-specific allelic-transcription [218]. So far, we have not investigated these regions in greater 
detail. Reports by others revealed an impact of endocrine disrupting agents, e.g., TCDD, on DNA 
methylation status of imprinted genes of embryos at the preimplantation period, influencing the 
expression of the imprinted genes and fetal development [219]. 
5.1.2.3 Stringent cutoff criteria for RRBS data secure reliable quantitative methylation data 
RRBS provided us a hands-on tool to explore the epigenetic effects of IF on MG development and the 
risk of MG tumor formation at single CpG site resolution. RRBS enables a direct quantitative readout 
of methylation levels between samples , theoretically, does not require independent validation.  
According to our knowledge, no study so far attempted a quantitative confirmation of RRBS-derived 
methylation data for validation of identified DMS using MassARRAY technology as second 
quantitative method. 
Results obtained in the puberty study 
In a first technical validation, ten candidate regions from the RRBS data of pre- and postpubertal ACI 
rats were selected for MassARRAY validation, using the same DNA samples that were used for the 
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RRBS run, to demonstrate the accuracy and reliability of the sequencing results. Each differentially 
methylated region (DMR) was represented by at least 2 single CpGs or a CpG unit consisting of 
2 CpGs. Six regions showed high absolute methylation >50 % and IF induced hypomethylation, 
whereas four regions with methylation levels below 50 % gained methylation in the animals receiving 
IF diet. Differential methylation detected by RRBS between C and H diet groups could not be 
confirmed by MassARRAY. Group wise methylation levels were much more homogeneous when 
determined by MassARRAY indicating that the methylation differences detected by RRBS were at 
least partly due to technical artifacts.  
Bisulfite treatment of the DNA might introduce a bias towards increased methylation levels since 
unmethylated non converted Cs will be considered as methylated Cs. PCR amplification errors have 
also been observed for bisulfite converted DNA (unpublished results Gerhäuser lab). Since RRBS 
libraries are prepared from low input material (<100 ng) and bisulfite conversion commonly destroys 
>99 % of intact DNA fragments due to the denaturing environment [220], sequence specific 
amplifications of preferentially un- or fully methylated DNA fragments have been reported (oral 
communication PD Dr. Dieter Weichenhan). 
However, although diet-induced methylation differences could not be confirmed by MassARRAY 
technology, in general, the methylation levels detected by both technologies were comparable and 
showed highly significant correlation (Spearman correlation coefficient rho: 0.7038).  
Results obtained in the carcinogenesis study 
For the second technical validation, eleven candidate regions from the RRBS data of the 
carcinogenesis experiment were selected for MassARRAY validation, using the same DNA samples 
that were used for the RRBS run. In order to reduce the number of low-confidence CpGs, we 
integrated additional filters to our selection pipeline to remove sites with high within-group variance. 
This was intended to limit the inclusion of sites with potential false (low or high) methylation which 
could contribute to inflated differences between groups in our data set. In a previous study, Watson 
et al. calculated outliers as maximal observed CpG value minus minimal observed CpG value. If the 
difference was >30 % CpGs were discarded. In their RRBS data set, bad quality CpGs represented one 
quarter of all high quality reads with more than 30x coverage per CpG (roughly, 208,000 of 776,000 
CpGs) [206]. Therefore, outlier removal with standard deviations exceeding >25 % absolute 
methylation is highly recommend. Taking this into consideration, we combined settings which best 
identify CpG sites that could be confirmed by alternative methods. We narrowed down the DMS list 
by increasing the methylation difference to >15 % and by stringently filtering for standard deviation 
<15 % absolute methylation to remove sites that were identified as DMS as a result of individual 
outlier values. Further, we focused on CpG sites with mean methylation levels between 5-95 % to 
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exclude sites which were either unmethylated or fully methylated, a signature which might be 
consistent with underlying genetic polymorphism. We were not able to confirm these large 
interindividual variations by MassARRAY analysis in the previous validation experiment as described 
above. Therefore, sequencing or bioinformatics artifacts, indeed, most likely account for these 
observations and it was reasonable to exclude these sites. 
Overall, by applying these optimized settings, we were able to confirm tumor-induced methylation 
changes as well as preventive effects by IF intervention. Due to the low number of identified DMS, 
we did not reduce the interindividual variation within one group by setting cutoff limits for standard 
deviation or overall mean methylation for the comparison of C vs. H groups. Consequently, we were 
not able to verify the IF effects in healthy MGs. However, overall, we demonstrated the consistency 
of the RRBS and MassARRAY data and calculated significant correlation (Spearman correlation 
coefficient rho: 0.7868).  
Although methylation differences at single CpGs have been demonstrated to influence gene 
expression patterns [221], it can be difficult to assess the significance and reliability of variation 
observed on a single CpG basis, particularly from a statistical perspective, when implementing 
multiple testing. Since we and others have shown that methylation levels are strongly correlated at 
CpGs that are in close proximity, methods that assess concordant changes in DNA methylation at 
neighboring CpGs would circumvent this issue. Thus, defining and analyzing DMRs with 2-3 
significantly concordant DMS (either hyper- or hypomethylated) would increase the reliability of the 
data analyzed and would further enhance the statistical power [222]. 
Additionally, RnBeads analyses have been based on differences in the group methylation mean 
values which is highly susceptible to artifacts due to outlier values. Calculations on group wise 
median methylation values might provide a more reliable tool to call DMS between groups. This 
option is now implemented in RnBeads. 
In order to improve the technical accuracy of RRBS and to identify reliable DNA methylation patterns, 
unique molecular identifiers (UMIs) can be used to control for amplification biases [223, 224]. These 
short nucleotide sequences can be tagged to the MspI digested fragments before bisulfite 
conversion. After PCR amplification, UMI-labeled DNA fragments are digested by enzymatic 
restriction. Libraries are prepared according to standard RRBS protocols, sequenced, and mapped to 
the genome. Since the same UMI is attached to different patterns and is therefore randomly 
distributed throughout the MspI fragments, non-uniquely labeled DNA fragments covering a CpG are 
considered as PCR-introduced duplicates. The numbers of each fragment can increase tremendously, 
when using low input material and high cycle numbers during amplification, yielding to a total 
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duplication rate up to 50 % [224] which can further increases when FFPE material or single cells are 
used (oral communication David Brocks). 
5.2 Biological effects 
5.2.1 Investigations on IF dose and exposure time in Wistar rats 
As discussed in section 5.1.1 we performed a genome-wide methylation analysis using MCIp-Seq to 
identify genomic regions differentially methylated between the MC and MH diet groups. These were 
exposed to intermediate levels of IF until OVX and differed only in IF exposure during the hormonal 
decline after OVX. Overall, we detected only few DMRs between these two groups, which might not 
be surprising, as the rats were similarly exposed to IF during important developmental periods (in 
utero until adulthood). In comparison to this exposure period, the post OVX period, when IF exposure 
of the rats was either stopped or even increased, was relatively short. Migration studies have 
demonstrated that environmental and life-style factors (e.g., diet) are able to affect susceptibility to 
specific types of cancers but might take several generations to occur [225]. 
We selected genomic regions for validation of the DMRs by MassARRAY. Although methylation 
differences between the MC and MH group could not be confirmed, quantitative methylation 
analyses of additional dietary groups revealed interesting time- and dose-dependent influences of IF 
exposure on DNA methylation and gene expression, as discussed in detail below. 
5.2.1.1 Specific TF are enriched in DMRs identified by genome-wide analyses 
In order to investigate whether IF-induced DMRs share common genomic features, a de novo 
transcription factor (TF) binding motif discovery as well as an enrichment analysis of known TF 
binding motifs was performed using the Homer suite of tools [172]. These motif analyses enabled a 
deeper insight into the molecular mechanisms affected by the IF-induced DMRs identified between 
MC and MH by MCIp-Seq. 
Distinct results were obtained when analyzing the datasets of the high salt (HS) vs. single fraction (SF) 
elution for motif enrichment. Only little overlap between enriched motifs was detectable between 
HS and SF protocols. Enrichment was predominantly found for basic leucine zipper (bZIP)-domain TFs 
(i.e., Atf3, Fosl2 and MafK) in hypomethylated DMRs. This family of TF plays important roles in 
cellular processes including cell proliferation, differentiation, and apoptosis and has been implicated 
in malignant transformation. The AP1 FOS/JUN heterodimer is a well-known member of this family 
which is activated by growth factors such as EGF, TGFα, IGF and E2. ERs also mediate gene 
transcription via AP1 binding sites particularly when transactivation properties are modified by the 
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ligand bound, e.g., tamoxifen and raloxifen with ERβ being 10-fold more efficient in activating AP1 
than ERα [226]. However, ER-stimulated transcription of AP1 targets is associated with an induction 
of cell proliferation and is regulated by cyclin D1 and E2F [227]. Thus, hypomethylation of regions 
with binding sites for bZIP-domain containing TF which potentially dimerize with JUN to form an 
active AP1 might reflect a mechanism by which the additional high IF exposure after OVX provokes 
the increased proliferative and estrogenic responses indicated by increased PR and PCNA IHC staining 
in MH group animals vs. the MC group. 
Motifs of E26 transformation-specific (ETS)-domain TF family members (i.e., ERG, SpiB and Ets1) were 
enriched in hypermethylated DMRs. ETS-domain proteins have been implicated to play important 
roles in promotion of differentiation, inhibition of apoptosis and in regulation of cellular senescence. 
Deregulation by inappropriate expression or expression as fusion proteins has been associated with 
the development of certain types of cancers, e.g., ovarian or prostate cancer [228]. Growth factor 
dependent phosphorylation via the proto-oncoprotein Ras and subsequent activation of the MAPK 
(mitogen-activated protein kinase) pathways has been tightly connected to ETS-domain containing 
TFs [229]. There is evidence that the transcriptional-regulation process also involves epigenetic 
modification of the targeted promoters, e.g., Ets-1 is able to bind to CBP/p300 and enhances 
transcriptional activation of downstream genes [229]. Therefore, hypermethylation of ETS-domain TF 
binding sites might provide a functional mechanism by which IF put their growth limiting and 
beneficial health effects into action.  
The finding that hypo- and hypermethylated regions are associated with functionally distinct TF 
motifs suggests that hypo- and hypermethylation may occur in distinct cell types. It is intriguing to 
speculate that there might be a common mechanisms targeting methylation changes to specific sites 
and alterations in distinct cell types might converge on pathways, regulating the ability of the MG to 
respond to IF exposure. 
Overall, these data provide evidence that IF affect gene categories by modulating DNA methylation 
and co-operative binding of transcription regulatory factors which consequently might affect the 
susceptibility of the MG to pathological processes. 
5.2.1.2 IF dose aspects 
One aim of the first project analyzing MGs of Wistar rats was to investigate the impact of two 
different doses of lifelong IF exposure on DNA methylation and estrogen responsiveness. A three-day 
uterotrophic assay was conducted to characterize the general physiological response and E2-
modulating ability of the different IF exposure scenarios.  
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IF doses were chosen based on reported dietary IF intake of Western and Asian populations [230]. 
The control diet contained very low IF amounts (3 mg/kg diet) yielding to a total intake of the animals 
of 0.3 mg/kg bw/d that resembles the dietary habits of the Western population with a daily intake of 
1-2 mg IF aglycone equivalents.  
Taking into account the IF exposure in Asians and the average daily food uptake of rats, we 
performed an allometric conversion to apply diets with different IF concentrations [231, 232]. Two 
experimental animal chows were enriched with the NovaSoy650® extract to a final concentration of 
68 mg/kg diet in low (L) and 503 mg/kg diet aglycone equivalents in high (H) IF-enriched diets. The 
medium IF concentration diet (M) was a standard soy containing diet provided by Ssniff GmbH which 
contains soybean meal and full fat soybeans as protein and fat source, resulting in a final 
concentration of 232 mg/ kg IF aglycone equivalents.  
Based on the allometric conversion (considering women with body weights of 60 kg), the L diet 
mimics an IF intake of 0.89 mg/kg bw and would imply a daily IF uptake of 53 mg. Regarding the 
average daily dietary IF intake of Japanese adults of 25-50 mg aglycone equivalents the L diet 
resembles the average Asian dietary behavior. Similarly, the M diet represented an IF intake of 
2.96 mg/kg bw, which can still be achieved by dietary soy consumption. A daily IF intake of 177 mg 
would represent approximately 10 % of the Asian population which ingest more than 100 mg/day 
[230]. In contrast, the H diet leads to a higher IF dose of about 5 mg/kg bw, which would imply a daily 
IF uptake of 390 mg. This represents a very high IF intake which might not be relevant as a dietary 
exposure scenario. However, women undergoing self-medication using IF-containing capsules as HRT 
can achieve IF intakes greater than 200 mg/d. Products on the market contain between 
40-150 mg IF/capsule, with a daily recommended dose of 2 capsules. Thus, elderly postmenopausal 
women might increase their IF intake far beyond what is observed for Asian women [7, 233]. 
Additionally, soy protein-based infant formulas represent a significant source of IF. Dinsdale et al. 
suggest that approximately 37-43 % of North American infants are formula fed from three to six 
months postpartum, thereby achieving IF doses of 5.7-11.9 mg/kg bw during the first months of life 
[234].  
Onset of puberty is accelerated by lifelong exposure to low and high IF doses 
In order to assess the estrogenic properties of a low (L) and high (H) dose lifelong IF intervention we 
investigated alterations of puberty onset and uterus wet weight. 
Interestingly, time to onset of puberty was reduced by both dietary regimes when compared to the 
control group. This is in line with previously published results, where administration of dietary IF in a 
multigenerational setting with different doses accelerated vaginal opening [235-237]. Also 
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investigations in humans that have examined markers of sexual development demonstrated 
significant effects of early IF exposure. Adgent et al. investigated 2920 white US American girls and 
identified a 4 month earlier onset of menarche among soy-based fed girls when compared to girls fed 
with non-soy-based infant formula [238]. Additionally, Kim et al. reviewed a number of studies 
conducted in US, UK, German and Korean populations and reported a positive association of 
premature thelarche (MG development) and/or menarche after early exposure to IF [239]. Since 
early onset of menarche is considered as a risk factor for developing MG tumors in humans these 
observations have to be interpreted as a potential adverse effect and hold a substantial public health 
relevance [240]. However, there was also conflicting data showing a deceleration of pubertal timing 
in response to dietary IF. Cheng et al. investigated 227 girls from the Dortmund Nutritional and 
Anthropometric Longitudinally designed study and reported a delayed Tanner stage 2 for breast 
development in girls of highest compared to lowest dietary IF tertile (1199 vs. 13 µg/d) [241]. 
Similarly, D´Aloisio et al. investigated 50,884 US and Puerto Rican women and identified associations 
for both, very early (<10 years) and late (>15 years) onset of menarche with postnatal soy-based 
formula nutrition [242]. Menarche is primarily controlled by the hypothalamic-pituitary-ovarian axis 
while thelarche and pubic hair development is modulated by hypothalamic-pituitary-adrenal axis. 
Therefore, IF exposure as well as several other factors, e.g., body mass, and body composition, as 
well as protein intake, and protein source might influence distinct pubertal events in a different 
manner [243]. 
Treatment with E2 for three days resulted in an increase of the UWW, whereas exposure to IF by the 
different diets exerted no effects on UWW. This is in line with a previous report from Molzberger et 
al. using an IF enriched diet containing 300 ppm aglycone equivalents [235] and argues against a 
direct estrogenic effect of IF exposure.  
Alternatively, impaired estrous cyclicity and ovarian function have been reported as a function of a 
complex influence of IF on the previously mentioned hypothalamic-pituitary-ovarian axis [239]. In the 
peripubertal period when endogenous E2 levels are low, GEN exposure induced increased sensitivity 
of the pituitary gland to gonadotropin-releasing hormone (GnRH), altering GnRH-induced luteinizing 
hormone (LH) release. This response seems to be dose-dependent. In CD rats, subcutaneous 
injections between PND 15-25±2 with low dose (10 µg/d) GEN increased and high dose (≥100 µg/d) 
GEN decreased LH release, resulting in altered time of ovulation [244]. 
These data indicate that indirect regulatory activities of IF also have to be taken into consideration 
when interpreting IF-mediated physiological effects. 
142   5. Discussion 
Lifelong high but not low IF doses reduce proliferative and estrogenic response 
We investigated the impact of IF on expression of PR as the prototypical marker for E2 
responsiveness in the MGs by IHC. E2 exposure stimulated PR protein expression, whereas this 
estrogenic response was clearly reduced by lifelong exposure to the H diet. In contrast, the IF dose in 
the L-diet group was not sufficient to reduce estrogen responsiveness. Interestingly, the 
intermediate IF level of the MC diet (but not of the MH diet) lowered the sensitivity of MGs towards 
E2 treatment.  
We further investigated the proliferation marker PCNA in the MGs by IHC. Similar to PR protein 
expression, E2 exposure stimulated PCNA protein expression. E2 response was clearly reduced by 
exposure to high as well as medium (MC, but not of MH diet) IF-containing diets, while the low 
lifelong IF dose was not sufficient to lower sensitivity of MGs towards E2 treatment. This is in line 
with earlier observations, where effects on differentiation of TEBs, highly fragile structures in the 
developing MG, were only achieved using higher doses of dietary GEN [245]. In contrast, in the 
absence of additional E2 stimulation a low dose of IF (L as well as MH diet) weakly induced the 
percentage of PCNA-labeled nuclei and increased mRNA transcript level of Ki67 (but not PCNA). 
Protein expression determined by IHC of the selected molecular markers (PR, PCNA) did not correlate 
well with mRNA expression. Pronounced E2-mediated induction of mRNA expression was only 
detectable for Pgr as well as for Greb1, a second E2-responsive gene investigated. Additionally, 
prevention of E2 stimulated mRNA induction was rather seen in the low instead of the high exposure 
group. While protein expression can be evaluated by IHC in the cells of interest, for example, MG 
epithelial cells, determination of mRNA expression is often performed with bulk tissue where 
additional cell types, e.g., adipocytes, fibroblasts, and lymphocytes contribute to mRNA levels. 
Additionally, these discrepancies might be due to differences in the kinetics of induction and the half-
life of mRNA and protein. The proliferation markers differ in their mRNA stability with PCNA showing 
faster mRNA degradation and stronger protein stability [246]. 
In summary, reduced proliferative response and reduced estrogenic sensitivity could only be 
observed in the animals exposed to medium and high IF doses. However, pro-estrogenic effects were 
particularly observed in the low dose group, i.e., induction of proliferative response without E2 
challenge as well as accelerated onset of puberty.  
Lifelong low IF exposure induces a U-shape like DNA methylation and mRNA expression profile  
In order to assess whether different IF doses are able to induce alterations in DNA methylation, we 
selected 14 DMRs identified between the MC and the MH group from both MCIp experiments for 
quantitative methylation analyses by MassARRAY technology. 
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First, we looked at all groups exposed to high IF levels post OVX and compared the trends of the 
different IF doses administered before OVX (i.e., no, intermediate, or high doses in groups CH, MH 
and HH). With increasing dietary IF concentration to medium and high levels pre OVX, methylation 
often increased with a linear tendency, whereas short-term exposure to high IF levels only after OVX 
(CH) largely lowered methylation levels relative to control.  
Next, we were interested whether a lifelong low dose IF treatment (group LL) would be sufficient to 
induce the effects obtained with medium (M) and high (H) IF diets. We compared the groups LL and 
HH, two treatment regimens with a constant lifelong IF exposure, to group CC with no IF exposure. 
Interestingly, lower IF levels exhibited opposite effects when compared to CC and HH groups and 
introduced pronounced hypomethylation in MGs of rats leading to a U-shape like dose-dependent 
DNA methylation and mRNA expression profile. In five out of 14 genes investigated different lifelong 
IF exposure dose-dependently induced alterations in gene expression i.e., Arpp21, PTEN, Cldn4, Esr1 
and Extl.  
Arpp21 (cAMP-regulated phosphoprotein 21) is located at chromosome 3p where loss of 
heterozygosity has been reported in 87 % of primary breast cancers. Embedded in the intron of the 
Arpp21 gene miR-128-2 is frequently downregulated along with Arpp21 in breast cancer, where it is 
negatively associated with clinico-pathologic characteristics and survival outcome [247]. Induced 
gene expression due to a high lifelong IF exposure would provide a clear benefit for individuals at 
high risk for breast cancer. PTEN (phosphatase and tensin homolog) is one of the most frequently 
mutated TSG. It negatively regulates the PI3K/AKT pathway that promotes cell proliferation, growth 
and motility and alters the functions of several AKT substrates, e.g., Mdm2, a proto-oncogene (E3 
ubiquitin protein ligase) that targets tumor suppressor proteins such as p53 for proteasomal 
degradation and BAD, a BCL2 antagonist of cell death [248]. Here, particularly the low IF diet 
increased gene expression representing a clear beneficial effect. Cldn4 (claudin 4) plays a crucial role 
in the formation and maintenance of tight junctions and is involved in breast cancer progression. Is 
has been shown that Cldn4 overexpression increased cell proliferation and migration in MCF-7 cells 
transplanted into nude mice and gene expression was regulated by DNA methylation [249]. Since the 
disruption of tight junctions can lead to the loss of intercellular cohesion, downregulation of Cldn4 by 
lifelong high IF might contribute to reduced cell invasiveness and increased differentiation of cancer 
cells [250]. Esr1 (estrogen receptor 1) encodes the ERα which plays a significant role in the 
development of breast cancer. One-third of all breast cancers lack ERα and rarely respond to 
hormonal therapies. They show higher proliferation and a worse clinical outcome than ERα-positive 
breast cancers [251]. Lifelong high IF exposure reduced Esr1 as well as Extl1 expression (exostosin-
like glycosyl-transferase 1) which was identified as one of the top E2-inducible genes in rat MGs 
144   5. Discussion 
[173]. However, its role in human breast carcinogenesis has not been investigated yet. A reduction of 
Esr1 mRNA levels in an ERα-positive MG might not be interpreted as a negative effect though since it 
might solely reflect a tissue-specific autoregulation of the ERα, as previously observed after 
exogenous E2 treatment [252]. 
Since we selected particularly IF affected DMRs for quantitative analysis, we did not see pronounced 
E2-induced DNA methylation or gene expression changes. Solely for Extl1, exposure to high IF levels 
increased the susceptibility to estrogen, but only when administered in a lifelong fashion.  
 
Overall, there seems to be a critical IF concentration leading to distinct biological effects. After 
exposure to the lower IF concentration, we observed opposing effects to those seen with medium or 
high IF levels mirroring maximum Asian exposure. These ‘hormetic’ or ‘biphasic’ dose-response 
models have been perceived as the pharmaco-dynamic nature of a number of substances particularly 
in tumor drug development [253, 254]. Therefore, the impact and efficacy of IF might be dependent 
on two situations; either low-dose stimulations lead to adverse effects (e.g., increased E2-sensitivity 
of the MGs, induced cell proliferation) or define the therapeutic zone and show beneficial effects 
(e.g., induced expression of TSGs) [255]. However, we could not always observe a clear dose–
response pattern. 
Interestingly, early studies already determined these biphasic effects of IF. Incubations with GEN in 
MCF-7 showed that GEN concentrations below the IC50 (10-50 µM) stimulated tumor cell growth in 
ERα-positive cells, while a higher GEN concentration lead to an inhibition of genes involved in cell 
cycle control [256]. Similar observations have been made for tamoxifen which induced prolactin 
secretion in rats when administered at low concentrations (100 mM) but not at higher levels [256]). 
Further, Iwasaki et al. investigated 24,226 pre- and postmenopausal women in the Japan Public 
Health Center–based prospective study and detected a similar biphasic effect regarding IF intake and 
breast cancer risk. There was an inverse association between plasma GEN levels and the risk of 
breast cancer since adjusted odds ratio (OR) gradually decreased with increasing GEN plasma levels 
up to 0.34 for the 4th quartile. Interestingly, OR were reduced to 0.79 in the 4th quartile by increasing 
DAI levels but were adversely affected by lower DAI levels as in the 2nd (1.50) and 3rd. (1.44) quartile 
(not significant) [257]. 
5.2.1.3 Critical time windows 
The timing of exposure seems to be the most critical factor. There is an ongoing debate whether IF 
need to be ingested for a lifelong period or if specific critical time windows are sufficient to induce 
the benefits associated with IF intervention. In order to gain a comprehensive insight into the action 
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of IF, we covered major developmental windows which have a key impact on MG development and 
health. 
Several earlier investigations have shown that especially a multigenerational and prepubertal 
exposure to IF modulate MG morphology and provide anti-tumorigenic effects [141, 245]. Several 
groups of rats in our study were kept on lifelong IF diets containing three different IF doses (L, M and 
H), which resembles the situation of the Asian population. Here, IF exposure starts already in utero, 
since IF are able to pass to placental barrier and accumulate to quantifiable levels in the amniotic 
fluid [258]. It is considered that the developmental effects attributable to chronic IF exposure in 
multi-generational studies result from this fetal exposure, since lactational transfer of GEN is limited 
as reported for Sprague Dawley rats [259]. 
We focused on two exposure periods compared to a lifelong exposure, i.e., exposure during puberty 
only, when the MG is developing, and exposure after OVX, mimicking postmenopausal exposure in 
humans, for example, for HRT. 
Exposure during puberty 
Beside pregnancy, the pubertal period is the major period of postnatal MG development and 
represents a critical time window for epigenetic reprogramming [144]. It is of great clinic-therapeutic 
interest whether IF exposure during puberty would be sufficient to introduce the beneficial effects 
observed for a lifelong dietary IF intake. Since daily application of high IF doses during this 
developmental window of susceptibility would be easier achievable in Western populations than 
lifelong exposure, this would represent a great achievement for primary chemoprevention 
approaches of breast cancer. 
In order to investigate whether dietary IF exposure only during puberty modulates the MG 
methylome, a group of rats was assigned to a non IF-containing diet before and after puberty and 
were exposed to the high level IF diet only during the pubertal period (group CHC). 
Interestingly, administration of dietary IF only during the pubertal phase accelerated the time to 
vaginal opening similar to lifelong IF exposure which is in line with previously published results [235]. 
In comparison to the control group, pubertal IF exposure prevented the E2-induced gain in UWW 
after whereas lifelong IF exposure sensitized the uterine tissue to the E2 treatment. It would be 
interesting to determine expression of ER and ER in uterine tissue under these exposure scenarios. 
Differential ER expression after pubertal vs. lifelong exposure might explain the differential response 
to E2. 
In our study, pubertal H exposure (CHC) prevented E2-induced Ki67 expression and increased E2-
sensitivity towards enhanced PCNA transcript levels. This was different from the results of 
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Molzberger et al. [235]. The physiological relevance of these findings needs to be further 
investigated. Expression of estrogen responsive genes was not affected by pubertal IF administration, 
indicating a lack of direct estrogenic effects. On the other hand, Vdr (vitamin D receptor), a negative 
growth regulator of breast cancer cells and the TF Gata3 were induced in the CHC group, whereas 
lifelong exposure reduced the expression of both genes. Wietzke et al. reported that IF-induced 
upregulation of Vdr may sensitize cancer cells to the effects of vitamin D(3) analogs since 80 % of 
human breast tumors express Vdr at low levels. Therefore, a high IF exposure during puberty may 
provide a concept to modulate the MG epithelium towards higher cellular vitamin D(3) sensitivity 
and eventually to reduced cell growth [260]. Gata3 is involved in E2 signaling and an important 
regulator for luminal differentiation. In a study by Thomsen et al. Gata3 was one of the top inducible 
genes by prepubertal IF exposure (270 mg Prevastein (46.19 % IF)/kg diet), and lactational E2 
treatment. Subsequently, the presence of luminal epithelial cells in the MGs increased which reflects 
an enhanced glandular differentiation, a phenomenon which can be associated with reduced breast 
cancer risk [261]. 
Exposure to the high IF dose exclusively during the pubertal period exhibited only minor effects on 
DNA methylation levels of the investigated candidate regions and did not seem to be responsible for 
the effects introduced by a lifelong IF exposure, as we observed opposing effects between the CHC 
and HH groups. Median DNA methylation of Extl1 was significantly reduced in the CHC group 
compared to the control, consistently with or without additional E2 exposure. Hypomethylation of 
Cldn4, which plays a crucial role in the formation and maintenance of tight junctions and is involved 
in breast cancer progression as well as Aldh1L1, a gene involved in one carbon metabolism and 
relevant for providing SAM for methylation reactions, were detected only in the E2 group (not 
significant for Cldn4). In contrast, we observed reduced methylation levels of Niacr1 only without 
additional E2 exposure. The niacin receptor 1 is a G protein-coupled receptor located predominantly 
on adipocytes that mediate anti-lipolytic effects. It is activated by the endogenous ligands β-
hydroxybutyrate and lactate, two metabolites produced during prolonged starvation and intense 
exercise, respectively. Regulation of expression of this receptor is crucial for whole body energy 
homeostasis and is highly influenced by high fat diet [262]. However, pubertal IF exposure did not 
significantly affect the expression of any of these genes analyzed for methylation changes.  
Differential effects between short-term pubertal and lifelong IF exposure might reflect direct 
(anti-)estrogenic properties of IF vs. an indirect influence on gene expression via the hypothalamic-
pituitary-gonadal axis as described above. In addition, Molzberger et al. demonstrated differential 
(microbial) metabolite levels between pubertal and lifelong IF exposed animals, with lower levels in 
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animals that were only exposed during puberty. This might be due to differences in the expression of 
genes involved in IF metabolism or changes in the gut microflora [235].  
Overall, our analyses revealed only few significant changes in gene expression or DNA methylation 
after pubertal exposure to IF. These results indicate that the pubertal period might not be the most 
critical time frame for the long term preventive effects of IF.  
In addition to the pubertal exposure, several earlier studies have investigated the impact of a pre-
pubertal IF exposure. Warri et al. reviewed several reports on various IF exposure scenarios and 
obtained a conflicting dataset for the pre- and peripubertal periods [245]. Thompson et al. 
investigated the effects of lactational and postweaning IF exposure in mice in comparison to E2 
administered during the lactation period. Interestingly, MG morphogenesis was significantly modified 
by all treatment regimens towards an increased number of branches of the ductal tree which depicts 
an early growth stimulatory effect of the prepubertal intervention. Further, the number of highly 
proliferative TEBs was increased at PND 28 and consequently reduced at PND 42-43 due to the E2 
and postweaning IF exposure, reflecting an acceleration of the MG differentiation potentially 
resulting in a reduced cancer risk [261]. In a study of Lamartiniere et al., prepubertal IF exposure 
accelerated differentiation of the epithelial cells by transient upregulation of EGF-signaling and 
protected against chemically induced cancer in rats later in life [263]. Wang et al. identified changes 
in the proteome of female offspring that was exposed prepubertally to GEN (250 mg GEN/kg diet) via 
the lactating dams. Using two-dimensional gel electrophoresis and mass spectrometry, more than 20 
proteins were detected as differentially expressed due to the lactation transmitted GEN compared to 
unexposed animals, including vascular endothelial growth factor receptor 2 (VEGF-R2) and EGFR 
[264].  
Collectively, these studies indicate that the MG might be more sensitive to IF exposure during the 
prepubertal phase than during puberty. In an ongoing study on DNA methylation in rat MGs, this 
aspect is currently taken into consideration. 
Exposure post OVX mimicking menopause 
IF-containing products are advertised extensively as a natural alternative for HRT, since they 
potentially reduce menopausal symptoms without adverse effects regarding increased risk for 
cardiovascular events or breast cancer. Ingestion of the products on the market can yield to high 
daily IF intakes (40 – 150 mg IF/ capsule). However, high dose IF exposure in postmenopausal women 
might induce a different response in the MG than lifelong intervention during all susceptible periods 
and might affect the MG in an adverse manner. This mechanism is not well understood so far. 
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In order to mimic the human postmenopausal situation, animals received a high IF dose (CH) after 
ovariectomy during the hormonal decline period. This group was compared to the control group 
without IF exposure and the group with lifelong high IF levels. These exposure scenarios resemble 
the Western and Asian population, respectively with a very low (<1 mg) and a rather high (>200 mg) 
daily premenopausal dietary IF intake. Here the main focus was whether a high dose IF exposure 
after menopause (ovariectomy) might induce a contraindicative pro-proliferative effect on the MG 
epithelium. 
As in the other parts of the project, we first analyzed the influence of the IF diets on uterine 
response, alone and in combination with E2 challenge. Interestingly, without E2 challenge the high 
dose IF exposure after OVX did not exert an estrogenic effect on UWW, whereas the same diet 
further sensitized the uterus towards E2 treatment. Detection of reference gene expression still 
indicated a weak estrogenic effect of the post OVX IF diet. mRNA expression of Pgr and C3 was 
induced with and without additional E2 stimulation. Also, transcript levels of PCNA were increased, 
indicating a pro-proliferative response. Esr1 and Gata3 expression were also clearly induced by post 
OVX IF exposure, alone and in combination with additional E2 exposure. Esr1 upregulation might 
explain the increased estrogenic response. However, a recent animal study did not show pro-
estrogenic and proliferative effects on the MGs of rats due to a post OVX IF exposure (150 mg/kg bw) 
as determined by IHC of Ki67 [265]. 
In comparison to lifelong IF exposure, post OVX IF intervention significantly affected DNA 
methylation in the opposite direction. This was the case for Cldn4, Extl1, Gsn, Niacr1, PTEN and Sirt4 
which were hypomethylated in the CH diet group and not affected or hypermethylated in the HH 
group. Further investigations have to address mechanistic aspects underlying this differential 
epigenetic response. Consistent with methylation changes in the promoter region, Cldn4 mRNA 
expression was induced in the CH group and downregulated in the HH group. High Cldn4 expression 
was recently detected in triple negative breast cancer, a breast cancer subtype with poor prognosis. 
Therefore, increased Cldn4 expression due to the post OVX IF exposure can be considered as an 
adverse effect regarding MG health [266]. Consistently, expression of the TSG PTEN was significantly 
reduced in the CH group, but not in the HH group. 
Taken together, our observations indicate a rather pro-proliferative, pro-estrogenic and pro-
carcinogenic role of a post OVX exposure to high IF levels compared to the more preventive effects of 
a lifelong exposure. Although these results cannot be directly translated to the human situation, 
uptake of high doses of IF as supplements after menopause should be considered with some caution 
[267-269]. 
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5.2.2 Investigations on the kinetics of DNA methylation and on carcinogenesis in ACI rats 
In the second part of our investigations, we focused on the impact of a lifelong dietary IF exposure on 
the kinetics of DNA methylation changes in MGs of ACI rats during all developmentally critical time 
windows, e.g., embryonic/fetal, early postnatal, and pubertal periods. MG samples were analyzed 
and information on UWW was obtained from animals at PND 21, 50, 80, 97 and 180. ACI rats are 
susceptible to E2-induced carcinogenesis. Therefore, we additionally focused on DNA methylation 
changes during MG tumorigenesis in ACI rats and the impact of lifelong IF exposure. 
5.2.2.1 Kinetic experiment 
Endocrinological parameters are not affected by lifelong high IF exposure 
Lifelong high IF exposure in ACI rats resulted in a weak acceleration of vaginal opening, although this 
effect was not significant due to high interindividual variation especially in the control group. As 
described before, we and others have observed estrogenic effects of a prepubertal and 
multigenerational IF exposure indicated by a clearly accelerated onset of puberty in Wistar (1.5 days, 
first study of this thesis; 3 days, [235]), as well as in Spraque Dawley rats (3 days, [236]), and mice (6 
days, [237]). Notably, vaginal opening in ACI rats was observed relatively late at a median age of 
about 46 days for the control group, in comparison to Wistar rat with vaginal opening at a median 
age of 38 days.  
Relative UWW was affected by age, but not by dietary IF. Since UWW is depicted relative to 
bodyweight, this age-dependent effect rather reflects a gain in bodyweight with comparably slower 
uterine growth than an actual decrease in the absolute UWW.  
Proliferative and estrogenic response is increased by lifelong high IF exposure in young rats 
During normal development, proliferation of the MG increased as measured by Ki67 mRNA 
expression resembling the normal expansion of the ductal tree. Expression of Pgr as the prototypical 
marker for E2 responsiveness gradually increased with normal MG development as determined by 
mRNA expression as well as by IHC. Interestingly, IHC but not mRNA expression revealed an 
estrogenic effect of lifelong IF intake, identified as increased Pgr and Ki67 expression in the pre- and 
postpubertal ACI rats. These E2 agonistic effects could not be identified with mRNA analysis of these 
markers, however PCNA levels were increased at the prepubertal phase after rats were exposed to IF 
suggesting an acceleration of the MG development and a potential mechanism that might explain an 
altered susceptibility to tumor formation and probably the IF-reduced tumor incidence (discussed in 
detail in section 5.2.2.2).  
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The TEBs represent a critical target for tumor initiation, since they are highly undifferentiated and 
possess high proliferative capacity during puberty. Animals with prepubertal exposure to dietary IF 
had fewer TEBs on PND 50 when compared to the placebo group (Möller et al., 2016 in revision, 
[263]). This observation probably reflects an earlier peak of maximum TEB formation rather than 
reduced TEB formation [261]. Shortening the window of vulnerability by an early differentiation of 
the TEBs in response to IF exposure probably represents an important contribution to the overall 
mechanism by which IF exert their protective effects on breast cancer development. This is in line 
with Fritz et al. who showed that early exposure (gestational day 0–PND 21) to physiological doses of 
GEN (0, 25, 250 mg/kg diet) induced cell differentiation in Sprague Dawley rats [270]. 
In our study, ACI rats were all intact (not OVX) and not estrus cycle synchronized. Therefore, we had 
estrus, met-estrus, di-estrus, and pro-estrus phases, as well as transitions between the phases 
present, and plasma levels of endogenous E2 and its metabolites varied essentially. Normal MG 
epithelium undergoes oscillating phases of cell proliferation and cell death during the estrus cycle 
leading to phases of normal hyperplasia. Therefore, individual rats might have passed different parts 
of the estrous cycle which might contribute to interindividual differences in expression of 
proliferation markers and hormone receptors within one diet group.  
Kinetics of DNA methylation is stronger affected by age than by diet 
Epigenetic modifications accompany developmental processes and persist until later in life. 
Therefore, we investigated the kinetics of interesting changes of DNA methylation identified by RRBS 
with age groups PND 21 and 50 (discussed in section 5.1.2.1) from early development until 
adolescence and adulthood in ACI rats using MassARRAY technology.  
MassARRAY analysis revealed significant age-dependent effects on DNA methylation with most 
pronounced effects during puberty. Methylation in the promoter regions of analyzed genes gradually 
changed up to 30 % starting from puberty onwards where lifelong IF exposure was not able to induce 
methylation changes within one age group. Methylation for Niacr1 and Fxyd2 was decreased while 
Arpp21, Mmaa, Zfp507, Shroom2, Extl1 and Esr1 underwent progressive hypermethylation. 
Interestingly, strongest effects were observed between pre- and postpubertal rats (PND 21 and 50) 
when hormone-dependent MG development is initiated.  
Niacr1, is a G protein-coupled receptor located on adipocytes mediating anti-lipolytic effects and 
Fxyd2, as the gamma subunit of Na, K-ATPase are important regulators of whole body energy 
homeostasis [262] and cellular homeostasis [271]. Both are involved in adipose tissue metabolism 
and stem cell differentiation, respectively. It is well known that increased bodyweight and obesity are 
strongly associated with postmenopausal breast cancer [272]. Hypomethylation of these genes by IF 
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exposure might be able to affect the adipose tissue metabolism leading to beneficial effects by 
inducing the anti-lipolytic machinery. Arpp21 is frequently downregulated in breast cancer, where it 
is negatively associated with clinico-pathologic characteristics and survival outcome and might be an 
interesting target for IF exposure [247]. Since Arpp21 promoter methylation drastically increased 
after puberty it is tempting to speculate that E2-induced hypermethylation might be the underlying 
trigger for Arpp21 silencing in breast cancer cells.  
Mmaa (methylmalonic aciduria (cobalamin deficiency) cblA type) is a protein causally involved in 
methylmalonic acidemia (MMA), an inborn error in vitamin B12 metabolism. Shroom2 proteins are 
essential regulators of cell shape and tissue morphology during animal development [273] and 
Zfp507 is a not further characterized zinc-finger protein that may be involved in transcriptional 
regulation. Although these genes underwent clear promoter hypermethylation with age, none of 
them has been implicated with human MG development or associated with breast carcinogenesis.  
 
However, age-induced methylation changes did not affect the expression of any of the genes 
analyzed in the kinetic experiment. 
Expression of epigenetic enzymes is modulated by age and IF exposure 
In order to provide an underlying mechanism of the gradual age-induced changes in DNA 
methylation during MG development, we analyzed relative mRNA expression of enzymes modifying 
DNA methylation. The transcript levels of all three DNMTs showed tendencies of modification with 
increasing age. DNMT1 expression was gradually increased whereas expression of DNTM3a and 
DNMT3b was lower at older age. This is in line with a study from Kovalchuk et al. who investigated 
ACI rats early after a subcutaneous E2 treatment in comparison to normal MG [212]. DNMT3a levels 
measured by IHC were gradually downregulated with increasing age in the healthy MG (PND 47-75), 
which in turn might mediate hypomethylation and enables binding of additional DNA- or chromatin-
modifying enzymes that are sensitive to DNA methylation. Accordingly, Kutanzi et al. verified a 
concomitant increase of H4K12Ac in MGs of aging ACI rats. H4K12Ac is a transcriptional active 
histone mark, involved in histone disposition and was shown to occupy E2-responsive gene 
promoters and EREs in ERα-positive MCF-7 cells in an inducible manner [274]. 
Lifelong IF intervention reversed the observed age-related alterations towards a bell-shaped pattern 
for DNMT1 and lower expression levels for DNMT3a and DNMT3b at PND 21 in the H compared to 
the C group. Since we did not see IF-induced effects on DNA methylation at PND 21 or 50, expression 
of the DNA methylation modifying enzymes might be of minor impact on epigenetic regulation of the 
investigated candidate regions. However, Tet1 mRNA expression was clearly reduced in the course of 
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MG development in both dietary groups. A reduced Tet1 activity probably leads to less active 
demethylation and lower 5hmC levels, and is linked to gene body hypermethylation a phenomenon 
that has been observed for several cancer types including breast cancer [66, 275]. Since our analyses 
are based on bisulfite converted DNA which does not distinguish 5hmC from 5mC, we are not able to 
detect this loss of 5hmC. Further manipulation such as chemical oxidation of 5hmC to 5fC which then 
reacts with sodium bisulfite and is identified as unmethylated C would be necessary to allow a 
precise readout of 5mC by bisulfite sequencing (oxBS-Seq). 5hmC levels can then be deduced by 
comparing oxBS-Seq (which identifies 5mC only) with BS-Seq (which identifies both, 5mC and 5hmC) 
[77]. Clearly, investigation of 5hmC levels would be interesting, since this DNA modification has been 
proposed to contribute to the transcriptional regulation of active and bivalent gene promoters [276]. 
DNA methylation changes reflect alterations in glandular structure 
Normal MG development involves a massive reorganization of the MGs cytoarchitecture. EGF 
controls early duct outgrowth and together with E2 promotes massive remodeling of the breast 
architecture. Ducts grow, divide and form TEBs which are highly proliferative structures that give rise 
to branches, ductules, and to a lesser extent alveolar buds with enhanced degree of differentiation. 
With increasing age, ductal elongation and infiltration of the surrounding fat stroma also increase the 
percentage of the ducts in the MGs [108]. Therefore, methylation differences of candidate regions 
induced by age probably just reflect the changes in tissue composition due to MG development. 
We showed that age-dependent epigenetic effects were observed mainly between PND 21 and 50. 
These changes were induced by endogenous E2 exposure. Ding et al. recently demonstrated that 
exposure of ACI rats to exogenous E2 for 1 week induced profound changes in proliferation and 
cytoarchitecture [194]. Therefore, we characterized the cellular composition of MGs during 
development and determined gene expression patterns for selected marker genes for epithelial cells 
(Krt8 and Cdh1) as well as myoepithelial cells (Krt5, SMA and Tp63). Analyzing mRNA expression of 
the epithelial cell markers, we observed increased transcript levels from puberty onwards with 
pronounced effects during the pubertal phase, indicating the proliferative activity during MG 
development. This observation fits to the gradually increasing gene and protein expression levels of 
the proliferation markers (PCNA and Ki67). Since ductal outgrowth and branching is vastly driven by 
the hormonal interplay of E2 and progesterone, epithelial cells expressed Pgr, Esr1 and Esr2 with only 
Pgr being highly upregulated from puberty onwards. This has been reviewed by Hennighausen et al. 
who described an increased Pgr expression of proliferative cells and that a part of E2-mediated 
effects were due to Pgr induction and did not depend on Esr1 or Esr2 upregulation [277].  
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Therefore, the gradually modified methylation patterns might be, indeed, a result of the increasing 
numbers of epithelial cells, contributing to the analyzed specimen rather than an actual change in 
methylation within the epithelial cells.  
Observation from gene expression studies could support this hypothesis since none of the genes 
investigated with significant promoter DMRs also resulted in gene expression alteration. mRNA level 
are normalized to housekeeping genes such as Hprt, TBP and β-actin which reflect gene expression 
patterns that arise due to normal development. Therefore, detection of tissue composition-related 
transcriptional changes might be lost, since relative mRNA expression is calculated. This would 
further explain the fact that changes in DNA methylation did not correlate with gene expression of 
the corresponding candidate regions. 
For further analyses, purification of specific MG cell populations (e.g., epithelial cells) prior to analysis 
of DNA methylation and gene expression by cell-surface expressing markers or specific digestion with 
collagenase/hyaluronidase would substantially increase the understanding of the diversity of 
epigenetic regulations in individual cell types. Additionally, it would be interesting to investigate the 
kinetics of epigenetic changes after exogenous E2-exposure to identify the earliest methylation 
changes as potential epigenetic drivers/triggers of carcinogenesis, since epigenetic instability has 
been described to precede genomic instability in the multistage process of breast carcinogenesis 
[278]. 
5.2.2.2 Carcinogenesis experiment 
The ACI rat is an animal model susceptible to develop MG tumors upon prolonged exposure to 
pregnancy levels of exogenous E2 [279] and is a highly relevant model with a close connection to 
human types of breast cancer. Distinct quantitative trait loci, i.e., estrogen-induced mammary cancer 
(Emca) underlie the breast cancer susceptibility with several orthologous loci in human [166] being 
associated with risk factors such as mammographic breast density [167]. 
It has been hypothesized by Barker et al. that early nutritional exposures are associated with disease 
onset later in life [280]. His theory of a fetal origin of disease has now widely expanded to the 
hypothesis of ‘Developmental Origins of Health and Disease’ (DOHaD) [281], linking an adverse 
developmental environment with increased risk of disease in adulthood. To date hormone 
dependent malformation of the reproductive tract of male and female have provided the strongest 
evidence for a developmental reprogramming and alteration of cancer susceptibility induce by, e.g., 
Diethylstilbestrol and to a less severe extent Bisphenol A [282]. Also limb mal formation caused by 
exposure to Thalidomide or higher incidences of coronary heart disease and obesity after famine 
exposure during the first trimester are well known examples [282]. Phytoestrogenic soy IF have been 
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shown to modulate MG morphology and provide anti-tumorigenic effects especially when exposed in 
a multigenerational setting [141]. Since in utero and additionally prepubertal exposure link fetal 
exposures and epigenetic programming, we assessed the cancer preventive impact of a lifelong 
dietary IF exposure on E2-driven carcinogenesis of the MG.  
IF exposure reduced incidence of E2-induced MG tumors but accelerated onset and growth 
Lifelong IF exposure showed a dualistic mode of action since it reduced incidence and multiplicity of 
MG tumors but shortened tumor latency and enhanced tumor growth if tumors escaped the 
preventive effect. This can be interpreted as an inhibitory impact of IF on the tumor initiation 
process, but also as a tumor promoting activity of IF on the E2-induced tumors. 
Since final tumor incidence was slightly reduced it can be stated that dietary IF intake protected 
against E2-induced breast carcinogenesis although tumor growth was not prevented. This is in line 
with Lamartiniere et al. investigating DMBA-induced MG tumors in female Sprague Dawley rats. It 
was shown that a prepubertal GEN exposure (250mg genistein/kg diet) reduced the number of 
DMBA-induced MG tumors through a decline in the number of TEBs at PND 50 of female rats 
associated with a decreased rate of cell proliferation by more than 50 % [283]. However, this 
protective action of GEN against chemically induced tumors was not detectable if administered 
prenatally only [263], highlighting that there are sensitive phases for beneficial dietary interventions 
which might be more represented by the postnatal MG development stages. 
However, the data also suggest that chronic intake of IF reduced the time-to-tumor appearance and 
promoted growth of initiated tumors. Similar findings by Watson et al. support these results. Here, 
MTB-IGFIR transgenic mice that develop MG tumors upon doxycycline-induced overexpression of the 
IGF receptor were chronically exposed to IF from conception onwards. Tumor incidence and onset 
was significantly increased in the IF group. Since markers of E2 signaling (e.g., Pgr, Areg) were 
upregulated, the authors assumed an ER-signaling dependent mode of action [284]. When comparing 
these finding with xenograft models, IF intervention was shown to induce growth of implanted ERα-
positive MCF-7 cells but not ERα-negative MDA-MB-231 cells in ovariectomized athymic mice [285, 
286]. Summarizing existing data suggest that dietary IF might stimulate growth of preexisting MG 
tumors in rodents but these adverse effects might be limited to ERα-dependent tumor cells. 
Estrogenic response is not affected by lifelong high IF exposure in adult rats 
During normal development proliferation of the MG increased as measured by Ki67 mRNA 
expression, resembling the normal expansion of the ductal tree. Further increase during 
tumorigenesis represents aberrant growth of the MG epithelium and expansion of the cell volume, 
an observation that was confirmed by IHC in MGs of E2-exposed animals that did not develop 
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palpable tumors. In these glands, E2 stimulates the expression of the proliferation marker Ki67 
before the development of pre-neoplastic lesions. Similar enhanced cell proliferation in mild to 
moderate hyperplastic MGs was observed by Kutanzi et al. who investigated E2-treated ACI rats at 
PND 100, 140 and 180 [287]. Additionally, the authors demonstrated an imbalance between cell 
proliferation and apoptosis in MG/T at PND 100 rather than an enhanced proliferation or suppressed 
apoptosis alone as the driving force towards neoplasia. Further, Mdm2, a proto-oncogene was 
sustainably upregulated from mild hyperplasia onwards, together with a significant increase in c-Myc 
expression. Taken together the data suggest that the dysbalance of cellular processes that trigger 
uncontrolled cell proliferation, genomic instability, and neoplastic transformation is detectable at 
early stages in E2-treated MGs and independent of the prevalence of tumors.  
Pgr as a marker for E2 responsiveness gradually increased with normal MG development and got 
massively upregulated by E2 treatment as determined by mRNA expression as well as by IHC. 
However, transcript levels of both Esr1 and Esr2 were rather downregulated in tumors independent 
of the diet administered. These findings support the idea that the increase in Pgr expression is 
accompanied with proliferative cells and is responsible for the E2-mediated effects that are, indeed, 
not derived from Esr1 and Esr2 upregulation [277]. 
The increase in transcripts and protein levels of the proliferation markers Ki67 and PCNA in tumor 
tissue could not explain the growth promoting effects of IF in a subset of tumors since these effects 
were independent of the dietary regime. However, single tumors of the H group showed a massive 
gain in Ki67 mRNA expression probably resembling those with highest tumor weights.  
DNA methylation and gene expression of candidate genes 
We performed RRBS to identify DMS related to either dietary exposure to IF, to carcinogenesis, or a 
combination of both (discussed in section 5.1.2.2). We selected eleven candidate genes for validation 
by MassARRAY. For six out of 11 genes, methylation levels correlated with expression levels. Most 
DMRs were annotated to promoter regions, emphasizing the relationship between promoter 
methylation and regulation of gene transcription.  
Methylation data for St3gal4 (ST3 beta-galactoside alpha-2,3-sialyltransferase 4 (siat4c), a gene 
involved in sialylation, which plays a crucial role in cell adhesion and regulates the biological stability 
of glycoproteins [193] was determined for an intergenic DMR roughly 138.4 kb downstream of the 
TSS with significantly correlating transcript levels. This DMR might overlap with an enhancer region 
which regulates gene expression of the target gene. So far, different from the human and mouse 
genomes, the exact mapping of enhancers in the rat genome is not well known.  
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Although methylation levels did not significantly change, mRNA transcript levels of Zfp507, a not 
further characterized zinc-finger protein, were low in placebo group tumors and expression was 
further reduced in tumors of the H diet group. Additionally, Mrc2 (receptor, C type 2), involved in the 
collagen turnover process, Thy (Thy-1 cell surface antigen), affecting cell-cell or cell-matrix 
interactions as well as Rnf8 (ring finger protein 8), an E3 ubiquitin protein ligase involved in 
chromatin remodeling underwent significant carcinogenesis related methylation and gene expression 
changes. However, we did not detect significant correlations in the carcinogenesis experiment 
indicating that additional epigenetic mechanisms such as histone tail modifications and non coding 
RNAs might account for these expression changes.  
However, mRNA levels of Fxyd2 downregulated during adipose stem cell differentiation and involved 
in basic cellular homeostasis, and Arpp21 increased in MG of the H diet-exposed animals vs. the 
placebo group, and were significantly repressed in tumors of both dietary groups. Since Arpp21 has 
been reported to be downregulated in 87 % of primary breast cancers, IF-induced upregulation 
would be a clear beneficial effect. No IF impact was detectable for relative Esr1 and Niacr1, a 
receptor located on adipocytes and involved in anti-lipolytic effects, but levels were significantly 
decreased due to the E2 treatment, supporting the idea of a tissue-specific autoregulatory 
mechanism of the Esr1 expression upon exogenous E2 stimulation [252]. 
Due to the breast carcinogenic process mRNA levels of epithelial cell markers Krt8 and Cdh1 got 
massively upregulated while myoepithelial markers Krt5, SMA and TP63 were downregulated. This 
opposing expression represents the E2-stimulated clonal expansion of luminal cells in the MG during 
the breast carcinogenic process. Similarly to the observed effects in the pubertal ACI rat study, 
methylation and gene expression differences of the candidate regions might be attributed to changes 
in tissue composition due to tumor development and vastly reflect the actual methylation changes in 
the hyperplastic epithelial cells. However, characterizing the average methylation across the bulk of 
cell populations certainly conceals cell type specific methylation profiles. The identified small 
changes in gene expression or methylation might originate from, e.g., a myoepithelial cell fraction 
which is basically underrepresented in this approach and, thereby, cell type specific effects are 
"diluted". Gascard et al. investigated different enriched primary human breast cell types from disease 
free women and defined comprehensive differences in epigenomic reprogramming between luminal 
and myoepithelial cells such as methylation of enhancer elements and transcriptional output (RNA 
yield/cell) [288]. Therefore, purification of specific MG cell populations based on cell-surface 
expressing markers or possibly even single-cell epigenomics could substantially unravel the diversity 
in the individual cellular states at its native resolution [289]. 
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Writers and erasers of DNA methylation 
In order to identify the underlying mechanism of the DNA methylation and gene expression changes 
during tumor development, we investigated effects on epigenetic modifiers induced by the 
environmental stimuli and endocrine signals. We selected epigenetic modifying enzymes involved in 
writing and erasing DNA methylation, i.e., DNMT1, 3a, and 3b, as well as Tet1.  
The relative mRNA expression of DNA methylation modifying enzymes show a divers pattern. During 
early MG development DNMT3a and 3b were significantly downregulated by lifelong IF intervention 
and were further decreased during tumor formation. DNMT1 expression was gradually increased 
during normal development with a bell-shaped pattern in the IF group and got further upregulated 
during tumor formation. This phenomenon was also observed by others, where higher levels were 
also present in the pre-neoplastic lesions of E2-treated ACI rats [168, 212]. However, lifelong IF 
exposure prevented the E2-induced upregulation of DNMT1 in tumors. This is in line with several 
observations regarding the potential of IF to alter DNMT activity by, e.g,. interacting with the 
catalytic domain and subsequent suppression of the DNMT activity [156].  
Transcript levels of Tet1 were also clearly reduced in the course of MG development and E2-induced 
tumor formation, an effect which was most pronounced in MG/T. This is in line with observations in 
colon cancer where Tet1 downregulation was detectable in very early stages of cell transformation 
[290]. Interestingly, mRNA levels of Tet1 and DNMT3b as well as DNMT1 are clearly opposing during 
MG development and tumor formation, respectively and most pronounced due to the IF exposure, 
demonstrating their roles as counterparts in shaping the DNA methylation landscape. 
The IF-mediated downregulation of DNMTs possibly inhibits the process of regional 
hypermethylation of promoter and enhancer regions of putative TSGs during tumor formation. The 
consequence of this prevention might be an increased accessibility of the transcription machinery 
and increased TSG protein levels. Therefore, IF-reduced prepubertal DNMT activity (as shown for 
DNMT3a and 3b mRNA levels) might alter the susceptibility of the MG towards tumorigenesis by 
reprogramming the pubertal methylome. 
Functional pathways affected by lifelong IF exposure  
Tissue development, organogenesis and cellular differentiation occur through a series of tightly 
regulated, temporally and spatially timed molecular and biochemical events [282]. Lifelong IF 
exposure reduced the incidence and multiplicity of MG tumors and induced more than 24,000 DMS 
between the tumors of E2-treated ACI rats (comparison C+E2 vs. H+E2). Using Ingenuity Pathway 
Analysis (IPA) we observed intriguing enrichments of DMS in distinct biological processes. 
Environmental IF intervention during development affected genes of several functional pathways 
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and reprogrammed tissue responses, e.g., in reproductive development and function, reproductive 
system disease, as well as in endocrine system development and function. Further, genes were 
enriched in cellular events such as growth and proliferation, development, movement, signaling, and 
interaction, as well as morphology etc. 
We identified differentially methylated genes that are related to several of these signaling pathways 
and that might be interesting targets for further analyses. Hypermethylation was identified for DMRs 
associated with: RAX, retina and anterior neural fold homeobox, a homeodomain-containing TF with 
functions in eye development which has not been implicated in tumor development, yet [291]. 
SMAD7, a nuclear protein that binds to E3 ubiquitin ligase SMURF2 and has been shown to promote 
EGFR signaling, via impairing ligand-induced ubiquitination and degradation of activated EGFR [292, 
293]. MafK that belongs to bZIP-domain containing TFs might be involved in regulation of NF-κB, of 
NF-E2 (Nrf2) which binds to the antioxidant-responsive element (ARE), and in production of ROS 
[294], [295]. Interestingly, MafK popped up in the TF enrichment analysis in the Wistar rats, as well. 
Therefore, the mechanistic impact of the bZIP-domain containing TFs might indeed represent a 
promising target for IF-mediated transcriptional regulation. Additionally Wnt5a, a ligand of the non-
canonical Wnt-pathway was highly methylated. This is in line with Su et al. who were interested in 
the potential biological and molecular pathways altered by IF in isolated mammary epithelial cells 
(MEC) of Sprague Dawley rats (PND 50). Using microarray technology they identified various 
biochemical pathways affected after administration of GEN- and SPI-enriched diets (250 and 400 
ppm IF aglycone equivalents, respectively). They provide evidence for the downregulation of the 
proto-oncogene Wnt5a [296] as well as Zhang et al. who identified a decreased AOM-induced Wnt5a 
expression in the colon due to a SPI (140 ppm GEN) intervention in Sprague-Dawley rats [297]. The 
Wnt-pathway is well known for its implications in colorectal cancer however the current results 
suggest a pivotal role in IF-mediated effects in MG carcinogenesis. 
Hypomethylated DMRs have been observed for: Trip11, thyroid hormone receptor interactor 11 
which has not yet been implicated in carcinogenesis and HOXD3, a homeodomain-containing 
transcription factor of the HOX family that determines cellular identity during development. 
Hypermethylation of HOXD3 is associated with clinico-pathologic features such as progression in 
prostate cancer and shorter survival in invasive breast cancer [298], [299]. Therefore, a 
demethylation of the HOXD3 promoter might be of beneficial effect regarding MG tumor 
development. Further, the promoter of PIK3R1, phosphoinositide-3-kinase regulatory subunit 1 
harbored a hypomethylated DMR. It has been reported that IF partially exert their cancer preventive 
properties by targeting the PI3K/AKT signaling pathway. Bredfelt et al. identified an interesting and 
rapid non-genomic signaling pathway upon binding of E2 or the endocrine disruptor Diethylstilbestrol 
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which however, is not fully understood, yet [300]. Ligand binding to the membrane-associated ER 
activates PI3K/Akt signaling and phosphorylates the histone methyltransferase enhancer of Zeste 
homolog 2 (EZH2) which adds methyl groups to the lysine 27 residue of histone 3 tails. The 
phosphorylation leads to an inactivation of EZH2 and a concomitant reduction of H3K27me3 levels, a 
transcriptional repressive histone mark in ERα-positive MCF-7 cells, uterine myometrial cells (ELT3) 
and in the postnatal myometrium of Eker rats. However, in a recent publication of Greathouse et al. 
subcutaneous injections of GEN (50 mg/kg per rat) from PND 10-12 induced the same effects in the 
uterus of Eker rats [301]. Furthermore, GEN developmentally reprogrammed E2-responsive genes to 
become hyper-responsive. Although DNA methylation levels were not particularly assessed in these 
studies the observed hypomethylation of the PIK3R1 promoter and a possible subsequent 
upregulation demonstrate how IF can regulate epigenetic mechanisms via DNA methylation changes.  
Since IF caused developmental reprogramming and affected control variables in many pathways it is 
tempting to speculate that several of these signals are responsible for the identified tumor 
preventive efficacy observed for IF containing diet. However, our results also identified a tumor 
promoting activity of IF on the E2-induced tumors that escaped the preventive effect. Since we 
compared frank tumors of either group for our analysis, primarily the physiological signals 
responsible for the adverse effects might be encompassed in the identified pathways. 
5.2.2.3 Quantitative DNA methylation analyses of enriched MG epithelial cells 
Validating the genome-wide data with MassARRAY technology, we observed that the cellular 
composition of the MGs might contribute to differences observed in DNA methylation 
measurements and complicates the identification of diet-induced effects. Therefore, it was desirable 
to assess homogenous epithelial cells. Since isolation of epithelial cells by flow cytometry using 
defined surface markers was not an option due to the nature of the specimen (cryo-sections), we 
performed laser capture microdissection to enrich for cells originating from the ductal tree.  
In contrast to our expectations, interindividual DNA methylation was often greater in the LCM 
samples when compared to samples obtained from the MG bulk of cells. Within one diet group 
methylation values showed massive divergence which did not enable a clear insight into epithelial 
DNA methylation changes unimpaired by other cell subtypes.  
As mentioned previously, bisulfite conversion commonly destroys >99 % of intact DNA fragments due 
to the denaturing environment. Since the amount of input material was already very low (<30 ng) 
only a few fragments were available for subsequent amplifications during MassARRAY PCR. Since this 
protocol involved more than 40 amplification cycles the residual intact fragments are amplified but 
do not necessarily represent the initially captured entirety of fragments. High duplication rates of un- 
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or fully methylated DNA fragments have been reported leading to a tendency to observe either 0 %, 
50 % or 100 % methylation (oral communication PD Dr. Dieter Weichenhan, Christoph Weigel). Thus, 
the technical artifacts might introduce less bias when fragments are analyzed by a different 
quantitative technique and PCR induced duplicates, amplicons with the exact same sequence pattern 
of CpG and non-CpG cytosines, are filtered out prior to the DNA methylation analysis, e.g., .bisulfite 
sequencing. 
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In the present thesis, two individual sequencing-based methodologies for methylation profiling, i.e., 
Methyl-CpG immunoprecipitation-sequencing (MCIp-Seq) and reduced representation bisulfite 
sequencing (RRBS) were implemented to achieve comprehensive insights into the genome-wide 
effects of IF on DNA methylation in the rat MG. Animals experiments were performed using three IF-
enriched diets containing low, medium and high concentration of IF, based on the reported dietary IF 
intake of the Western and Asian population.  
We identified that i) IF are able to modify DNA methylation patterns in the MGs of rats on a genome-
wide scale, although with smaller absolute methylation changes compared to those observed during, 
e.g., carcinogenesis, ii) the impact of IF on DNA methylation was highly dependent on the IF dose 
administered as well as on iii) the timing of exposure, and iv) the chemopreventive efficacy on E2-
induced breast carcinogenesis indicated a dualistic mode of action. 
Using MCIp-Seq and RRBS, we identified IF-mediated methylation changes, including both hypo- and 
hypermethylated regions. More than 90 % of the differential methylation occurred outside of 
classical regulatory regions, but also included differential methylation at specific TF binding sites. 
Therefore, we assume that IF predominantly exert their functional roles by engaging distal regulatory 
elements and by modifying TF regulated gene transcription. So far, there is not much known about 
enhancers and distal promoters in the rat genome. Therefore, it would be of great interest to 
investigate specific histone tail modifications such as H3K27ac, H3K4me1 and H3K4me3 in order to 
identify genomic locations of active distal enhancers and/or promoters in the rat MG, for an 
integrative analysis in combination with our methylation data. Differentially methylated promoters 
have been associated with signaling pathways in reproductive tissue homeostasis and endocrine 
system. For future studies, transcriptomic data for comparative analysis would further improve our 
understanding of the biological impact of a dietary IF exposure on epigenetic regulation. 
Comparing different lifelong IF exposure protocols we observed a biphasic dose response profile, 
with the low dietary IF concentration being not sufficient to reduce estrogenic and proliferative 
response (measured by PR and PCNA protein expression). Overall, IF induced U-shaped dose-
dependent DNA methylation and mRNA expression changes. These results allow the conclusion that 
high IF levels are needed to achieve potential beneficial health effects. High IF intake (>100 mg 
IF/day) is a phenomenon observed for approximately 10 % of the Asian population, represented by 
the diets containing higher IF concentrations in our study (corresponding to a daily intake of about 
177 mg and 390 mg IF, respectively, calculated for a 60 kg woman). Therefore, the reduced breast 
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cancer risk as seen for the Asian population might only be in parts be explained by the anti-
proliferative and anti-estrogenic effects of a lifelong exposure to high IF concentrations.  
In contrast to lifelong exposure to the highest IF concentration, intervention exclusively during 
puberty showed no clear impact on proliferation markers and exhibited only minor effects on DNA 
methylation and mRNA expression levels. We assume that the pubertal period is not the most critical 
time window responsible for introducing long-term chemopreventive effects. Earlier developmental 
windows such as the postnatal or prepubertal phase might therefore hold the key for preventive 
epigenetic reprogramming of the MG and should be taken into consideration for further preventive 
approaches. However, a short term exposure to high IF levels after menopause, as often observed in 
Western countries as alternative to HRT, displayed pro-proliferative as well as pro-estrogenic 
properties in MGs of adult rats. Contraindicative effects were also identified for DNA methylation 
and mRNA expression patterns since they were affected in an opposed direction when compared to 
lifelong exposure to the highest IF concentration. Although our results do not permit a clear risk 
assessment regarding the commercially available natural alternatives to HRT, supplementation of 
high doses of IF after menopause should not be recommended without any concerns. 
With respect to lifelong IF-mediated effects on E2-induced rat mammary carcinogenesis, we 
identified a dualistic mode of action. Incidence and multiplicity of MG tumors were reduced, but we 
observed a shortened tumor latency and enhanced tumor growth if tumors escaped the preventive 
effect. Further, lifelong exposure to high IF levels induced estrogenic and proliferative response of 
the MGs at puberty, as measured by PR and Ki67 protein expression. We assume that the pro-
proliferative effects during early MG development, in contrast to later stages, might be interpreted 
as an advantage regarding MG health. Since an acceleration of the MG differentiation shortens the 
window of vulnerability of the MG, these early pro-estrogenic effects might provide a mechanism by 
which IF exert their chemopreventive effects and reduce the susceptibility of the MGs towards the 
subsequent E2 treatment. Epigenetic modifying enzymes, such as DNMT3a and 3b were 
downregulated by lifelong IF exposure from early MG development onwards and represent 
interesting targets for IF to shape the DNA methylation landscape. Since a number of the promoter 
DNA methylation changes that we investigated did not result in gene expression alterations of the 
target genes it would be of great interest to investigate the corresponding chromatin-modifying 
enzymes as well as putative non-coding RNAs such as miRNAs using, for example, nCounter 
Nanostring technology or RNA-Seq. This knowledge would enable a comprehensive overview of the 
epigenetic modifying potential of a lifelong soy IF exposure on MG health and disease. 
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Our results cannot be directly translated to the human situation since rodent IF, and E2 metabolism, 
as well as microbial intermediates differ substantially. The human relevance of our data needs to be 
clarified in further studies; however, with our results in hands, we do not unreservedly recommend 
the use of IF-containing capsules as a safe alternative to HRT. 
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8. Supplements 
 
Supplemental table 1: MCIp-Seq statistics for HS and SF elution protocol. 
Animals sequenced  
[number of lanes] 
Elution protocol Total reads [mio] PF reads [mio] PF reads [%] Read length PF bases [%] PF bases [mio] GC content [%] 
 
12 [2] 
HS 214,2 165,9 77.45 51 92.69 8,461 53.15 
HS 214,1 167,1 78.08 51 91,09 8,525 52.91 
 
 
18 [4] 
SF 197,8 147,3 74.45 51 93,75 7,513 46.17 
SF 206,2 135,3 65.64 51 92,57 6,902 46.12 
SF 189,9 157,1 82.70 51 93,56 8,013 49.10 
SF 187,3 159,7 85.26 51 94,18 8,155 49.13 
Numbers given per lane sequenced, HS: High salt elution, SF: Single fraction elution, PF: Purity filtered bases/reads with more than 30x coverage 
  
8. Supplements  XLIII 
Supplemental table 2: Selected MCIp-Seq candidates with 4-fold enrichment difference and EpiTYPER amplicon information. 
 Gene Name Refseq Gene Description Chr. Strand Start End 
Distance 
to TSS 
Annotation Methylation CC diet [%] 
C
an
d
id
at
e
s 
fr
o
m
 M
C
Ip
-S
eq
 
PTEN NM_031606 phosphatase and tensin homolog chr1 + 258712627 258713086 61027 intron (7 of 8) 95 
Extl1 NM_001107985 exostosin-like glycosyltransferase 1 chr5 - 156387536 156387929 -1851 promoter-TSS 61 
Sirt4 NM_001107147 sirtuin 4 chr12 - 48667613 48668016 2223 intron (2 of 4) 56 
Gadd45b NM_001008321 growth arrest and DNA-damage-inducible, beta chr7 - 11809261 11809588 6141 intergenic 24 
Wap NM_053751 whey acidic protein chr14 - 80533289 80533673 3 promoter-TSS 72 
Wif1 NM_053738 Wnt inhibitory factor 1 chr7 + 63116145 63116580 38674 intron (2 of 9) 81 
Cdh13 NM_138889 cadherin 13 chr19 + 61925599 61925934 304332 intron (2 of 13) 79 
Gsn NM_001004080 gelsolin chr3 + 19799763 19800214 59 promoter-TSS 0.05 
Esr1 NM_012689 estrogen receptor 1 chr1 - 42666924 42667302 -72 promoter-TSS 3 
Cldn4 NM_001012022 claudin 4 chr12 - 26762009 26762384 716 promoter-TSS 23 
Aldh1L1 NM_022547 aldehyde dehydrogenase 1 family, member L1 chr4 + 186989977 186990328 -664 promoter-TSS 77 
Cyp2c6v1 NM_001013904 cytochrome P450, family 2, subfamily C, polypeptide 
6, variant 1 
chr1 - 154015365 154015688 9598 exon (3 of 9) 80 
Chr.: Chromosome; TSS: transcription start site ; C: control diet; n.d. not determined 
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Supplemental table 3: Sequencing result of the puberty study of ACI rats. 
Sample 
ID 
Species Sex 
Age 
[PND] 
Tissue Diet No. of lanes 
Reads 
total 
[mio] 
Reads 
aligned 
[mio] 
Align-ment 
rate [%] 
Total sequenced 
motifs [mio] 
Unique 
sequenced 
motifs [mio] 
Mean 
coverage 
[x) 
Bisulfite 
conversion 
rate [%] 
Global 
Methyl. 
mean [%] 
ACI_AR1-1 rat female 21 MG C 1 43.84 32.00 76.00 57.37 1.230 46.63 98.16 62.36 
ACI_AR1-2 rat female 21 MG C 1 22.07 15.49 74.00 27.26 0.949 28.73 98.19 63.98 
ACI_AR1-3 rat female 21 MG C 1 17.79 12.86 75.00 23.47 0.830 28.26 98.22 63.20 
ACI_AR1-4 rat female 21 MG C 1 23.37 16.73 74.00 30.74 0.926 33.18 98.31 63.53 
ACI_AR1-5 rat female 21 MG C 1 25.08 17.93 74.00 33.16 0.946 35.06 98.32 63.46 
ACI_AR1-6 rat female 21 MG C 1 23.66 16.80 74.00 30.97 0.921 33.61 98.32 64.01 
ACI_AR2-1 rat female 21 MG H 1 17.06 12.32 75.00 22.75 0.779 29.22 98.34 62.57 
ACI_AR2-2 rat female 21 MG H 1 35.37 25.07 74.00 45.56 1.051 43.36 98.38 66.47 
ACI_AR2-3 rat female 21 MG H 1 24.95 17.75 74.00 32.63 1.416 23.04 98.10 64.83 
ACI_AR2-4 rat female 21 MG H 1 38.77 26.95 74.00 48.12 1.259 38.24 98.18 64.15 
ACI_AR2-5 rat female 21 MG H 1 28.51 20.10 74.00 37.53 1.078 34.82 98.29 60.67 
ACI_AR2-6 rat female 21 MG H 1 24.24 17.53 75.00 31.83 1.380 23.07 98.07 65.74 
ACI_AR7-1 rat female 50 MG C 1 29.62 21.70 76.00 39.74 1.044 38.07 98.27 62.50 
ACI_AR7-2 rat female 50 MG C 1 47.60 32.84 73.00 59.33 1.234 48.09 98.28 62.73 
ACI_AR7-3 rat female 50 MG C 1 23.83 17.15 75.00 31.85 1.461 21.80 98.05 66.09 
ACI_AR7-4 rat female 50 MG C 1 33.41 23.45 74.00 44.09 1.648 26.75 98.06 65.61 
ACI_AR7-5 rat female 50 MG C 1 31.12 21.54 73.00 39.51 1.588 24.88 98.05 65.10 
ACI_AR7-6 rat female 50 MG C 1 22.26 16.12 75.00 29.59 1.442 20.52 98.01 65.50 
ACI_AR8-1 rat female 50 MG H 1 32.05 23.08 76.00 41.50 1.148 36.16 98.19 63.68 
ACI_AR8-2 rat female 50 MG H 1 18.41 13.01 74.00 24.22 0.877 27.62 98.28 62.30 
ACI_AR8-3 rat female 50 MG H 1 28.52 20.12 74.00 37.55 1.059 35.45 98.27 60.06 
ACI_AR8-4 rat female 50 MG H 1 38.21 27.01 74.00 50.30 1.196 42.07 98.35 64.79 
ACI_AR8-5 rat female 50 MG H 1 25.20 18.05 75.00 32.83 1.087 30.22 98.18 62.84 
ACI_AR8-6 rat female 50 MG H 1 24.37 17.08 74.00 31.00 1.052 29.48 98.16 63.35 
PND: post natal day, MG: mammary gland, C: control diet, H: Isoflavone enriched diet  
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Methylation [%] 
Supplemental table 4: RRBS candidates from the puberty and the carcinogenesis study of ACI rats and EpiTYPER amplicon information. 
 Gene Name Refseq Gene description Chr. Strand Start End 
Distance 
to TSS 
Annotation 
 
CC diet 
 
PND 21 
C diet 
PND 285 
C diet 
C
ar
ci
n
o
ge
n
e
si
s 
st
u
d
y 
(P
N
D
 2
8
5)
 
Ndrg3 NM_001013923 NDRG family member 3 3 + 158615598 158615949 1578 promoter-TSS n.d. n.d. 57 
Lect2 NM_001108405 leukocyte cell-derived chemotaxin 2 17 - 10664435 10664658 983 promoter-TSS n.d. n.d. 20 
Mrc2 NM_001024687 mannose receptor, C type 2 10 + 93277747 93278013 -1038 promoter-TSS n.d. n.d. 15 
Npas1 NM_001107479 neuronal PAS domain protein 1 1 + 79684310 79684665 3492 Intergenic n.d. n.d. 34 
Msx1 NM_031059 msh homeobox 1 14 + 77689344 77689577 -1530 promoter-TSS n.d. n.d. 14 
Rita NM_001044226 RBPJ interacting and tubulin associated 1 12 - 43344158 43344363 -851 promoter-TSS n.d. n.d. 26 
Gbp2 NM_133624 guanylate binding protein 2, interferon-
inducible 
2 + 266802593 266802868 -2504 5' UTR n.d. n.d. 79 
Thy1 NM_012673 Thy-1 cell surface antigen 8 + 46885215 46885651 -113190 Intergenic n.d. n.d. 55 
Rnf8 NM_001025727 ring finger protein 8, E3 ubiquitin protein ligase 20 + 10486954 10487240 2202 intron (1 of 7) n.d. n.d. 55 
St3gal4 NM_203337 ST3 beta-galactoside alpha-2,3-sialyltransferase 
4 
8 + 36194911 36195342 138471 intron (4 of 15) n.d. n.d. 66 
Mir10a NR_031814 microRNA 10a 10 + 83965989 83966312 -2532 Intergenic n.d. n.d. 29 
P
u
b
er
ty
 s
tu
d
y 
(P
N
D
 2
1-
5
0
) 
            
Nr1h3 NM_031627 nuclear receptor subfamily 1, group H, member 
3 
3 - 86722683 86722979 1335 promoter-TSS n.d. 55 n.d. 
Rbm42 NM_001014159 RNA binding motif protein 42 1 + 90265254 90265482 -524 promoter-TSS n.d. 17 n.d. 
Tlr3 NM_198791 toll-like receptor 3 16 - 49739421 49739691 258 promoter-TSS n.d. 67 n.d. 
Bpgm NM_199382 2,3-bisphosphoglycerate mutase 4 - 61649927 61650191 822 promoter-TSS n.d. 8 n.d. 
Niacr1 NM_181476 niacin receptor 1 12 - 40029765 40029999 -98 promoter-TSS 50 72 42 
Arpp21 NM_001135045 cAMP-regulated phosphoprotein 21 8 - 119786799 119787190 -1247 promoter-TSS 83 49 85 
Shroom2 NM_001047893 shroom family member 2 X - 24066659 24067122 -714 promoter-TSS n.d 28 37 
Zfp507 NM_001106248 zinc finger protein 507 1 + 93252329 93252728 -1902 promoter-TSS n.d 66 62 
Fxyd2 NM_017349 FXYD domain-containing ion transport regulator 
2 
8 - 48337077 48337170 -957 promoter-TSS n.d 73 46 
Mmaa NM_001106174 methylmalonic aciduria type A protein 
mitochondrial 
19 - 43204987 43205226 -14004 promoter-TSS n.d 72 85 
Chr.: Chromosome; TSS: transcription start site; CC: and C diet: control diet; n.d. not determined, RRBS: Reduced representation bisulfite sequencing 
  
8. Supplements  XLIX 
Supplemental table 5: Sequencing result of the carcinogenesis study of ACI rats. 
Sample 
ID 
Species Sex 
Age 
[PND] 
Tissue Diet No. of lanes 
Reads 
total 
[mio] 
Reads 
aligned 
[mio] 
Align-ment 
rate [%] 
Total sequenced 
motifs [mio] 
Unique sequenced 
motifs [mio] 
Mean 
coverage 
[x) 
Bisulfite 
conversion 
rate [%] 
Global 
Methyl. 
mean [%] 
ACI_BA1-1 rat Female 285 MG C 2 60.10 45.37 75.56 95.13 1.494 63.65 98.80 56.59 
ACI_BA1-3 rat Female 285 MG C 2 63.87 55.04 86.46 126.96 1.709 74.30 99.01 49.32 
ACI_BA1-4 rat Female 285 MG C 2 65.55 57.04 87.16 126.55 1.680 75.34 99.01 52.41 
ACI_BA1-7 rat Female 285 MG C 2 59.76 52.46 88.08 115.84 1.642 70.54 99.02 52.93 
ACI_BA1-9 rat Female 285 MG C 2 81.54 68.01 83.67 162.00 1.800 89.99 98.99 48.22 
ACI_BA4-2 rat Female 285 MG H 2 65.15 49.10 75.43 103.72 1.565 66.29 98.82 56.36 
ACI_BA4-3 rat Female 285 MG H 2 65.75 50.88 77.45 106.57 1.570 67.88 98.82 57.36 
ACI_BA4-4 rat Female 285 MG H 2 73.63 60.49 82.19 136.63 1.570 87.02 99.17 52.27 
ACI_BA4-5 rat Female 285 MG H 2 57.43 46.67 81.34 97.16 1.560 62.27 98.82 57.75 
ACI_BA4-6 rat Female 285 MG H 2 73.27 58.94 80.48 134.27 1.599 83.99 99.17 50.08 
ACI_BA4-9 rat Female 285 MG H 2 69.52 54.16 77.98 116.74 1.586 73.63 98.82 54.22 
ACI_BA3-1 rat Female 285 T C 2 68.94 53.75 78.09 117.16 1.654 70.86 99.02 50.37 
ACI_BA3-3 rat Female 285 T C 2 67.85 55.69 82.21 122.77 1.650 74.42 99.04 49.88 
ACI_BA3-5 rat Female 285 T C 2 63.87 54.48 85.33 118.10 1.498 78.82 99.19 53.6 
ACI_BA3-6 rat Female 285 T C 2 71.85 55.59 77.50 122.01 1.664 73.32 99.03 54.89 
ACI_BA3-8 rat Female 285 T C 2 72.64 55.20 76.02 121.53 1.541 78.88 99.19 50.54 
ACI_BA3-10 rat Female 285 T C 2 58.96 46.22 78.65 102.64 1.607 63.87 99.01 51.49 
ACI_BA6-2 rat Female 285 T H 2 72.67 49.68 68.40 110.55 1.498 73.79 99.18 53.26 
ACI_BA6-2 rat Female 285 T H 2 60.27 48.07 79.89 103.47 1.538 67.27 99.01 54.14 
ACI_BA6-3 rat Female 285 T H 2 72.45 26.60 36.75 54.51 1.256 43.41 98.83 56.38 
ACI_BA6-8 rat Female 285 T H 2 55.93 45.54 81.47 97.13 1.379 70.45 99.18 54.62 
ACI_BA6-8 rat Female 285 T H 2 79.74 49.12 61.70 105.30 1.568 67.15 99.02 55.64 
ACI_BA6-9 rat Female 285 T H 2 62.04 48.90 79.08 104.06 1.609 64.68 99.01 51.99 
ACI_BA6-10 rat Female 285 T H 2 62.12 53.19 85.90 114.28 1.599 71.47 99.02 55.07 
PND: post natal day, MG: mammary gland, T: tumor, C: control diet, H: Isoflavone enriched diet 
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Supplemental figure 1: Summary of DNA methylation in MC and MH groups. 
Each dot in the scatter plots represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-97). 
Median values per group are indicated by a horizontal line, vertical lines indicate interquartile range. Median methylation of 
CC group is indicated as horizontal dashed line and summarized in Supplemental table 1. No statistically significant 
differences between MC and MH have been observed (Supplemental figure 2). Group names indicate dietary IF exposure 
relative to pre and post OVX (IF-free control diet (C), medium (M), and high (H) IF diets). 
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Supplemental figure 2: Statistical overview of 14 candidate genes for DNA methylation in Wistar rats. 
For statistical analysis contrast tests based on the beta-regression model were used to make pairwise group comparisons 
which were adjusted for multiple testing (Tukey test). Different shades of grey indicate the negative decadal logarithm of 
three distinct significance levels (from light to dark: p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, white = not significant). Numbers in 
boxes correspond to median difference in methylation between corresponding groups. With (B) and without (A) E2 
treatment. Group names indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), low (L), medium 
(M), and high (H) IF diets). 
A 
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Supplemental figure 3: Statistical overview of 14 candidate genes for gene expression in Wistar rats. 
For statistical analysis contrast tests based on the linear regression model were used to make pairwise group comparisons 
which were adjusted for multiple testing (Tukey test Different shades of grey indicate the negative decadal logarithm of 
three distinct significance levels (from light to dark: p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, white = not significant). Numbers in 
boxes correspond to fold change expression compared to corresponding group. With (B) and without (A) E2 treatment. 
Group names indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), low (L), medium (M), and 
high (H) IF diets). 
 
 
 
 
Supplemental figure 4: Statistical overview of interaction effects in 14 candidate genes in Wistar rats. 
For statistical analysis interaction term was tested to identify E2-dependent group effects. Different shades of grey indicate 
the negative decadal logarithm of three distinct significance levels (from light to dark: p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, 
white = not significant). Letters in boxes indicate changes in median difference in methylation (M) or relative mRNA 
expression (G). Group names indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), low (L), 
medium (M), and high (H) IF diets). 
 
A 
B 
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Supplemental figure 5: Summary of DNA methylation across all experimental groups of Wistar rats. 
Each dot in the aligned dot plot represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-97). Median methylation differences  per group is indicated by a 
horizontal line, vertical lines indicate interquartile range. For group wise comparison see Supplemental figure 2. Group names indicate dietary IF exposure relative to pre and post OVX (IF-free 
control diet (C), low (L), medium (M), and high (H) IF diets). 
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Supplemental figure 6: Summary of relative mRNA expression across all experimental groups of Wistar rats. 
Each dot in the aligned dot plot represents one animal (dark grey, without E2; light grey, with E2 stimulation from PND 94-97). Relative mRNA expression to pooled housekeeping genes (HKG) 
of the CC group is indicated as horizontal lines, with vertical lines depicting interquartile range. Median rel. expression of the CC group is indicated as horizontal dashed lines. For group wise 
comparison see Supplemental figure 3. Group names indicate dietary IF exposure relative to pre and post OVX (IF-free control diet (C), low (L), medium (M), and high (H) IF diets). 
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